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ABSTRACT 
Inhibition of angiogenesis is an effective and low toxic therapeutic avenue for the 
treatment of cancer patients in addition to traditional interventions. Majority of current availa-
ble angiogenesis inhibitors for cancer therapies are growth factor inhibitors and small molecule 
tyrosine kinase inhibitors. A number of endogenous proteins and/or proteolytic fragments of 
extracellular matrix proteins are shown to have the activity of inhibition of angiogenesis by di-
rectly targeting endothelial cells. Structural analyses have indicated that a common structure of 
anti-parallel β-sheet with a highly positively charged surface presents in many of those inhibi-
tors. This common structural feature is critical for the maintenance of their anti-angiogenic 
function. With this structural information, we have designed and developed a new class of anti-
angiogenic proteins by integrating the short anti-parallel β-sheet forming sequences of endo-
genous anti-angiogenic proteins into a stable host protein, the extracellular domain-1 of cluster 
of differentiation 2 molecule (CD2D1). 1D 1H NMR spectra analyses indicated that the designed 
anti-angiogenic protein (ref to as ProAgio) folded as a β-sheet structure similar to that of the 
parental protein, CD2D1. ProAgio inhibited the growth of human umbilical vein cells (HUVECs) 
without affecting the growth of epithelial cells, suggesting a specific effect to endothelial cells. 
ProAgio effectively reduced endothelial tubules formed by the co-culture of HUVECs and PC3 
cells on matrix gel in vitro. The designed anti-angiogenic protein was further site-specifically 
PEGylated in order to improve PK/PD properties and reduce immunogenicity. Examinations 
with PC3 xenografts showed that both ProAgio and the PEGylated ProAgio dramatically inhi-
bited tumor growth. Immunofluorescence staining analyses of the endothelial marker CD31 in-
dicated dramatic decreases in tumor vessels in lengths and branching points. Histological and 
immunofluorescence staining analyses of tissue slices of major organs indicated that there were 
no pathological damages to the tissue structure or disruption of normal vessels associated with 
the treatment of our designed anti-angiogenic agent. Overall, our studies developed a novel 
anti-angiogenesis agent that may have great clinical potentials. Our concept of protein design 
can be extended to the development of other novel protein drugs.  
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 Angiogenesis in Life and Diseases 
Blood vessels distribute oxygen and nutrients, and remove waste from distant organs. 
Understanding the mechanism of blood vessels formation is a primary yet challenging field (re-
viewed in [1] ).  Most vasculature is developed during embryogenesis under multiple tightly re-
gulated processes involved in vasculogenesis, angiogenesis and arteriogenesis (reviewed in ref-
erences 1 – 11 and 13 – 16).  Vasculogenesis gives rise to a primitive vascular network where 
mesodermal angioblasts proliferate, migrate, differentiate to endothelial cells (ECs) and align to 
tubular structures [2, 3]. These primitive vessels are further expanded by sprouting or splitting, 
then pruned and remodeled into a functional circulatory system, termed as angiogenesis [3]. 
Subsequent arteriogenesis coats vessels with pericytes and smooth muscles, and forms mature 
blood vessels [4]. After birth till adolescence, angiogenesis becomes the main mechanism that 
produces new blood vessels for organ growth and development [1].  
In normal adult tissues, vasculature is quiescent except for female reproductive cycles 
[1-5]. Despite an extremely low turnover rate, ECs respond quickly to tissue stimuli and divide 
rapidly to turn on angiogenesis facilitating wound healing and tissue repair [1, 6]. Prolonged 
stimuli lead to excessive angiogenesis, which have been implicated in many pathological 
processes, such as inflammatory and autoimmune disorders, tumor growth and metastasis, 
ocular diseases, obesity, asthma, diabetes, bacterial infections and other conditions [1, 7]. Con-
versely, insufficient angiogenesis prevents revascularization and tissue regeneration, a condi-
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tion that is related to ischaemic diseases, cardiac failure, preeclampsia, Alzheimer’s disease [1]. 
To date, anti- and pro-angiogenic therapies have prominent roles in treatments of malignant 
diseases, myelodysplastic syndrome, and age-related macular degeneration [8]. With increasing 
in depth insights into how angiogenesis affects health and diseases, angiogenesis is considered 
as an important target that will enable us to combat a broad range of human diseases [7-11]. 
 
1.2 Angiogenesis is a Multi-step Process 
Under normal physiological conditions, angiogenesis is a complex multi-step process [3, 
5]. Wound, hypoxia, and inflammation are signals that activate angiogenesis. Vascular endo-
thelial growth factor (VEGF), also referred as VEGF-A, is a critical player for angiogenesis initia-
tion. In mature blood vessels, EC lining is surrounded by a mural capsule composed of base-
ment membrane and a layer of pericytes. VEGF increases vascular permeability, promotes ECs 
entering mitotic cycles, and leads to dissociation of pericytes [8, 12, 13]. Simultaneously, matrix 
metalloproteinases (MMPs) and other enzymes locally degrade the basement membrane and 
extracellular matrix (ECM), which allows ECs to disconnect with each other, change shapes and 
migrate toward the stimulus. Only ECs in the leading edges continuously proliferate, while ECs 
along the trail reattach to each other and form intact monolayer capillary tubes. Then different 
tubes are connected into loops. At last, blood flows into the newly formed vasculature and es-
tablishes circulation. In large blood vessels, fibroblasts and smooth-muscle like cells are also 
recruited to the nascent vessels to recoat them.   
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1.3 Angiogenesis Switch during Tumorigenesis 
In addition to serial genetic and epigenetic events, angiogenesis is a prerequisite for 
transformation of normal tissue into cancers [14, 15]. Several lines of evidence observed from 
transgenic animal models, human breast, cervical and skin cancers have demonstrated that an-
giogenesis switch is a critical rate limiting step for tumor malignancy and metastasis [5, 7, 14]. 
Virtually all cells in human tissue are situated within the range of 100 µm around blood vessels 
for adequate oxygen and nutrient supplies. Before neovascularization occurs, a stage defined as 
avascular phase, most solid tumors enter a dormant state and will not exceed 1 to 2 mm3 in size 
[16-18]. Inadequate access to vasculature leads to necrosis and/or apoptosis inside solid tu-
mors, therefore restrains them from continuously expanding despite the high proliferation 
rates of unaffected cancer cells [19] and reviewed in [5, 19, 20]. Exponential growth of tumors 
only occurs in the following vascular phase when new blood vessels are established [5, 18]. 
These principles also apply to metastatic tumors. 
Angiogenesis switch is controlled under the balance between pro- and anti-angiogenic 
factors (reviewed in [5, 21]). Once formed, vasculature quickly matures and is stabilized by en-
dogenous inhibitors. Interferon α/β (IFN-α/β) and platelet factor-4 (PF-4) are the first identified 
anti-angiogenic factors that inhibit ECs migration and proliferation [22-24]. Thrombospondin-1 
(TSP-1) is an endogenous anti-angiogenic protein secreted by platelets [25]. Notably, a variety 
of endogenous angiogenesis suppressors is released from extracellular matrix proteins by pro-
teolytic degradation to inhibit ECs migration and adhesion. For example, endostatin and angios-
tatin are fragments of type XVIII collagen and plasminogen, respectively [26, 27]. Dormant tu-
mor lesions have to adapt disparate methods to break through the avascular phase supervised 
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by all those known and unknown inhibitory mechanisms. In contrast, many growth factors and 
cytokines secreted or induced by tumor cells have been proven to promote angiogenesis. 
Among them, VEGFs and their receptors (VEGF/VEGFRs) are crucial stimulants that promote 
ECs proliferation and increase vessel permeability and remolding [28, 29] and reviewed in [28]. 
Integrins (especially intergrin αᵥβ3 and αᵥβ5), extracellular matrix metalloproteinases-3 and -9 
(MMP-3 and -9), angiopoietin-1 and -2 (Ang-1 and -2) and their receptor Tie2 are important 
regulators of angiogenesis [4, 29]. Besides, many growth factors and chemokines such as plate-
let-derived growth factor β (PDGF-B), epidermal growth factor (EGF), fibroblast growth factors 
(FGFs), and interleukin-6 and -8 (IL-6 and -8) also promote angiogenesis and their distinct me-
chanisms were reviewed by Wang and coworkers [11]. 
Depending on different origins and microenvironments, tumor cells adapt unique me-
chanisms to tip this balance in favor of switching on angiogenesis: either by silencing endogen-
ous anti-angiogenic proteins for example TSP-1 gene mutations, or secreting/inducing pro-
angiogenic factors such as growth factors and MMPs (reviewed in [5]). In many cases both are 
applied.   
 
1.4 Tumor Vasculature Morphology 
Tumor vasculature are formed by angiogenesis (sprouting for existing vessels), co-opting 
host vessels, and postnatal vasculogenesis (recruiting endothelial progenitors from bone mar-
row) (reviewed in [30]). A broken balance between negative and positive angiogenic factors in 
tumors results in a constant growth of new blood vessels, a condition described as “wounds 
that never heal” (reviewed in [31]). In the presence of excessively increased levels of VEGF, an-
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giopoietin-1 and -2, and other pro-angiogenic stimulants, newly formed tumor vessels are 
structurally and functionally abnormal: (i) they are often dilated and leaky as a consequence of 
missing cell-cell adhesion junctions between ECs with discontinuous basement membranes [12, 
32-34]; (ii) vessels are also disorganized with tortuous paths, haemorrhages, dead ends, and 
without a clear hierarchy of arterioles, venules and capillaries [15]; (iii)  cancer cells occasionally 
integrate into the vessel walls (reviewed in [35]); (iiii) structural abnormalities along with com-
pression from proliferating cancer cells contribute to heterogeneous and insufficient blood 
flows [34].  
 
1.5 Molecular Pathways of Tumor Angiogenesis  
1.5.1 VEGF Signaling Pathways  
VEGFs and their receptors are the most important mediators of angiogenesis. In 1983, 
Serger and coworkers first reported a vascular permeability factor (VPF) secreted by a tumor 
cell line significantly increases vascular permeability [12]. Later on, its cDNA sequence proved 
that it is the same protein as VEGF (or VEGF-A) isolated by Ferrara et al in 1989 [36]. So far, five 
other glycoproteins are identified to be products of the VEGF gene family members, including 
VEGF-B, C (also known as c-fos-induced growth factor, FIGF), D, E, and placental-induced 
growth factor (PIGF, also referred as PGF) [37-39].  Among them, VEGF is the most potent EC-
specific mitogen that promotes both physiological and pathological angiogenesis. VEGF strongly 
induces angiogenesis in vitro and in vivo [40-42]. Studies in transgenic mice embryonic studies 
show that loss of a single VEGF allele is lethal accompanied with severe abnormalities in angi-
ogenesis and blood vessel formation [43].  
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The VEGF gene (vegf) located in chromosome 6 is formed by eight exons and seven in-
trons [44-46]. Exon 7 codes for an Arginine (Arg) and Lysine (Lys) enriched c-terminal motif, 
meanwhile exon 6 is translated into a 24 amino acids long insertion that is also highly positively 
charged [44]. Alternative splicing of exons 6 and 7 generates different length of isoforms with 
or without the binding ability to the highly negatively charged glycosaminoglycans (GAGs) (he-
parin, for example) and ECM. So far, the identified isoforms mainly are VEGF121, VEGF145, 
VEGF148, VEGF165, , VEGF183, VEGF189 and VEGF206 [44, 47-49]. The diversity of those isoforms is 
believed to mediate the biological function and tissue specificities of VEGF [50-52]. VEGF165 is 
the predominant and most characterized VEGF isoform. Many studies have demonstrated that 
VEGF165 is responsible for specific receptor binding and VEGF bio-functions [51-57]. With the 
basic motif coded by exon 7, 50-70% secreted VEGF-A165 binds to ECM creating an extracellular 
VEGF storage pool [51]. Plasminogen, an extracellular protease and MMPs, especially MMP-3 
and -9, can cleave VEGF165 and VEGF189, which produces shorter VEGF fragments that are active 
and diffusible [29, 54]. During tumor angiogenesis, degradation of ECM and proteolytic clea-
vage of VEGF-A have been considered as two important mechanisms that upregulate VEGF sig-
naling pathways by releasing sequestered VEGF [29, 54].  
Two tyrosine kinase receptors can be recognized by VEGF: VEGFR-1 (also known as Flt-1) 
and VEGFR-2 (also known as Flk-1 or KDR) [58, 59]. Although VEGFR-1 has 10-fold higher bind-
ing affinity than VEGFR-2 does, VEGFR-2 is the major receptor for VEGF angiogenic signaling 
[60-62]. Certain tumor types and ECs also express Neuropilin-1 (NPR-1) as co-receptor that en-
hances the binding of VEGF165 to its receptor VEGFR-2 [63]. The protease cleaved VEGF isoforms 
without the c-terminal basic motif encoded by exon 7 cannot bind to NPR-1, thus do not have 
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the enhancement effect. The 40 -kDaa glycoprotein VEGF binds to VEGFR-2 in a homodimeric 
form. Upon ligand binding, VEGFR-2 undergoes conformational changes and dimerization, 
which activates its receptor tyrosine kinase (RTK) activity that leads to receptor autophosphory-
lation followed by a cascade of downstream signaling [64, 65].  VEGF strongly stimulates proli-
feration of ECs from arteries, veins and lymphatics via activation of the protein kinase c (PKC) 
and Raf-Mek-Erk pathway [66]. It also protects ECs from apoptosis by inducing the expression 
level of anti-apoptotic proteins, suppressing pro-apoptotic proteins such as p53, p21, Bax, and 
up-regulating the phosphatidylinositol-3’ kinase (PI3K)-Akt signaling pathway [40, 67]. VEGF po-
tently enhances vascular permeability by rearranging and loosing cell adhesion junctions be-
tween ECs [68]. VEGF also promotes ECs migration by enhancing the expression of urokinase- 
and tissue-type plasminogen activator (uPA and tPA) in ECs [69, 70]. Both uPA and tPA convert 
plasminogen to its active form plasmin. The proteolytic activity of plasmin degrades ECM com-
ponents paving the way for ECs migration and vessel remodeling.  In addition, VEGF also mobi-
lizes bone marrow-derived (BM) endothelial progenitor cells (EPCs) to promote postnatal vascu-
logenesis in different types of tumors [71-73]. 
Other VEGFs and VEGFRs have their distinct biological functions. VEGF-B and PIGF selec-
tively bind to VEGFR-1, but not other VEGFRs [74, 75]. VEGFR-1 does not have established role 
in angiogenesis yet. Early studies show that VEGFR1 may function as a “decoy” receptor for 
VEGFR-2 that negatively regulates its function by reducing its ligand binding. Recent studies 
suggest a role of VEGFR-1 in pathological angiogenesis like tumor metastasis via activation of 
MMP-9 [76, 77]. A more recent study draws a contrary conclusion on inhibition of VEGFR-1 as a 
valid target to reduce spontaneous metastasis in mouse models [78]. VEGF-C and -D mainly 
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recognize VEGFR-3 (also known as Flt-4) and mediate lymphangiogenesis. VEGF-C and -D also 
bind to VEGFR-2 after protease cleavage [38, 79].  
 
1.5.2 Angiopoietins 
In addition to VEGF/VEFGR, early studies also demonstrated that Angiopoietin-1 and -2 
(Ang-1 and -2) and their receptor Tie-2 (also known as Tek) also have crucial roles in mediating 
angiogenesis [80-82]. Tie-2 is an RTK expressed in the surfaces of ECs, smooth muscle, fibroblast 
and some immune cells [83, 84]. Ang-1 is the primary agonist of Tie-2. Unlike VEGF, Ang-1 alone 
does not induce in vitro angiogenic effects [83]. Transgenic mouse embryos that lack Ang-1 or 
Tie-2 developed relatively normal vasculature, but eventually died at late stage due to defects 
in blood vessel remodeling [83]. The physiological roles of Ang-1 lay in recruiting pericytes and 
mediating the interactions between ECs and their surrounding environment, stabilizing the 
newly formed blood vessels [85].  Ang-1 also prevents blood vessel leakage countering the po-
tent permeable effect of VEGF [86]. Ang-2, however, has a rather complex role in angiogenesis. 
It functions partially as an antagonist to Tie-2, which promotes ECs detachment from smooth 
muscle cells and ECM [81, 87].  The destabilization effect of Ang-2 either leads to vessel regres-
sion, or increases in EC sprouting under excessive level of VEGF-A and other growth factors [88, 
89]. The ratio of Ang-1/Ang-2 can function as a check-point for tumorigenesis. Recent studies 
show that elevated Ang-2 expression levels correlate with poor prognosis in patients with tu-
mors [90-92]. Furthermore, specific inhibition of Ang-2 reduces tumor growth in xenograft 
models [93, 94].  
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1.5.3 Fibroblast Growth Factor 
In an early review, Folkman and a coworker pointed out that many EC growth factors 
have strong affinity to heparin [95]. The acid fibroblast growth factor (aFGF/FGF-1) and basic 
fibroblast growth factor (bFGF/FGF-2) are among the first identified angiogenic growth factors 
that separated by heparin-affinity chromatography. As suggested by a review of this family, 
there are more than 20 different FGF isoforms that bind to four different types of FGF receptors 
(FGFRs) regulate a range of physiological and pathological functions such as organ develop-
ment, neurogenesis, angiogenesis, and cancer growth (reviewed in [96]). In addition to receptor 
binding, the interaction between FGFs to cell-surface associated heparan sulfate proteoglycans 
plays an important role in transduction of FGFs signaling. FGF1 and -2 have similar angiogenic 
functions as VEGF-A during tumorigenesis (reviewed in [96, 97]). Both FGF-1 and -2 promote EC 
proliferation and migration. Up-regulation of FGF-2 protects ECs from apoptotic stimuli via dis-
tinct mechanisms such as expression of Bcl-XL and Bcl-2, or activation of Raf-1 [98, 99].  FGF-1 
and -2 facilitate blood vessel remodeling through mediation of uPA, MMPs, and collagenase 
[11, 97, 100].  FGF-2 also indirectly promotes angiogenesis by increasing VEGF and VEGFR ex-
pression level in ECs (reviewed in [97]). Although studies using monoclonal antibodies that neu-
tralize FGF-2 did not produce anti-tumor effect, a recent study has shown that up-regulation of 
FGF signaling is one of the possible causes for resistance of anti-VEGFR2 tumor treatment in 
RIP-Tag mouse model [101, 102].  
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1.5.4 Platelet-derived Growth Factor  
Platelet-derived growth factor (PDGF) family and their receptors (PDGFR-α and PDGF-β) 
share great structural and amino-acid sequence similarity with that of the VEGF/VEGFR family 
(reviewed in [103]). PGDF was initially found to be released into circulation from α-granules in 
platelets but subsequent studies show that fibroblasts, ECs, osteoblasts, and many other cell 
types also secret PDGF (reviewed in [97, 103]). There are four individual PDGF polypeptide 
chains encoded by different genes:  PGDF-A, -B, -C, and D. Homo- or hetero-dimerization be-
tween those polypeptide chains produces five active isoforms, including PDGF-AA, BB, AB, CC, 
and DD (reviewed in [103]). Hoch and workers suggested that formation of the heterodimeric 
PDGF-AB is rare in vivo and without clear known biological significance [104]. PDGFs isoforms 
initiate signaling pathways via binding to the two RTKs (PDGFR-α and –β); for example, PDGF-
AA activates PDGFRα, whereas PDGF-BB mainly activates PDGFR-β. PDGFs play essential roles in 
organogenesis during embryonic development, but they are expressed in low levels under nor-
mal physiological conditions in adults (reviewed in [103]). Similar to other growth factors, all 
four homodimeric PDGFs promote carcinogenesis via activation of a variety of cellular signaling 
molecules such as Ras, PI3K, phospholipase C-γ (PLC-γ),  and Akt (reviewed in [103, 105]). The 
PDGF-BB/PDGFR-β signaling is one of the major regulatory molecules of angiogenesis. PDGF-BB 
is mainly expressed in ECs and neurons, while PDGFR-β is expressed in vascular smooth muscle 
cells and pericytes (reviewed in [103]). PDGF-BB and PDGFR-β knockout mice died prenatally 
with widespread hemorrhage and edema as consequences of vascular pericytes losses, suggest-
ing the crucial role of PDGF-BB/PDGFR-β in recruiting vascular pericytes and promoting blood 
vessel maturation [106]. PDGFs also contribute to tumor growth and angiogenesis also by re-
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cruiting either PDGFR-β+ or PDGFR-α+ fibroblasts to tumor stroma [107-109]. PDGF-BB also in-
duces ECs to secret VEGF and successively stimulates tumor angiogenesis [110, 111]. Several 
lines of evidences have demonstrated that inhibition of PDGF/PDGFR signaling pathways are 
potential avenues to inhibit tumor angiogenesis [112-115]. In addition, Suzuki and colleagues 
suggested that PDGF-B may have more dominant role than VEGF does in the maintenance of 
angiogenesis in certain types of gastric carcinomas. Therefore stratified anti-angiogenic reme-
dies may favor the overall survival rate in patients with gastric cancer [114].    
 
1.5.5 Other Growth Factor Signal Pathways  
Besides the above described signaling pathways, many other growth factors have been 
demonstrated to promote angiogenesis via different mechanisms (reviewed in [11, 97, 116]). 
Both epidermal growth factor (EGF) and transforming growth factor-α (TGF-α) promote angi-
ogenesis via epidermal growth factor receptor (EGFR). EGF signaling and EGFR inhibitors will be 
introduced in 1.7.2.2. Although transforming growth factor-β (TGF-β) family is reported to have 
multiple physiological functions including angiogenesis, the roles in angiogenesis is context-
dependent with both anti- and pro-angiogenic effects documented. By switching downstream 
signaling transduction pathways in different cell types, TGF-β may prevent angiogenesis in early 
stage of tumorigenesis, while becoming pro-angiogenic as cancer progresses into late stages 
when the growth factor is usually expressed at high levels ( reviewed in [117, 118]). Recent stu-
dies have demonstrated that inhibition of TGF-β by different methods reduces tumor angioge-
nesis and tumor growth (reviewed in [117, 119]).     
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1.5.6 Integrins 
Integrins are a group of transmembrane glycoproteins that regulate cell adhesion, mo-
bility and survival.  Integrins are heterodimers composed of distinct α and β chains [120]. Dif-
ferent combinations between 18 α-subunits and 8 β-subunits by non-covalent interactions gen-
erate 24 mammalian integrins (reviewed in [120, 121]). The αv and α5β1 integrins are receptors 
for a variety of ECM components, such as fibrinogen (αvβ3, α5β1), fibronectin (αvβ3, α5β1), 
osteopontin (αvβ3), and activated vitronectin (αvβ3, αvβ5). A conserved tripeptide sequence, 
Arg-Gly-Asp (RGD), is displayed in those ECM proteins, and is required for the ligand-receptor 
reorganization. Integrin αvβ3, αvβ5 and α5β1 have roles in tumor angiogenesis. They are not 
expressed or expressed in low levels in normal tissues, but induced or up-regulated in a wide 
range of tumor types, particularly in tumor ECs [122, 123]. Studies have shown that integrins 
crosstalk with specific growth factors that are crucial for tumor angiogenesis. For example, 
blockage of integrin αvβ3 abolishes the angiogenic effects of TNF-α and bFGF, whereas integrin 
αvβ5 is required for the effects of TGF-α and VEGF on angiogenesis [124]. Different antagonists 
targeting αvβ3, αvβ5 and α5β1, including monoclonal antibodies, RGD mimetic peptides, non-
peptide compounds and antisense RNAs, have shown significant anti-angiogenic and anti-tumor 
effects by inhibiting tumor cell and EC growth (reviewed in [120]). Many of them are under clin-
ical trials for treatment of patients with different types of cancers. Integrins and RGD mimetic 
peptides are also under extensive investigations as targeting moieties for tumor imaging and 
drug delivery (reviewed in [125]).  
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1.5.7 Matrix Metalloproteinase  
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases with a broad 
spectrum of activities which control ECM remolding by degrading all known EC proteins (re-
viewed in [126]). A total of 23 human MMPs have been characterized as either secreted MMPs 
or transmembrane-type MMPs (MT-MMPs) that together regulate tissue remodeling, organ 
development, inflammatory processes, and pathological conditions such as cancer (reviewed in 
[127]). MMPs are not or expressed in low levels in quiescent ECs, but are strongly induced and 
activated during pathological angiogenesis such as tumor and inflammation (reviewed in [126]). 
Depending on their expression patterns and availability of substrates, MMPs tightly regulate 
tumor angiogenesis by exerting dual functional effects (reviewed in [127, 128]).  On one hand, 
MMPs, particularly MMP-2, MMP-9 and MMP-14, are essential for the formation of tumor vas-
culature as they degrade ECM, which clears the way for EC migration and also proteolytically 
activates angiogenic factors (reviewed in [128]). MMP-9 serves as an example; in addition to 
degradation of ECM components, it potently accelerates the angiogenic switch by releasing 
ECM-bound VEGF isoforms to activate VEGFR-2 [129]. MMP-9 also catalytically induces the ac-
tivation of TGF-β and bFGF-2 signaling pathways [130, 131]. On the other hand, MMPs cleave 
ECM proteins to generate a diverse range of endogenous protein fragments to block active an-
giogenesis. For example, MMPs cleave type IV, XVII collagen, plasminogen and perlecan, which 
respectively produce tumstatin, endostatin, angiostatin and endorepellin that strongly inhibitor 
tumor angiogenesis (reviewed in [128]).  
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1.6 Tumor Angiogenesis as a Therapeutic Target  
In 1971, Dr. Judah Folkman first proposed “anti-angiogenesis” as a tumor therapy given 
the fact that tumor growth depends largely on new vasculature formation [16]. This hypothesis 
has greatly driven an enthusiastic wave of pursuing therapeutic angiogenesis inhibitors as effec-
tive cancer therapies. In past three decades, a great body of knowledge regarding mechanisms 
of angiogenesis has been gained as a result of studying tumor angiogenesis. In 2004, avastin 
(also known as bevacizumab, Genentech Inc.) became the first U.S. Food and Drug Administra-
tion (FDA) approved anti-angiogenic drug by for the treatment of advanced colorectal cancer, 
which opened a new era for targeting tumor vasculature as an anti-cancer therapy. 
Back in 2004, anti-angiogenic therapy was predicted as “the fourth modality” for cancer 
treatment. Compared to traditional chemotherapy, radiotherapy, and surgery, it has several 
clinical advantages. Firstly, anti-angiogenic therapies mainly target the proliferating ECs, thus 
they are less likely to lead to side effects related to inhibition of actively dividing cells, such as 
bone marrow suppression, gastrointestinal (GI) disturbances, and hair loss. Secondly, clinical 
data clearly show that anti-angiogenic reagents significantly lower the dose ranges of cytotoxic 
and radioactive cancer therapies, thus reduces side effects among cancer patients [132-134]. 
Thirdly, data support that anti-angiogenic therapies also normalize tumor vasculature and pro-
mote drug delivery (reviewed in [135]). Lastly, a broad spectrum of malignant and benign tu-
mors can be treated because angiogenesis is a universal mechanism for tumorigenesis and me-
tastasis (reviewed in [136]).     
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1.7 Overview of Anti-angiogenic Reagents in Cancer Therapy 
1.7.1 VEGF and VEGFR inhibitors 
Current development of anti-angiogenic therapies for cancer treatment is heavily fo-
cused on inhibition of VEGF/VEGFR signaling pathway. Several inhibitors targeting this pathway 
have been developed into clinical usage including the humanized anti-VEGF monoclonal anti-
body, Bevacizumab, and small molecular inhibitors such as Sunitinib (Sutent®) and Sorafenib 
(Nexavar®). 
 
1.7.1.1 Monoclonal Antibodies    
1.7.1.1.1 Bevacizumab  
 Bevacizumab (rhuMab A.4.6.1, Avastin; Roche)  is the first U. S. FDA approved anti-
cancer drug that specifically target angiogenesis. Bevacizumab neutralizes all VEGF isoforms 
preventing their activation of VEGFR-2. In 1993, Kim and coworkers first demonstrated that 
blockage of VEGF signaling pathway by the murine precursor of bevacizumab (muMab A.4.6.1 ) 
sufficiently suppressed different types of human cancers implanted in immunodeficient mice 
[137].  Later studies show that bevacizumab has the same in vitro and in vivo anti-angiogenic 
effects as Mab A.4.6.1 [138]. A final three armed phase III clinical trial led to the approval of be-
vacizumab in combination of 5-fluorouracil (FU)/leucovorin (LV) as the first-line therapy for pa-
tients with previously untreated metastatic colorectal cancer [132]. Bevacizumab is also ap-
proved to treat nonsquamous non-small-cell lung cancer (NSCLC), glioblastoma, and renal cell 
carcinoma (RCC). Its application for treatment of metastatic HER-2 negative breast cancer is 
under FDA repeal process. 
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1.7.1.1.2 VEGF Trap 
        Soluble VEGF traps represent another approach to specifically inhibit VEGFR signal-
ing pathway. Aflibercept (Regeneron and Sanofi-Aventis) is a recombinant protein created by 
fusion of the Fc fragment of human IgG1 with both the extracellular domains of VEGFR1 and 
VEGFR2 [139]. In contrast to the VEGF neutralizer, bevacizumab, aflibercept has three major 
differences. First, it acts as a soluble VEGF receptor that traps all three types of VEGFs (VEGF, 
VEGF-B, and PIGF). Second, the binding affinity of aflibercept to VEGF is greatly enhanced with a 
Kd value around 1 pM compared to 800 pM of bevacizumab [139]. Third, it has improved phar-
macokinetic behavior with prolonged circulating half-life [139]. It shows potent anti-tumor ac-
tivities in a number of pre-clinical animal models, such as pancreatic carcinomas, neuroblasto-
ma, and human ovarian cancer [140-142]. In pre-clinical animal models, aflibercept not only 
inhibits formation of new blood vessels, but also promotes vascular remodeling and regression 
of pre-existing vasculatures [139, 143-145]. Similar to bevacizumab as a single-agent, in a num-
ber of phase II clinical trials, treatment with aflibercept in patients with recurrent or metastatic 
urothelial cancer, pretreated lung adenocarcinoma, and recurrent malignant glioma have 
showed minimal response rates [146-148]. As reported by Regeneron and Sanofi-Aventis in 
2011, aflibercept in combination with chemotherapy achieved positive results in phase III clini-
cal trial in patients with metastatic CRC, but failed to improve overall survival rate when it was 
combined with docetaxel to treat patients with NSCLC (www.genengnews.com and company 
report). An aflibercept ophthalmic solution (Eylea) has been approved by FDA for treatment of 
age-related macular degeneration. 
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1.7.1.1.3 VEGF Intraceptor 
 Intracellular disruption of VEGF secretion is a novel method to inhibit tumor angi-
ogenesis. A C-terminal KDEL (Lys-Asp-Glu-Leu) motif is an endoplasmic reticulum (ER) retention 
signal for ER-resident proteins [149]. Flt23k plasmid was designed by Singh and colleagues as an 
anti-angiogenic gene therapy [150]. It encodes Flt23k, a recombinant protein composed of do-
main 2 and 3 (VEGF binding domains) of VEGFR1 coupled with KDEL. Intracellulary expressed 
Flt23k binds VEGF in ER, and prevents its secretion, which will down-regulate VEGF signaling. 
Intrastromal injection of Flt23k plasmid sufficiently inhibits injury-induced corneal neovasculari-
zation in a marine model [150]. Nanoparticles have been used to delivery Flt23k plasmid and 
increase its expression duration [151]. A dual targeting tumor endothelium by nanoparticles 
carrying RGD (Arg-Gly-Asp) peptide and Flt23k plasmid has further enhanced its effects in vivo 
[152]. Compared to antibodies, it represents a novel approach to sequester VEGF from VEGFR. 
 
1.7.1.1.4 Other VEGF Antibodies 
 Many other monoclonal antibodies are under clinical development. CDP791 (UCB 
Pharma) and IMC-1121B (ImClone Systems Inc) are VEGFR-2 antibodies that under phase II and 
phase III clinical trials (reviewed in [153]). In addition to aflibercept, pegaptanib sodium (Macu-
gen®, Eyetech Pharmceuticals), a VEGF aptamer and ranibizumab (Lucentis®, Roche), an anti-
body fragment have been approved by FDA for the treatment of age-related macular degenera-
tion [154, 155].  
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1.7.1.2 Small-molecule VEGFR Inhibitors  
 Sunitinib (SU11248, Sutent®; Pfizer) and Sorafenib (Bay-43-9006, Nexavar®; Bay-
er/Onyx) are small-molecule tyrosine kinase inhibitors (TKIs) that prevent phosphorylation of 
RTKs by targeting their intracellular ATP-binding pockets. Functioning as ATP analogues, TKIs 
usually have multiple targets by competitively binding to the ATP-binding pockets of different 
RTKs. They  are considered “selectively” but not specifically as inhibitors of VEGF signaling 
pathways, so their anti-tumor effects are complex rather than just suppression of tumor angi-
ogenesis alone (reviewed in [153]). Sunitinib blocks signal transduction from a variety of RTKs 
including all three types of VEGFR, colony stimulation factor receptor type 1 receptor, Fms-like 
tyrosine kinase 3 (FLK-3), PDGF-α and –β, glial cell line-derived neurotrophic factor receptor 
(RET), and stem cell receptor (KIT) (reviewed in [156]). Beside inhibition of angiogenesis in-
duced by PDGF-β and VEGFR-2, sunitinib also represses tumor cell proliferation. Sunitinib is ap-
proved to treat imatinib (ST11571, Gleevec; Novartis)-resistant gastrointestinal stromal tumor 
(GIST), RCC, NSCLC, and thyroid cancer (reviewed in [156-159]). Different from bevacizumab, 
sunitinib is used as a stand-alone therapy for RCC and GIST. Sorafenib is a Raf-1 (a se-
rine/thereonine protein kinase belong to RAF kinase family) inhibitor that blocks the Raf-Mek-
Erk MAPK signaling pathway [160]. The anti-angiogenesis and anti-tumor effects of sorafenib 
are mainly involved in VEGFR-2 and -3, PDGF-β, Flt-3, and c-kit inhibition. Sorafenib is approved 
by U.S. FDA as an anti-cancer therapy for advanced RCC and unresectable hepatocellular carci-
noma (HCC) (reviewed in [161]).  
 Many other small-molecule TKIs inhibit the VEGFR, EGFR, PDGFR, RET, and c-kit sig-
naling pathways are under clinical development (reviewed in [153]). Some successful examples 
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are axitinib (Pfizer), motesanib (Amgen), cediranib (AstraZeneca), and vandetanib (AstraXene-
ca).  
 
1.7.2 Other Reagents that Inhibit Angiogenesis 
1.7.2.1 Mammalian Target of Rapamycin (mTOR) Inhibitors  
 Temsirolimus (CCI-779, Torisel®; Wyeth) is an mTOR inhibitor derived from rapamy-
cin. mTOR is a serine/threonine kinase that controls cell growth, proliferation, and response to 
hypoxic stress by regulating ribosome function and tRNA synthesis. In addition to anti-tumor 
effects, temsirolimus prevents tumor angiogenesis through the down-regulation of hypoxia-
inducible factor-1α (HIF-1α) induced VEGF synthesis in cancer cells and direct inhibition of EC 
proliferation (reviewed in [162]). Temsirolimus is used for the treatment of patients with ad-
vanced RCC [163]. 
 
1.7.2.2 Epidermal Growth Factor Receptor Inhibitors  
 Several lines evidence have shown that anti-angiogenesis is part of the tumor sup-
pressive mechanisms of EGFR inhibitors (reviewed in [164]).  First, EGFRs and their two major 
ligands, EGF and TGF-α, potently activate proliferation and survival pathways in ECs (reviewed 
in [97]).  Secondly, EGFR signaling also increases the secretion of VEGF and a series of other an-
giogenic factors [165, 166]. Furthermore, VEGFRs and EGFRs activate common pathways such 
as MAPK and PI3K [167]. Therefore, treatments of cancer patients with EGFR inhibitors can also 
be considered as anti-angiogenic therapies. The main category of EGFR inhibitors are monoc-
lonal antibodies such as trastuzumab (Herceptin; Roche), panitumumab (Vectibix; Amgen) , and 
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cetuximab (Erbitux; Bristol-Myers Squibb and Imclone). Other are small-molecule TKIs, for ex-
ample erlotinib (Tarveca, Roche). 
 
1.7.2.3 Immuno-modulatory Agents and Others  
 Thalidomide (Thalomid; Celgene) and its derivative lenalidomide (Revlimid; Cel-
gene), interferon (IFN-α) and IL-12 are immuno-modulatory agents that have anti-inflammatory 
and anti-angiogenesis effects [153, 168, 169]. Their angiogenic inhibitory mechanisms are not 
clear yet. Some research links them with regulation VEGF expression (reviewed in [153]). Thali-
domide in combination of dexamethasone is approved for treatment of multiple myeloma.  
  
1.8 Pitfalls for Using Current Anti-angiogenesis 
 After bevacizumab was approved by FDA, anti-angiogenic therapy has quickly inte-
grated into traditional anti-cancer treatments. In contrast to the fact that angiogenesis is an ef-
fective and low toxicity target for a broad range of solid tumors and non-malignant diseases, 
three decades of numerous pre- and clinical studies only provide us with a handful of anti-
angiogenesis reagents that approved by FDA for clinical usage. Among them, as introduced 
above, most are monoclonal antibodies or small molecular TKIs that specifically or selectively 
block VEGF/VEGFR and other pro-angiogenic signaling pathways. As suggested by clinical data 
compiled within past several years of experience with this novel anti-cancer strategy, several 
drawbacks of currently available anti-angiogenic reagents have clearly emerged.  
 First, no matter VEGF/VEGFR, EGF/EGFR or other growth factors that promote an-
giogenesis, all are widely expressed in various normal tissues with diverse physiological roles. 
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Inhibition of those signaling pathways yields adverse effects. Inhibition of VEGF/VEGFR was in-
itially assumed to only block developmental and pathological angiogenesis sparing ECs in nor-
mal tissues (reviewed in [170]). Interference with wound healing is a common risk related to 
angiogenesis inhibition; however, other systematic adverse events have become evident with 
VEGF/VEGFR inhibitors treatment. Since profound cardiovascular side effects were associated 
with administration of VEGF/VEGFR inhibitors, more and more studies have demonstrated that 
VEGF is essential in maintaining normal cardiovascular function (reviewed in [171]). VEGF in-
duces endothelial type nitric oxide (NO) and prostacyclin (PGI2) in endothelium, which are es-
sential for endothelial-dependent vasodilation in coronary arteries [172-174]. Lee and col-
leagues also show that autocrine of VEGF is required for EC survival and blockage of this signal-
ing pathway by small molecule kinase inhibitors results in increased ECs apoptosis in normal 
tissues, and subsequent rarefaction in small arteries and arterioles [175]. VEGF/VEGFR inhibi-
tors also increase arterial stiffness possibly by interaction with endothelin, a vasoconstrictor 
[176, 177]. Therefore, hypertension is the most common side effects associate with 
VEGF/VEGFR inhibitors due to defects in vessel vasodilation, rarefaction and increase in vessel 
stiffness (reviewed in [171]). From 11 to 32% of patients under bevacizumab treatment have 
been reported to experience elevated blood pressure (reviewed in [178]). Around half of those 
who develop to hypertension require pharmacologic interventions. The incidence of hyperten-
sion with VEGF TKIs treatment is about 15% to 60% (reviewed in [171]). Data have also shown a 
tendency of increasing in incidents of hypertension when patients are treated with higher po-
tency TKIs (reviewed in [171]). More serious cardiac side effects, such as myocardial infarction 
(MI) and congestive heart failure, and bevacizumab treatment-related deaths during clinical 
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trials have been reported (reviewed in [178]). Those events may be related to microvascular 
rarefaction upon VEGF inhibition. Outside the cardiovascular system, VEGF is also plays impor-
tant roles in maintaining mucosal homeostasis, platelet function, and neuron protection, so 
that bleeding, gastrointestinal perforation, thromboembolism, voice change, upper and lower 
digestive tract mucositis, and neurological complications are also reported with inhibition of 
VEGF/VEGFR (reviewed in [179]). VEGF is expressed in normal renal cortex and mediates glo-
merular inflammation and repair, which is possible reason that bevacizumab and VEGFR TKIs 
treatments are associated with proteinuria and oedema [170, 180]. Small molecular TKIs inhi-
bits many other receptors other than VEGFR, and therefore are accompanied by more compli-
cations other just inhibition of VEGF signaling pathway alone.  
 Resistance to VEGF/VEGFR inhibitors has been observed in preclinical and clinical 
studies. Bergers and coworkers developed a two-mode theory to explain the phenomena (re-
viewed in [181]). In general, there are two outcomes after treatment with VEGF/VEGFR inhibi-
tors, either initial disease regression followed by restoration of tumor growth (referred as “eva-
sive resistance”), or no beneficial effects in tumor inhibition (referred as “intrinsic resistance”). 
Among many possible mechanisms responsible for these two types of drug resistance, up-
regulation of alternative pro-angiogenic signaling pathways play essential roles. Ferrara pointed 
out that other signaling pathways mediating VEGF-independent tumor angiogenesis exist in var-
ious types of preclinical and clinical tumor models (reviewed in [182]). Treatments with VEGFR 
inhibitors in cancer patients are reportedly increase circulating pro-angiogenic growth factors 
such as FGF and PIGF. In some cases, FGF leads to a new wave of revascularization that enables 
tumor to escape treatment with VEGFR inhibitors. Tumors that intrinsically resist treatment 
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with VEGF/VEGFR inhibitors may due to pre-existing redundant pro-angiogenic signals. For ex-
ample, in early stage of human breast cancer biopsies VEGF is the major pro-angiogenic signal, 
but in late stage FGF and other growth factors become dominant. Recently, FDA is considering 
withdrawal of bevacizumab from breast cancer treatment due to adverse effects and contro-
versial benefits in patient survival rates.   
At last, large efforts have been made to overcome the resistance to VEGF/VEGFR inhibi-
tors, such as developing multi-targeting TKIs and combinatory therapy with reagents that target 
parallel pro-angiogenic signaling pathways. Selective TKIs usually cause more side effects due to 
off-target inhibitory effects. In addition, they may not necessarily increase clinical efficacy as 
expected. For example, a phase 3 clinical trial showed that axitinib (AG013736; Pfizer), a potent 
selective inhibitor of VEGFR-1, 2, and 3, cKIT and PDGFR does not improve overall survival in 
advanced pancreatic cancer when it is combined with gemcitabine [183]. Both VEGF and EGFR 
are over-expressed in advanced NSCLC, colorectal carcinoma, RCC and many other solid can-
cers. Although VEGF and VEGFR are considered valuable therapeutic targets for NSCLC treat-
ment, the introduction of monoclonal antibodies (mAbs) that target either of these two signal-
ing pathways have marginally increased survival rates in certain types of cancer, for example in 
advanced NSCLC patients eligible for these agents (reviewed in [184]). Several clinical trials 
demonstrated that even the combination of bevacizumab with anti-EGFR inhibitors produces 
controversial benefits (reviewed in [185]). Many preclinical models showed promising effects 
when VEGF/VEGFR inhibitors are combined with other pro-angiogenic inhibitors targeting 
PDGF, mTOR and FGF, but their efficacies require further clinical investigation [102, 186, 187]. 
Hence, resistance to VEGR/VEGFR inhibitors may not be solved simply by blocking multiple pro-
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angiogenic signaling pathways, which urges the development of agents with novel anti-
angiogenic mechanisms that will further validate angiogenesis as a therapeutic target. 
 
1.9 Endogenous Angiogenesis Inhibitors and their Therapeutic Implications 
 As discussed above, current anti-angiogenic therapies for cancer have highly fo-
cused on inhibition of VEGF/VEGFR and other pro-angiogenic growth factors. Since most 
growth factors function in a wide range of physiological processes or distributed outside the 
endothelium, this approach brings drug resistance and unnecessary sides effects. Furthermore, 
collective clinical evidence has shown that tumor cells develop drug resistance to those thera-
pies by producing multiple redundant angiogenic growth factors. Recent advances in identifica-
tion of endogenous angiogenesis inhibitors shed light on development of low toxicity, EC-
specific protein agents with a broad spectrum of angiogenesis targets.  
 In 1989, Bouck and coworkers first demonstrated that tumor angiogenesis is a re-
sult of a shift in balance between pro- and anti-angiogenic factors in a tumor (reviewed in 
[188]). Based on this study, Dr. J. Folkman proposed the angiogenesis switch theory and in-
itiated diligent efforts to discover endogenous angiogenesis inhibitors (reviewed in [189]). From 
1980 to 2003, his laboratory reported 11 angiogenesis inhibitors with 5 of them being novel 
molecules. To date, many endogenous angiogenesis inhibitors are documented. Those mole-
cules can be roughly divided into two major categories, matrix-derived and non-matrix-derived 
endogenous inhibitors (reviewed in [21]). Most of them are matrix-derived proteins, such as 
thrombospondin-1 (TSP-1), endostatin, and protein fragments derived from collagens and fi-
bronectins. The non-matrix-derived endogenous inhibitors are compromised of growth factor, 
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cytokines, and fragments of blood coagulation factors such as platelet factor-4, ILs, interferons 
(INFs), and angiostatin. Other endogenous inhibitors could not be classified into either above, 
for example tissue inhibitors of metalloproteinases (TIMs) and 16-kDa prolactin fragment.  
 
1.9.1 Matrix-Derived Endogenous Inhibitors of Angiogenesis  
1.9.1.1 Endostatin  
 As one of the first documented ECM-derived endogenous angiogenesis inhibitors, 
endostatin is the only clinically approved therapeutic agent in this category. In comparison with 
VEGF/VEGFR inhibitors, endostatin has low toxicity and EC-specific angiogenesis inhibition with 
a broad spectrum of anti-angiogenic targets. Instead of blocking specific signaling pathways, 
microarrays studies suggested that endostatin affects about 10% of the genes in human micro-
vascular ECs genome. In September 2005, Chinese State FDA approved the human recombinant 
endostatin (Endostar®) for the treatment of NSCLS [190]. Endostatin was initially separated 
from the urine of tumor-bearing mice by O’Reilly and colleagues in Dr. Judah Folkman’s labora-
tory [26]. This discovery was inspired by Dr. Judah Folkman’s hypothesis that certain primary 
tumors release angiogenesis inhibitors to suppress remote metastases (reviewed in [7]). The 
same theory also led to the earlier discovery of angiostatin ( a plasminogen fragment ) [191].  
The 20-kDa endostatin is a proteolytic fragement from C-terminal NC1 domain of colla-
gen XVIII cleaved by elastase or by cathepsin-L [26, 192-195]. The initial purified endostatin was 
not soluble, but showed dramatic tumor inhibitory effects when the protein pellets were in-
jected subcutaneously into mice on daily bases [26]. Hundreds of literatures demonstrated that 
endostatin inhibits more than 20 different types of murine and human tumors with tumor re-
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sponse rates from 47% to 91% at doses from 10mg/kg to 100 mg/kg/day  (reviewed in [196]). 
Endostatin inhibits proliferation of ECs, hence suppresses tumor angiogenesis. Several studies 
reported that endostatin also inhibits migration and invasion of human head and neck squam-
ous cell carcinoma cells and AIDS-related Kaposi’s sarcoma cells so that it may also exert anti-
tumor effect in vivo [197, 198].  
 The role of circulating endostatin in preventing angiogenesis related diseases is well 
demonstrated within the population with Down’s syndrome. Individuals with Down’s syndrome 
have an extra copy of collagen XVIII due to chromosome 21 trisomy. The serum endostatin level 
in the individuals with Down’s syndrome is 39±11 ng/mL compared to 20±11 ng/mL in normal 
controls [199]. This slight increase in circulating endostatin not only significantly decreases inci-
dences of all types of solid tumors except for testicular cancer but also decreases occurrences 
of other angiogenesis-related disease such as diabetic retinopathy and atherosclerosis [199]. In 
transgenic mice over-expressing endostatin, a similar level (1.6 fold) of increase in circulating 
level of endostatin is sufficient to slow down tumor growth [200].  
 The mechanisms of how endostatin inhibits tumor angiogenesis remain elusive. The 
proposed mechanisms include inducing G1 rest in ECs, blocking activities of MMP-2, 9 and 13, 
preventing VEGF isoforms binding to VEGFR, and stabilizing adhesion junctions [201-205]. En-
dostatin contains RGD motifs and is known to associate with integrin αvβ3, αvβ5 and α5β1 
[206, 207]. Cell surface glypicans and the actin-binding protein, tropomyosin, are also possible 
receptors for endostatin [208]. Although endostatin affects about 10% of genes in EC genome 
and induces EC apoptosis, endostatin does not interfere with wound healing [196, 209]. Toxici-
ties have not been observed in animal models or in clinical settings. Four cancer patients with 
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continuous self-administration of a daily dose of endostatin for more than 3.5 years did not re-
port any side effects (Reviewed in [196]).  
 
1.9.1.2 Thrombospondin-1  
 The 450-kDa thrombospondin-1 (TSP-1) is a homotrimeric protein initially found to 
be the most abundant protein in the platelet α granule (reviewed in [210]). It stabilizes platelet 
aggregates in blood clots and wounds. The secreted TSP-1 is also incorporated into basement 
membrane, vessel walls and other interstitial tissues with multiple biological roles involved in 
mediating cell adhesion, cell cycle, and angiogenesis. Unlike other anti-angiogenic protein 
fragments, the full length TSP-1 potently inhibits in vitro and in vivo angiogenesis, but its large 
size and multifunctional character hinders it from being used directly as an anti-angiogenic rea-
gent [211]. Many efforts focus on development of TSP-1 fragments that could effectively inhibit 
angiogenesis, which will be further discussed in section 1.9.3.2. Studies have demonstrated that 
the inhibitory effect of native TSP-1 lies in its properdin type I repeats and procollagen homolo-
gy region (PHR) [212].  
 
1.9.1.3 Other Matrix-Derived Endogenous Angiogenesis Inhibitors 
 The vascular basement membrane, composed of thin layers of insoluble extracellu-
lar matrix proteins, also mediates angiogenesis in addition to its structural roles. Type IV colla-
gen is the major component in vascular basement membrane, and it forms a scaffold network 
for other macromolecules (reviewed in [213]). A total of six genes encode distinct collagen IV α-
chains, known as α1- α6. Each α-chain comprises three domains: the N-terminal 7S domain, the 
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middle triple helical domain, and the c-terminal globular non-collagenous (NC1) domain [214]. 
Similar to type XVIII collagen with cryptic endostatin, the NC1 domain of type IV collagen pro-
duces varies of anti-angiogenic fragments through proteolytic degradation of the α1, α2, α3 
and α6 chains. For example, arresten is a 26-kDa anti-angiogenic protein derived from the NC1 
domain of the α1 chain with selectively inhibitive effects in EC proliferation and tube formation, 
whereas canstatin is a 24-kDa fragments from the α2 chain of type IV collagen [215, 216]. The 
NC1 domain in α3 chain of type IV collagen contains a 28-kDa fragment named as tumstatin 
[217]. Systematic administration of tumstatin demonstrates anti-tumor and anti-angiogenic ac-
tivities in mouse xenograft models. Although, arresten, tumstatin, and endostatin are all de-
rived from the NC1 domains of basement membrane collagens, their anti-angiogenic mechan-
isms are different. All three proteins recognize integrin but arresten blocks the binding of inte-
grin α1β1 to the type I collagen, tumstatin inhibits tumor angiogenesis via integrin αvβ3, and 
endostatin decreases EC migration by binding to integrin α5β1. Furthermore, tumstatin only 
shares 14% amino acid sequence similarity to endostatin [217].  
Another example is anastellin, a 76-amino-acid anti-angiogenic fragment from the first 
type III repeat in fibronectin [218]. Anastellin inhibits angiogenesis by inducing the polymeriza-
tion of soluble fibronectins to form fibril. Because the first type III repeat domain has a similar 
function and structure as that of the NC1 domain from collagen IV, it is suggested that proteo-
lytic degradation of ECM is a common mechanism to produce structurally related endogenous 
angiogenesis inhibitors with unique downstream signaling networks. This information has been 
utilized to facilitate the discovery of new anti-angiogenic molecules. For example, restin is a 22-
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kDa endostatin-like anti-angiogenic fragment protein fragment from collagen XV discovered by 
computational homology search using endostatin as a model [219].  
 
1.9.2 Non-Matrix-Derived Endogenous Angiogenesis Inhibitors 
1.9.2.1  Angiostatin 
 Angiostatin was identified in Dr. Judah Folkman’s laboratory using the same me-
thod as the discovery of endostatin from Lewis lung carcinoma-bearing mouse [220]. Its paren-
tal protein, plasminogen, contains five kringle domains (kringle 1-5). Plasminogen does not in-
hibit angiogenesis. Proteolytic degradation of plasminogen produces 38–45-kDa anti-angiogenic 
peptides that contain different kringle domains [221]. They are collectively called angiostatin. 
Recent studies showed that different kringle domains contribute differently to its function in 
inhibition of angiogenesis. Kringle-1 potently inhibits EC proliferation, whereas kringle-4 only 
inhibits EC migration with no effects on cell growth [222]. Cao and coworkers also suggested 
that, although Kringle-5 is not included in angiostatin, it also inhibits angiogenesis [223].  
 
1.9.2.2          Pigment Epithelium-derived Factor  
 Pigment epithelium-derived factor (PEDF) is a 50-kDa naturally secreted glycoprote-
in that was first identified and isolated from human retinal pigmented epithelial (RPE) cell-
conditioned medium [224]. The biological functions of PEDF have been indicated in inducing 
neuronal differentiation in retinoblastoma (Rb) cells [224], neurotrophic activity in embryonic 
retina and cerebellar granule cells [225, 226], and maintenance of retinal and ureal avascularity 
[227, 228]. PEDF has been documented as one of the most potent natural anti-angiogenic pro-
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teins. It inhibits EC-proliferation and prohibits in vitro EC-migration with an ED50 of 0.4 nM, 
which is more potent than these of angiostatin, TSP-1, and endostatin [227]. PEDF inhibits angi-
ogenesis via down-regulation of VEGF signaling [229, 230]. A balance between levels of PEDF 
and VEGF is importance in mediating tissue and tumor angiogenesis. For example, a low 
PEDF/VEGF ratio contributes to ischemia-induced angiogenesis in retina [231]. Yang and col-
leagues have shown that angiostatin decreases VEGF/PEDF mRNA ratio in murine ocular mela-
noma [228]. In addition to inhibition of angiogenesis, PEDF also exerts direct anti-tumor effects 
[232-234].  Overexpression of PEGF reduces tumor angiogenesis and inhibits tumor growth in a 
wide range of tumor types, such as Rb, melanoma, gastric carcinoma, cervical carcinoma, and 
osteosarcoma [227, 234-237]. The role of PEDF in inhibition of tumor metastasis is also been 
investigated. Studies have demonstrated that overexpression of PEDF prevents liver metastasis 
in pancreatic adenocarcinoma, human melanoma, and mouse uveal melanoma [234, 238, 239]. 
 
1.9.2.3 Interferons and Interleukins  
 Interferons (IFNs) and interleukins (ILs) are multi-functional cytokines released by 
lymphocytes. Besides regulating immune responses to infections and tumors, IFNs and ILs also 
mediate angiogenesis in embryos and under pathological conditions. IFN-α is the first identified 
endogenous anti-angiogenic regulators [22]. Since 1988, IFN-α has been used for the treatment 
of hemangiomatosis, pediatric hemangiomas, angioblastomas and high-grade giant cell tumors 
[240, 241]. IFN-α and -β have direct anti-proliferative effects by promoting G1 and S phases ar-
rest of the cell cycles [242]. The anti-angiogenic mechanisms of IFN-α and -β are not well un-
derstood. Studies suggest that they partially rely on inhibition of bFGF-2, VEGF, and MMP-9 in-
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duced tumor angiogenesis [243-245]. IL-12 and IL-18 also suppresses FGF-regulated angiogene-
sis. Their expressions are induced by IFN-γ [246, 247]. Other ILs, such as IL-1β and IL-4, also pre-
vent bFGF induced angiogenesis [248, 249].  Although IFNs have showed promising anti-
angiogenic effects, their short half-lives and systemic side-effects have restricted their clinical 
applications [241]. 
   
1.9.2.4 CXC Chemokines 
 CXC Chemokines are a group of heparin-binding proteins with distinct functions in 
mediating angiogenesis. CXC family members share a similar 3D structure. Each member con-
tains four conserved cysteine (Cys) residues with the first two separated by one non-conserved 
residue (reviewed in [250]). A second conserved N-terminal glutamic acid-leucine-arginine (ELR) 
motif determines receptor selectivity and angiogenic effects. Members with the ELR motif 
(ELR+), such as IL-8, granulocyte chemotactic protein-2 (GCP-2), and growth-related gene alpha-
α, β, γ (GRO-α, β, γ), strongly promote angiogenesis via CXC receptor-1 and-2 (CXCR-1 and -2) in 
many tumor models (reviewed in [251]). By contrast, PF4, neutrophil activating protein-2 (NAP-
2) and interferon-γ-inducible protein 10 (IP-10) are CXC chemokines that lack the ELR motif 
(ELR-) which potently inhibits angiogenesis by mediating signaling pathways downstream of 
CXCR-3 (reviewed in [250, 252]).  This unique structure-function characterization has drawn 
growing interest in studies of the regulatory roles of the CXC chemokines in tumor angiogene-
sis. PF4 is the first identified endogenous angiogenesis inhibitor, and also the most studied CXC 
chemokines family member (reviewed in [253]). PF4 inhibits EC proliferation, migration, and 
formation of endothelial tubes in vitro [254]. Systematic administration of PF4 also inhibits dif-
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ferent types of tumor growth in animal models. Different mechanisms have been proposed to 
explain the anti-angiogenic effect of PF4 (reviewed in [255]). First, as a strong heparin binding 
protein, PF4 is able to displace VEGF and FGF-2 from interacting with glycosaminoglycans 
(GAGs). Since GAGs serve as low-affinity binding co-receptors for these growth factors, PF4 
could partially block VEGF and FGF-2 from binding to their high-affinity receptors. Second, PF4 
may directly associate with those growth factors and reduce their activities. Last, PF4 binds to 
its receptor CXCr3, which reduces ECs proliferation by mediating the expression of a cell cycle 
protein, p21Cip1 [256].  
 
1.9.2.5 Tissue Inhibitors of Matrix Metalloproteinases and PEX  
 Tissue inhibitors of matrix metalloproteinases (TIMPs) can block the activity of 
MMPs, therefore play a critical role in regulation of the homeostasis of ECM (reviewed in 
[257]). However, TIMPs have paradoxical effects during tumorigenesis and angiogenesis. On 
one hand, because MMP-2 and -9 significantly contribute to angiogenesis switch during tumori-
genesis, TIMPs can inhibit angiogenesis by blocking protease activities of MMP-2 and -9 [257]. It 
also has been reported that TIMP-2 down-regulates angiogenesis in an MMP-independent 
manner through directly suppressing ECs proliferation [258]. On the other hand, TIMPs can 
promote angiogenesis because the protease activity of the MMPs is required to produce many 
endogenous angiogenesis inhibitors such as angiostatin and endostatin [193, 259]. In addition, 
TIMPs are multifunctional proteins that stimulate cell growth and protect cells from apoptosis 
(reviewed in [260]). The net effect of TIMPs during tumor angiogenesis may depend on the tis-
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sue type, local TIMPs concentration and the disease progression. Elevated plasma TIMPs levels 
are also considered as a sign for poor prognosis in many types of cancers (reviewed in [257]).  
 A naturally occurring MMP-2 inhibitor, PEX, is able to inhibit in vivo angiogenesis 
[261]. PEX is a breakdown product consisting of the C-terminal hemopexin-like domain of 
MMP-2. Detectable amounts of PEX are located in vivo in conjunction with αvβ3 and reach peak 
levels during the late-stage of vessel maturation. Compared to TIMPs, PEX inhibits angiogenesis 
in vitro and in vivo through the direct blockage of MMP-2 binding to αvβ3.   
 
1.9.2.6 Other Non-Matrix-Derived Endogenous Angiogenesis Inhibitors 
 Many other endogenous proteins have a role in reducing angiogenesis (reviewed in 
[21]). For example, pigment epithelium-derived factor (PEDF) is responsible for the avascularity 
of ocular compartments and it selectively inhibits the growth of new vessels in normal prostate, 
pancreas, and murine xenograft tumors [262]. Vasostastin is the N-terminal fragment of calreti-
culin that specifically inhibits ECs attachment to laminin and blocks EC proliferation [263]. A 
peptide hormone, prolactin, is associated with lactation with pro-angiogenesis effect. Its natu-
rally occurring breakdown product, a 16-kDa N-terminal fragment of human prolactin (16k 
hPRL), can inhibit angiogenesis 100 times more potently than endostatin does [264]. The in-
creasing number of endogenous inhibitors discovered has colored a bright future for the devel-
opment of anti-angiogenic reagents for cancer patients.  
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1.9.3 Peptide-based Anti-angiogenic Peptide Drugs 
1.9.3.1 Development of Peptide-based Anti-angiogenic Peptide Drugs 
 Currently, synthesis of peptides originated or modified from endogenous angioge-
nesis protein inhibitors has become the most common approach to develop novel anti-
angiogenic reagents. There are several reasons for using peptides instead of the whole protein: 
a) to reduce side effects by avoiding undesired protein functions; b) to increase solubility; c) to 
facilitate large-scale productions. First, most discovered endogenous anti-angiogenic inhibitors 
are fragments derived from parental proteins with or without anti-angiogenic property. Stri-
kingly, in majority of these inhibitors, only a small portion or region is responsible for blocking 
the complex angiogenesis networks. Since most of those proteins have “default” functions in 
mediating a number of biological events instead of specifically inhibiting angiogenesis, utilizing 
the anti-angiogenic portion will not only enhance the anti-angiogenic function, but reduce the 
risk of side effects in most case. Second, many endogenous anti-angiogenic proteins are derived 
from large, insoluble ECM proteins. Dissecting them into small peptides will solve the solubility 
issue and make them more suitable for therapeutic treatments. In addition, production of short 
peptides by solid-phase synthesis can avoid the batch differences produced by protein biosyn-
thesis through bacterial, yeast or mammalian expression. Those reasons have encouraged a 
worldwide wave of development of synthetic peptides derived from existing endogenous inhi-
bitors.  
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1.9.3.2 TSP-1 Peptides 
 TSP-1 was the first endogenous angiogenesis inhibitor recognized  in 1990 [25]. Al-
though the whole protein potently inhibits angiogenesis, it is difficult to use a 450-kDa extracel-
lular glycoprotein that regulates various biological processes directly as a valuable therapeutic 
reagent. Tolsma and colleagues located the angiogenesis-inhibitory region of TSP-1 into two 
separate domains in the 70-kDa central region of each of the polypeptide chains, the procolla-
gen domain and the three type 1 repeats (TSRs) [212]. Peptides derived from both domains 
have confirmed anti-angiogenic properties, but peptides derived from the TSRs are more po-
tent than that derived from the procollagen domain. The smallest peptide that retains the anti-
angiogenic activity is a 9-residue fragment from the procollagen-like region. Small synthetic 
TSP-1 peptides from the second and third TSRs of TSP-1, Mal II (residues 424-442) and Mal III 
(residues 481-499), block new vessel formation in rat cornea and granulation tissues.  Peptides 
derived from TSRs of other TSR-containing proteins, such as spondin 1, CYR61, connective tis-
sue growth factor (CTGF), and WISP-3 have also shown potential to inhibit angiogenesis in vitro 
and in vivo, which suggests that TSRs is a conserved protein structure that inhibits angiogenesis 
[265].      
Therapeutic TSP-1 peptides have been developed for clinical studies. The original Mal II 
peptide contains amino acid mutations SPWSSA*SVTA*GDGVITRIR (where A* indicates cysteine 
was replaced by alanine when peptides were synthesized), and Mal III contains similar amino 
acid mutations SPWDIA*SVTA*GGVQKRSK when tested [212]. The intact TSP-1 protein inhibits 
a variety of in vitro angiogenesis assays at a concentration range of 0.5 – 20 nM, but Mal II 
failed to show inhibitory effects. Dawson and coworkers improved the in vitro activity of Mal II 
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by 100 – 1000- fold by substituting either three of the L-amino acids 4, 5, and 14 with their D-
enantiomers [266]. They also confirmed that the anti-angiogenic activity of Mal II is fully re-
tained by its last seven amino acids (GVITRIR), known as peptide 1. However, the modified pep-
tide (NAc-Gly-Val-DILe-Thr-Arg-Ile-ArgNHEt) has no therapeutic effects because of short half-life 
in rodents [211]. Haviv and colleagues further modified the peptide at positions 5 and 7 with N- 
and C-terminal capping to create two heptapeptides mimetics, ABT-526 (NAc-Sar-Gly-Val-DIle-
Thr-Nva-Ile-Arg-ProNHEt) and ABT-510 (NAc-Sar-Gly-Val-DalloIle-Thr-Nva-Ile-Arg-ProNHEt) 
[211, 267]. Both heptapeptides have improved pharmacodynamic/pharmacokinetic (PD/PK) 
profiles and increased activities compared with Mal II. ABT-510 has increased water solubility 
compared to ABT-526 and is formulated as an acetate salt. It blocks TSP-1 binding to its recep-
tor CD36, suggesting that it inhibits angiogenesis by the mechanism similar as TSP-1 does [267]. 
In a human bladder carcinoma xenograft mouse model, continuously administration of 30 – 90 
mg/kg ABT-50 by osmotic minipumps reduced neovascularization in tumor tissues [211]. A 
phase II clinical study showed that, when administrated subcutaneously with doses of 20mg 
once a day or 200mg twice a day, ABT-510 failed to meet the objective response rate (ORR), 
which suggested that ABT-510 is not suitable to be used as a single-agent [268, 269]. A similar 
phase II clinical study in patients with previously untreated advanced renal cell carcinoma also 
leads to the same conclusion that ABT-510 is not sufficient as a stand-alone agent although it 
has a favorable safety profile  [270].  
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1.9.3.3 Tumstatin Peptides  
 The 28-kDa tumstatin is an endogenous anti-angiogenic protein fragment of the 
NC1 domain of type IV collagen α3 chain [271].  Tumstatin inhibits tumor growth by reducing 
new blood vessel formation and directly repressing the growth of tumor cells. The anti-
angiogenic effect of tumstatin is located between N-terminal amino acid residues 54 and 132 
(known as Tum-5), while the anti-tumor activity is possessed between residues 185-203 [217, 
271]. Tum-5 is 10-fold more effective than endostatin does in inhibition of human prostate can-
cer (PC-3) xenografts in nude mice [271]. A series of overlapping synthetic peptide further nar-
rowed its anti-angiogenic region to even smaller peptides, T3 (amino acids 69-88) and T7 (ami-
no acids 74-98) [272] . 
 
1.9.3.4 PF4 Peptides 
 PF4 was identified as a heparin-binding protein released from platelet α-granules in 
1950s [273]. The major recognized physiologic role of PF4 is to neutralize heparin and other he-
parin-like molecules such as GAGs on endothelial cell surfaces; therefore, it plays an important 
role in thrombosis, immune modulation, and angiogenesis (reviewed in [274]). PF4 was original-
ly developed as a clinical alternative to protamine for heparin neutralization. With a confirmed 
tumor-suppressive effect by reducing angiogenesis in different xenograft animal tumor models, 
PF4-derived peptides have become a popular pipeline to produce new alternative venues to 
current anti-angiogenic therapies (reviewed in [275]). Development of PF4-derived peptides has 
been focused on reducing toxicity and improving bioactivity.  PF4 is a homo-tetramer composed 
of four 70 amino acids subunits. The C-terminal of PF4 is critical to its anti-angiogenesis effect. 
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The naturally occurring PF4 fragment PF417-70 is a proteolytic cleavage product by elastase be-
tween Thr-16 and Ser -17. Although the two cleavage fragments (amino acid 1-16 and amino 
acid 17-70) still remained attached together through disulfite bonds, it is reported to be 30 – 50 
folds more potent than the full length PF4 [276]. Another 24-amino-acid fragment, PF4 47-70 
(NGRKICLDLQAPLYKKIIKKLLES), possesses anti-angiogenic effects and also blocks the binding of 
either FGF-2 or VEGF to ECs [255, 277].  Further stabilizing the C-terminal PF4 fragments by leu-
cine zipper motif also produces anti-angiogenic peptides [278]. Nesmelova and colleagues 
showed that a heterodimic hybrid peptide derived from both PF4 and the pro-angiogenic IL-8 
sequences has stronger anti-proliferation effects than PF4 alone [279].  
 
1.9.3.5 Anginex 
 As growing numbers of anti-angiogenic peptides are derived from endogenous pro-
teins. Van der Schaft and coworkers engaged in designing combinatorial peptides from different 
endogenous anti-angiogenic β-sheet proteins [280]. In contrast to PF4 peptides discussed 
above, anginex is 33-amino-acid peptide that forms anti-parallel amphipathic β-sheet structure 
[281]. The amino acid sequence of anginex is originated from analysis of the β-sheet hydro-
phobic core part of PF4 family proteins including PF4, IL-8, and bactericidal-permeability in-
creasing protein (BPI) [281, 282]. The hydrophobic core parts of those described proteins have 
several common features: 1) ratio of positive to negative charge residues falls between 4/2 and 
6/2, the non-charged polar residues (N,Q, T, S) are around 20%, 2) there are  40% - 50% of hy-
drophobic residues (e.g. I, L, V, M and A), 3) there is alternation between those charged/ polar 
residues and hydrophobic residues with specific turns between β-sheet strands, and 4) there is 
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proper placement and pairing of the hydrophobic residues in the sequences [283]. The synthet-
ic peptide anginex inhibits in vitro ECs proliferation, induces ECs apoptosis, and inhibits tumor 
growth in xenograft mice models [281, 284]. The β-sheet structure is the bioactive form of an-
ginex suggesting that the β-sheet structure is critical to inhibit angiogenesis [285]. Further se-
quence scanning study also demonstrated that the critical N-terminal SVQMKL and the C-
terminal IIVKLN are the most essential residues for maintaining its anti-angiogenic activity 
[286].   
 
1.9.4 Drawbacks of Anti-angiogenic Peptides   
 Currently, dissecting endogenous angiogenesis inhibitors or even stimulators into 
small peptides that are less than 50-amino-acid in length dominates the field of developing the-
rapeutic agents. Compared to drugs that are acting on specific pro-angiogenic signaling path-
ways such as VEGF/VEGFR, FGF, or EFG inhibitors, those peptides effectively block angiogenesis 
produced by a variety of in vitro and in vivo models. The rising concerns about the side effects 
seen for the available VEGF/VEGFR inhibitors and the emergence of drug-resistances made the 
peptide-based drugs attractive. The biological and chemical nature of small peptide-based drug, 
however, could impede the clinical application or therapeutic outcomes in cancer patients.  
First, peptide drugs by nature have unfavorable pharmacological properties. Enzymatic 
degradation in serum and oral bioactivity could make them less effective than predicted (re-
viewed in [287]). Secondly, short length often gives the peptides less defined secondary struc-
tures that are required for their targeting and function. Thirdly, although the modifications such 
as N-terminal capping or substitution with non-nature amino acids confer protease-resistance 
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to peptide drugs, those so called designer peptide drugs are expensive for synthesis. The cost of 
inclusion of one or two non-natural amino acids could reach up to $1,000 per gram (reviewed in 
[287]). Occasionally, it is necessary to substitute non-natural amino acids in order for peptide 
drugs to be fully effective. For example, as discussed above, ABT-510 (NAc-Sar-Gly-Val-DalloIle-
Thr-Nva-Ile-Arg-ProNHEt) is the modified version of a TSP-1 derived peptide. In contrast to the 
nanomolar range medium effective dose (ED50) reported for ABT-510, its natural counterpart 
was not active in angiogenesis assays [266]. 
 In summary, although peptide-based drugs remain a valuable approach to develop 
new therapeutic anti-angiogenic reagents, limitations such as high cost, restrictions on produc-
tion and lack of pharmacological properties largely impede their development. Numerous in-
vestigations have been productive in producing potent peptides with demonstrated in vitro ef-
fects, but few have succeeded in the clinical trials. Most of them showed no beneficial effects 
when applied to cancer patients.  
 
1.9.5 A structural link of Endogenous Angiogenesis Inhibitors 
 It is noted that many of these endogenous angiogenesis inhibitors share distin-
guishable regional structural similarity. As pointed out by Dings and coworkers a majority of 
them fold as or contain anti-parallel β-sheet structures with highly positively charged ly-
sine/arginine-rich surfaces (Reviewed in [288]). The 3D structure of a protein’s determined by 
its amino acid sequence, which in turn conveys biological activity. This proposed structural in-
formation may provide important benefits for de novo design of peptides and proteins with de-
sired anti-angiogenesis effect. 
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As shown in Figure 1.1, a number of endogenous angiogenesis inhibitors are derived 
from ECM proteins depicted with highly positively charged β-sheet structure (reviewed in 
[288]). ECM proteins usually are composed of frequent repeats within the same molecule or 
similar structured modules shared between different ECM families (reviewed in [213]). One 
such example is the C-terminal NC1 domain of XVIII that contains a 180 amino acids globular 
domain known as endostatin [26]. The crystal structure of endostatin shows that it folds into 
predominantly an anti-parallel β-sheet structure with extended loops and two α-helices [289]. 
This structure is distantly related the C-type lectins and LINK domains in CD44 and TSG-6 (re-
viewed in [213]). Two clusters of arginines (Arg155, 158, 184, and 270; Arg193 and 194) com-
posing an extensive basic patch on its surface is responsible for bFGF binding [208].  
Another such example is anastellin, an all-β-sheet endogenous angiogenesis inhibitor 
derived from fibronectin. Fibronectin is another ECM protein that exits as a soluble protein in 
plasma and also as self-assembled fibrils in the ECM (reviewed in [213]). The 250-kDa fibronec-
tin are assembled by multiple copies of three types of repeated modules: type I (FN1), II (FN2) 
and III (FN3) repeats. Anastellin is derived from the first FN3 repeat in fibronectin [218]. The full 
length FN3 has a well characterized 3D structure that can be described as a “β-sandwich”. It 
consists of two sets of anti-parallel β-sheets enclosing a hydrophobic core. One set of the sheet 
comprises three (A, B and E) β-strands, whereas the other has four (C, D, F and G) strands. 
Anastellin is a truncated FN3 without the first two β-strands (A and B) and also highly positively 
charged with an array of solvent exposed lysines and arginines on both sides of its surfaces.  
A third example of such endogenous angiogenesis inhibitors is the extensively positively 
charged chemokine PF4. Native PF4 exits as a homo-tetramer composed of two asymmetric 
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dimers. Each 70-amino-acid PF4 polypeptide chain contains an N-terminal glutamate-rich ape-
riodic region. A central core part consists of three anti-parallel β-strands and a C-terminal am-
phipathic α-helix [273]. The N-terminal region is constrained to the central core by two disulfide 
bridges, Cys10-Cys36 and Cys12- Cys52. One of the unique structural features of PF4 is the exis-
tence of an array of three basic amino acids clusters in its sequence (reviewed in [255]). The 
first cluster of basic residues is located in the N-terminus (Arg20, Arg22, and His23). The central 
β-sheet core region hosts the second basic cluster (Arg49 and Lys50). The last distinct  basic 
area is in the C-terminal helix (residues 61-68 ) featured by the alternation of lysines and pairs 
of hydrophobic leucines or isoleucines  (Lys61-Lys62-Ile63-Ile64-Lys65-Lys66-Leu67-Leu68) 
[273]. The central anti-parallel β-sheets regions of two PF4 subunits associate with each other 
and form a dimer. The central β-sheets regions are then further positioned laterally to the 
another dimer and stabilize the tetrameric structure [290]. This structural arrangement makes 
the lysine residues (Lys61, 62, 65 and 66) of the four α-helices of the teramer forming an equa-
torial cationic ring that is responsible for heparin binding [255, 278]. Butcher and colleagues 
showed that when a PF-4 sequence unrelated leucine zipper motif was crafted with the residue 
61-68 of PF4 featured with Lysine 61, 62, 65 and 66, it showed significant heparin binding activi-
ty [278]. Those structure characters of endogenous anti-angiogenesis inhibitors could serve as 
enlightenment for novel protein drug design. 
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1.10 Rational for Design Anti-angiogenic β-sheet Proteins 
1.10.1 Rational for Design Anti-angiogenic Protein using a Stable Host  
 Angiogenesis has been proven to be a valuable target for inhibition of tumor growth by 
numerous investigations and clinical studies.  As reviewed above, most available FDA approved 
anti-angiogenic reagents are humanized monoclonal antibodies, or small molecular 
VEGF/VEGFR kinase inhibitors, or inhibitors that targeting other growth factor pathways. There 
are growing numbers of growth factors that have been demonstrated to mediate tumor angi-
ogenesis dependent or independent on VEGF, which is the primary mechanism of which tumors 
to escape current treatment leading to a “second wave of angiogenesis”. As discussed above, 
emerging number of endogenous inhibitors have been shown to effectively induce proliferating 
EC apoptosis and block tumor angiogenesis. In contrast to inhibiting growth factors that stimu-
lated ECs, this method represents new revenue to directly reduce the building blocks (ECs) of 
tumor angiogenesis. Because tumor vessels have disrupted structure with less-to-no protection 
from pericytes or basement membranes, these agents are less likely to disrupt normal vessels. 
In addition, VEGF or other growth factors, such as PDGF, EGF, usually play important roles in 
the maintenance of normal body homeostasis. Inhibition any of those pathways bring conse-
quent side effects. To this end, endogenous proteins or fragments are less likely to affect func-
tions of normal organs and are well tolerated by cancer patients.   
 To date, only one recombinant endogenous protein, endostatin, is further modified and 
approved for clinical applications. Instead of developing protein fragments or peptides derived 
from endogenous anti-angiogenic proteins, we proposed to rational design of an anti-
angiogenic protein using a stable host protein, CD2D1. Anti-angiogenic peptides are crafted into 
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an angiogenic unrelated β-sheet host protein. The rational is based on two facts: first, amphi-
pathic β-sheet structure is critical for endogenous anti-angiogenic protein; second, the β-sheet 
structure has to be well-maintained for angiogenic inhibition. In the following section, we will 
discuss in detail on the choice of the host protein and strategy of design. CD2D1 is a suitable 
choice to maintain the critical β-sheet structure of anti-angiogenic peptides. After being crafted 
to the host protein, not only the anti-angiogenic peptides exit as an amphipathic β-sheet fold-
ing but their hydrophilic surface is fully solvent-exposed to function in blocking angiogenesis.  
One major goal of dissecting endogenous anti-angiogenic protein is to avoid possible 
side-effects since most of the parental proteins have “default” physiological functions in the 
cases like TSP-1 or PF4. In other cases, even the parental proteins have unknown physiological 
roles, which brings up the possibility of occurrences of unexpected side-effects. In our designed 
model, the host protein, CD2D1 is the most extensively studied adhesion molecule to date. The 
stable structural features and defined roles in immune processes make it easy to predict the 
expected function of our designed protein. Since the host protein has very low affinity to its 
target, it is less likely to cause any non-targeting effect except inhibit angiogenesis in growing 
tumor. Even if there is any, it could be avoided by altering the designed model.  
 
1.10.2 The CD2 Adhesion Molecule 
Cluster of differential 2 (CD2) is one of the most extensively studied cell surface adhe-
sion molecules (reviewed in [291, 292]). CD2 is a transmembrane glycoprotein expressed on T 
lymphocytes, natural killer (NK) cells and thymocytes [293]. The binding partner of CD2 is CD48 
and CD58. The biological function of CD2 is mainly as a cell surface co-receptor molecule for T 
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cell receptor (TcR) that mediates T cell activation and adhesion to antigen presenting cells 
(APC), therefore mediating immune responses (reviewed in [294]). In addition to cell adhesion, 
it is also known that CD2 triggers IL-2 production in T cells upon binding to CD58 in human 
[295]. CD58 is not found in marine species, so that CD48 is recognized as the primary ligand in 
marine. The binding affinity between CD2 and CD48 is weak (Kd = 60 – 90 µM), but monoclonal 
antibodies that blocks CD2-CD48 interaction inhibits marine T-cell activation [296, 297].  
 
1.10.3 Structure of the Host Protein CD2D1 
 Both rat and human CD2, and their ligands (CD48 and CD58, respectively) consist of two 
extracellular domains, a transmembrane domain, and a proline-rich cytoplasmic tail. CD2 be-
longs to the well-studied immunoglobulin superfamily (IgSF) [292, 298]. The overall extracellu-
lar portions of CD2 have an Ig-fold illustrated in Figure 1.2 [298]. The N-terminal extracellular 
Domain 1 of CD2 (denoted as CD2D1) consists of nine anti-parallel -strands named as A, B, C, 
C’, C’’, D, E, F and G. Two layers of GFCC’C’’ and ABED strands compromise a β-sheet sandwich 
structure that was described as a Greek Key architecture [298]. The GFCC’C’’ strands form the 
adhesion surface that is critical for CD48 binding. This binding surface is fully solvent exposed. It 
also has 45% of charged residues in this region compared to average of 29% charged residues in 
most endogenous proteins. Extensive mutagenesis and structural studies have demonstrated 
that the binding between CD2 and CD48 is mostly due to charge-charge interaction [299].  
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1.10.4 CD2D1 as a Host Protein 
The N-terminal domain of CD2 was selected as the host protein for several reasons. 
First, CD2D1 is small (10-kDa, 99 amino acids) with several resolved crystal and NMR structures 
at high resolutions [298, 300-303]. Second, CD2D1 is highly mutation tolerant. Previous studies 
have reported that single mutations at 40 different locations on the CD2D1 have no apparent 
effects on the expression, solubility, and structural integrity of the protein [304-306]. Using 
computational design methods, Yang and coworkers created de novo Ca(II) binding sites in 
CD2D1 that were shown to maintain their native-like conformations [307]. The grafting ap-
proach established in the same laboratory also demonstrated that mutations at the terminal-
end and 22-23, 52-53, and 83-84 do not alter the folding or conformation of the CD2 [308]. 
Third, high resolution NMR studies show that CD2D1 is able to maintain its native structure and 
conformation in a pH range from 1 to 10, suggesting that electrostatic interactions play a minor 
role in the folding of CD2 [304]. Fourth, the dynamic properties of CD2 are well studied by Dris-
coll and coworkers [303, 309]. Yang and colleagues have previously reported the dynamic prop-
erties of CD2 with a designed Ca(II) binding site. These important features and knowledge of 
CD2D1 allow us to specifically explore the conformational and dynamic properties of the host 
protein with the engineered anti-angiogenic sites [310]. 
 
1.10.5 Our Designed Model 
 Our designed model is base on the host protein CD2D1 N- and C-terminus β-sheets. The 
designed agent is denoted as ProAgio. A total of 8-amino-acid differences between CD2D1 and 
ProAgio are shown as bold in Table 1.1 and Figure 1.3. Several reasons led us to choose this re-
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gion as the engineer site for incorporating the anti-angiogenic peptides. First, as shown in Table 
1.1, this region has the highest sequence similarity to the anti-angiogenic peptides. Secondly, all 
the side chains of hydrophilic residues will be exposed to solvent, so that the amphipathic fea-
tures of the anti-angiogenic peptides will be well maintained. Thirdly, those two β-sheets have 
less side-chain interactions between the hydrophobic core located near Trp32, which will allow 
the highest structure stability after alteration.  
 The simulated model structure was shown in Figure 3.1. In our designed model, anti-
angiogenic peptides (TVQMKL and NLKVII) are crafted into the 5-10 of N-terminal β-strand A 
and 94-99 of and C-terminal β-strand G of CD2D1, respectively. The complete amino acid se-
quence of ProAgio was illustrated in Figure 1.5. Since the hydrophobic core region of CD2D1 
located near Trp32 is not disrupted by this design, the overall β-sheet sandwich structure will 
be maintained and remain as a structural restraint to the crafted peptides. Individual residues 
involved in the anti-angiogenic function were illustrated in a simulated ProAgio model as Figure 
1.4. In the simulated structure, the side chains of Thr5 pairs with Asn94, Glu7 pairs with Lys96, 
and these side chains are facing the solvent surface of CD2D1. Lys9 and Ile99 in the end of A 
and G β-strands form interaction and their side chains are expected to face the same direction 
of Thr5, Glu7, Asn94, and Lys96 although with greater flexibility. Most other designed residues 
(Val6, Met8, Leu10, Leu95, Val97 and Ile99) are hydrophobic residues expected to be facing the 
opposite direction (to the β-sandwich core region). A Met23Cys mutation is further designed 
into the BC loop region that will not interfere with the structural stability and anti-angiogenic 
function of our designed ProAgio.  
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1.11 Significance and an Overview of this Study    
 Angiogenesis is a rate limiting step for tumor growth and metastasis. Although it has 
been 40 years since angiogenesis was proposed as a valuable target for cancer therapy, only a 
limited number of agents were developed in this field. Angiogenesis is mediated by a fine bal-
ance between pro- and anti-angiogenic factors. Current therapeutic drugs have been heavily 
focused on inhibition of pro-angiogenic factors especially VEGF/VEGFR inhibitors. Many of 
those developed agents have shown undesired side-effects. In addition, inhibition of single or 
several signaling transduction pathway(s) could not effectively prevent tumor cells from releas-
ing alternative stimulants that initiate new waves of angiogenesis. In contrast, endogenous an-
giogenesis inhibitors have emerged as a new category of anti-angiogenic therapy. Compared to 
growth factor inhibitors, they usually target ECs with a broader range of mechanisms. Further-
more, these endogenous angiogenesis inhibitors show low toxicity and high selectivity toward 
ECs. Most endogenous angiogenesis inhibitors are proteolytic fragments derived from ECM pro-
teins, so that they are limited to drug development because of solubility and structural stability.    
 In this study, a novel anti-angiogenic protein agent was developed to specifically target 
ECs. Different from existing strategies, we used rational design of peptide sequences derived 
from native angiogenic proteins in a stable β-sheet host protein. This is not only the first agent 
development of this kind, but these studies also shed lights on applying a novel approach to 
tackle challenges in clinical anti-angiogenic drug research and development. Compared to 
VEGF/VEGFR and other growth factor inhibitors, our designed agent directly exerts anti-
angiogenic effects by direct targeting ECs, which is more efficient and minimizes drug resis-
tance. As far as other endogenous anti-angiogenic proteins and monoclonal antibodies are con-
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cerned, our designed agent has a molecular weight of 10-kDa, which allows it to have better 
tissue penetration. In addition, the stable host protein will enable the crafted anti-angiogenic 
peptides to adopt a β-sheet structure and increase their biological effects. Furthermore, our 
host protein resists extensive mutations, so that multiple functional sites could be easily incor-
porated. For example, a single mutation of Met23Cys allows PEGylation of our designed pro-
tein, which significantly improves its solubility, increases blood circulation half-life, and de-
creases immunogenicity.  
  
Chapter 2 in this dissertation documents material and methods used to carry out this 
research project. Different techniques are categorized as below. First, techniques include mole-
cular cloning to create mutations in the wild type and mutant CD2D1 host proteins, protein ex-
pression and purification procedures utilizing ion-exchange and size exclusion chromatogra-
phies, cell culture techniques, and site-specifically PEGylation of the designed protein using a 
20-kDa maleimide-PEG. Second, evaluation of the anti-angiogenic functions of designed pro-
teins utilizes cell viability assays, BrdU cell proliferation assays, and tube formation assays. Each 
of these in vitro models use human umbilical cord vein cells (HUVECs) and their procedures are 
discussed in detail. Third, in vivo evolution of anti-tumor effect uses a xenograft human pros-
tate cancer cell line PC3 in immunodeficient nude mice. Procedures of tumor cell implantation 
and methods of monitoring tumor growth are documented. Furthermore, studies are per-
formed to investigate the mean vessel density (MVD) using fluorescence labeled anti-CD31 an-
tibody. Procedures of immunofluorescence (IF) staining and imaging process are also listed. In 
additional, organ toxicities of treated mice are analyzed by hematoxylin and eosin (H&E) stain-
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ing of fixed organs. Pathological examines of HE stained organ slides were done by Dr. Hans 
Grossniklaus. The vessel integrity of each major organ was also examined by CD31 IF staining. 
 
Chapter 3 focused on our designed anti-angiogenic protein, ProAgio. First, detailed 
strategies used for rational designs are discussed and illustrated in great details by simulated 
computational model structures. Side-chain directions of each amino acid residues involved in 
the anti-angiogenic region and site-specific PEGyaltion are examined one by one in order to 
demonstrate the best design strategy. Molecular cloning, purification, and site-specific PEGyla-
tion of ProAgio enabled us to carry on in vitro and in vivo evaluations of ProAgio on its anti-
angiogenesis effect are discussed.  
 
In Chapter 4, humanization of ProAgio using a human homologue of rat CD2D1 
(huCD2D1) are discussed in detail. Side-chain directions of each amino acid in rat and human 
CD2D1 are compared one-by-one in order to provide detailed structural information for huma-
nization of ProAgio. The 3D structures of both host proteins are aligned to confirm the regions 
for crafting of anti-angiogenic peptides. The final designed model contains several aspects of 
mutations with different purposes including anti-angiogenesis, glycosylation, and PEGylation. 
The designed huProAgio is expressed, purified, and further tested using in vitro and in vivo an-
giogenesis models. Since the protein showed limited solubility, protein refolding under pH gra-
dients and buffer selections are also discussed. 
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 In Chapter 5, molecular cloning, protein purification, PEGylation, and evaluation of de-
signed anti-angiogenic protein agents are summarized. Our initial designed model using a 
CD2D1 variant 6D31 is discussed and summarized. A set of in vivo anti-angiogenesis assays us-
ing ProAgio-PEG is also documented in this chapter.  
 
 Conclusions were drawn and summarized in Chapter 6. The future clinical outlook of 
ProAgio and significance of this study was also discussed in this chapter.  
 
 Proteins expressed and purified in this dissertation and their related sections or chap-
ters were listed in Table 1.2.  
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Figure 1.1 Structural Similarity between Endogenous Anti-angiogenic Proteins.  A number of 
endogenous angiogenesis inhibitor share similar β-sheet structure [288]. β-sheet structures usually con-
sist the hydrophobic core region of those proteins as highlighted. The platelet factor structure 4 is from 
PDB (access ID: 1RHP). Other structures were illustrated by R. Dings and colleagues [288].  
  
Endostatin
Fibronectin type III repeat domainThrombospondin-1 (TSP-1)
Platelet factor 4 (PF4)
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Figure 1.2 Crystal Structure of Rat CD2D1.  The rat CD2D1 folds as a β-sheet structure with 9 β-
strands (PDB accession ID, 1hng). The D, E, B and A β-strands consist one layer of β-sheet. G, F, C and C’ 
strands compose a second layer of β-sheet [298]. There is a hydrophobic core region in between.  
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Table 1.1 N- and C- Terminal Residues of CD2D1 and ProAgio 
 
 
*: Amino Acids in ProAgio that are different from CD2D1 are shown in bold.  
 
 
 
 
        10         20         30         40         50         60  
RDSGTVQMKL GHGINLNIPN FQCTDDIDEV RWERGSTLVA EFKRKMKPFL KSGAFEILAN  
 
        70         80         90  
GDLKIKNLTR DDSGTYNVTV YSTNGTRILN KALNLKVII  
 
 
Figure 1.3  The Protein Sequence of ProAgio with a Cysteine PEGylation Site.  Total 8 mu-
tations in ProAgio compared to CD2D1. Anti-angiogenic peptides (TVQMKL and NLKVII) were grafted 
into the C- and N- terminal of CD2D1 and shown in bold. A M23C mutation was made to facilitate site-
specific PEGylation of ProAgio.  
 
  
Amino 
Acid 
5 6 7 8 9 10 94 95 96 97 98 99 
CD2D1 Thr Val Trp Gly Ala Leu Asp Leu Arg Ile Leu Glu 
*ProAgio Thr Val Glu Met Lys Leu Asn Leu Lys Val Ile Ile 
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Figure 1.4 Designed Anti-angiogenic Region in ProAgio. The homology model of ProAgio was built 
by a computer program, Modeller, using the C-ray crystal structure of CD2D1 (PDB accession ID, 1HNG) 
as a template. Amino acids involved in anti-angiogenic function are color coded. Orange represents po-
lar residues, magenta represents hydrophobic residues, and blue indicates positively-charged residues. 
(B and C) Different views of the ProAgio model structure.   
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Table 1.2 Index for Protein Expressed and Studied in this Dissertation 
*Abbreviation Description Related Contents 
CD2D1 
Extracellular domain 1 of rat cluster of differential 2 
with CD48 as its natural ligand   [298] 
1.10.4 
HuCD2D1 
Extracellular domain 1 of human cluster of differential 2 
as CD58 its major natural ligand [302] 
4.1.3 
6D31 
A de novo designed metal-binding protein using rat 
CD2D1 as the parental host protein [311] 
5.1 
6D31-ProAgio 
Initial designed anti-angiogenic protein using 6D31 as 
the parental host protein 
5.1 – 5.4  
ProAgio 
The de novo designed anti-angiogenic protein using rat 
CD2D1 as a parental host protein 
1.10.5; Chapter 3; 
and 5 
Met23Cys-ProAgio ProAgio with a Met23Cys mutation 5.9 
ProAgio-PEG 
ProAgio was conjugated with a Y-shaped 20-kDa ma-
leimide-PEG at the Cys23 residue in order to improve 
PK/PD parameters 
5.9 and Chapter 3 
huProAgio 
Based on ProAgio, the anti-angiogenic peptide regions 
were re-designed into huCD2D1 for future clinical stu-
dies 
Chapter 4 
His-huProAgio A purified his-tagged huProAgio  4.5 
CD2D1-PEG 
A Met23Cys CD2D1 mutant with with a Y-shaped 20-
kDa maleimide-PEG at the cys23 residue   
Chapter 3 
*: Only proteins expressed and purified in this dissertation were listed. 
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CHAPTER 2 
METHODS AND MATERIALS 
2.1 Cell lines 
Human umbilical vein endothelium cells (HUVECs) (Invitrogen, Grand Island, NY) cryo-
preserved at the end of the primary culture in a frozen medium containing 10% dimethyl sulfox-
ide (DMSO) were recovered into cell culture flasks at a density of 1.25×104 viable cells/mL. Cells 
were maintained at a 37˚C, 5% CO2, and humidified cell culture incubator in medium 200 (Invi-
trogen, Grand Island, NY) supplied with 1× low serum growth supplement (LSGS) (Invitrogen, 
Grand Island, NY). When 500 mL of medium 200 was supplemented with 10 mL of LSGS, the 
final concentrations of the components in the full growth medium for HUVECs were:  2% v⁄v of 
fetal bovine serum (FBS), 1 µg⁄mL of hydrocortisone, 10 ng⁄mL of human epidermal growth fac-
tor (EGF), 3 ng⁄mL of basic fibroblast growth factor (bFGF), and 10 µg⁄mL of heparin. Initial cul-
tures were maintained for 5 – 6 days until they were 80% confluent with medium-changing 
every other day. Confluent cultures could be maintained by changing medium every day. Sub-
culturing HUVECs was performed by digesting cells with 0.25% trypsin/EDTA (Mediatech, Ma-
nassas, VA) and seeding cells into a new culture vessel at a cell density of 2.5×103 cells/cm2. 
Cryopreserved HUVECs (Invitrogen, Grand Island, NY) showed reduced viability compared to 
the primary culture.  
A human prostate cancer cell line, PC-3M-luc-C6 (PC3) (Caliper Life Sciences, Hopkinton, 
MA) was a kind gift from Dr. Ritu Aneja from Georgia State University (GSU). PC-3M-luc-C6 is a 
bioluminescent light producing cell line derived from PC3M human adenocarcinoma cells by 
stable transfection of the North American Firefly Luciferase gene expressed from the SV40 
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promoter. PC3 cells were maintained in MEM medium (Mediatech, Manassas, VA) supplied 
with 10% FBS (HyClone, Waltham, MA), 1mM glutamine. Cells were passed at 1:5 to 1:10 ratios 
every 2-3 days using 0.25% Trypsin/EDTA.  
Other human cell lines including HCT-116 (Catalog #CCL-247, human colon carcinoma) 
and M4A4 (Catalog #CRL-2915, human metastatic breast ductal carcinoma) were purchased 
from the American type Culture Collection (ATCC, Manassas, VA). All above cell lines were 
maintained and preserved in ATCC recommended culture medium and protocols. 
 
2.2 Site-directed Mutagenesis to Produce Anti-angiogenic Protein cDNA 
2.2.1 Site-directed Mutagenesis  
Desired mutations were introduced to plasmids of interest using QuikChange® II XL Site-
Directed Mutagenesis Kits (Stratagene, Santa Clara, CA). Complementary mutagenic primers 
were designed either by placing desired point mutation, deletion or insertion in the middle of 
the primer flanked with 10 – 15 unmodified base pairs (bps) on both sides or using the online 
software, QuikChange primer design application (www.genomics.agilent.com). Site-directed 
mutagenesis polymerase chain reactions (PCR) were carried out following the manufacturer's 
exact instructions. After the reactions were complete, an amount of 10 units of Dpn I was add-
ed to each reaction, which was incubated for 1 hour at 37˚C to digest the parental plasmid DNA. 
The mutated DNA plasmids were then transformed into XL-1-Blue competent cells provided by 
the kit. Bacterial were applied to a LB agar plate containing 100ng/mL ampicillin and allowed to 
grow overnight. Usually 3 – 6 colonies were chosen to be mini-cultured in 1 – 5 mL of ampicillin 
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containing LB medium. Plasmids were purified and sent for sequencing in a DNA sequencing 
core facility located at GSU.  
 
2.2.2 Multi Site-directed Mutagenesis  
QuikChange® Multi Sit-Directed Mutagenesis kits (Stratagene, Santa Clara, CA) were 
used to generate multiple mutations that were located in the separate termini of the parental 
cDNAs. Different from QuikChange® II XL Site-Directed Mutagenesis Kits, a single mutagenic 
primer instead of a pair is required to mutagenize each site, using a double-stranded DNA tem-
plate. The kit contains a PCR enzyme blend featured with a unique Pfu fusion-based DNA poly-
merase that provides a one step mutation at multiple sites. Mutagenic primers were designed 
using online software, QuikChange primer design application (www.genomics.agilent.com). The 
protocols were provided by the manufacturer.  
 
2.2.3 Transformation Escherichia coli (E. coli) strains  
The JM109 (Promega, Madison, WI) competent cells and XL-blue Super competent Cells 
were used for amplifying a particular plasmid in large quantities. BL-21 (DE3), BL-21 (DE3) pLysS 
competent cell lines were kind gifts from Dr. Jenny Yang from the Chemistry Department at 
GSU. A BL-21 CodonPlus® (DE3) competent cell line was purchased from (Stratagene, Santa Cla-
ra, CA). All three BL-21 cell lines were used to express the proteins of interest in this study. 
When transformations were performed, suitable competent cells were thawed on ice in pre-
chilled 14 mL polypropylene tubes (BD). BL-21 CodonPlus® (DE3) competent cells were incu-
bated with β-mercaptoethanol for 10 minutes prior to transformation as suggested by the 
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manufacturer. Next, 10-100 ng of desired plasmids were added into 50-100 µl of competent 
cells followed by incubation on ice for 30 minutes. Then the mixture was heat shocked by 20-90 
seconds water bath at 42˚C as recommended by manufacturers or established protocols. A vo-
lume of 500 µl of pre-warmed S.O.C medium was added to each tube. After cooling for 2 mi-
nutes on ice, the tubes were incubated at 225 rpm for 1 hour in a shaker set at 37˚C. Each bac-
teria culture was then spread onto individual LB agar plate containing a proper concentration of 
antibiotics for different plasmids.  LB plate was incubated overnight at 37˚C. 
 
2.3 Cloning of the CD2 variants into pGEX-2T Expression Vector 
2.3.1 Mini Prep 
DNA purification from bacterial culture in Small scales (0 – 20 µg) was performed using 
Qiaprep® spin Mini Kit (Qiagen, Hamburg, Germany). A single colony from the freshly trans-
formed plate of bacteria was added to 1 – 5 mL of LB media containing proper concentrations 
of antibiotics. The culture was incubated overnight in a shaker set at 37˚C and 225 rpm. The 
bacterial pellet was collected by centrifugation at 8,000 rpm for 5 minutes at room temperature 
followed by removal of the LB media. Next, cells were re-suspended in 250 µL of buffer P1. An 
equal volume of Buffer P2 (the cell lysis buffer) was then added to the solution. The tube was 
gently inverted 4-6 times to mix followed by immediately adding 350 µL of Buffer N3 (the neu-
tralization buffer). The solution was further mixed by gentle inversion for 4-6 times. The cell 
debris was clarified from the mixture by centrifugation at 13,000 rpm for 10 minutes at room 
temperature. Then the supernatant was transferred to a spin column and centrifuged at 13,000 
rpm for 1 minute, which allowed the plasmid DNA bound to the column membrane. For endA+ 
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bacteria strains, the column was washed once with 500 µL buffer PB by centrifugation at 13,000 
rpm for 1 minute to remove trace nuclease activities. The column was then washed with buffer 
PE and dried by centrifugation for additional 1 – 2 minutes after washing. The plasmids were 
eluted with elution buffer (10Mm Tris-HCl, pH 8.5) or distilled water if further restriction diges-
tion or ligation was desired. The purified DNA usually was used for DNA sequencing to verify 
the construction.  
 
2.3.2 Midi prep 
Moderate amounts (10 µg – 200 µg) of plasmids were purified using the Wizard® Plus 
DNA Purification System (Promega, Madison, WI). The purification procedures were performed 
according to the manufacturer’s instruction. An overnight plasmid-containing bacterial culture 
of 50-100 mL was collected by centrifugation at 8,000 rpm for 10 minutes at 4˚C. The cell pellet 
was completely re-suspended by pipetting in 3 mL of suspension buffer and transferred in an 
autoclaved centrifuge tube (Nalgene, Rochester, NY). A volume of 3 mL of the lysis buffer was 
added into the tube. Then the tube was gently inverted 4-6 times followed by immediately add-
ing 3 mL of the neutralization buffer. The mixture was further gently inverted 4-6 times to mix. 
The cell debris was clarified from the solution by centrifugation for 15 minutes at 14,000 rpm at 
4˚C. The resultant supernatant was transferred into a clean 50 mL conical tube and mixed with 
10 mL of DNA purification resins. The DNA/resin mixture was then loaded to a midi prep col-
umn connected to a Vac-Man® Laboratory Vacuum (Promega, Madison, WI). The supernatant 
was removed by vacuuming followed by washing twice with 15 mL of Column Wash Solution. 
When the last run of wash was complete, the vacuum was allowed to run for additional 30 
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seconds to dry the resins. The column reservoir was then separated from the column, and 
excess Column Wash Solution was removed by centrifugation at 13,000 rpm for 2 minutes. A 
volume of 300 µL of pre-hearted (65˚C) Elution buffer (Tris-HCl, pH 8.5) or distilled water was 
added to each the column and incubated for 1 minute. Next, the eluate was collected by centri-
fugation at 13,000 rpm for 1 minute. The residual amount of ethanol that might interfere with 
following enzymatic reactions was removed from the sample using an evaporation method by 
leaving the cap open overnight at room temperature. The purified plasmids were then stored at 
-20˚C or -80˚C for longer time.  
 
2.3.3 DNA Concentration and Quality Measurement  
The OD260 and OD280 of DNA solutions were measured using a spectrophotometer. DNA 
concentrations were calculated based on the following formula using common extinction coef-
ficient of 50 (µg/mL)-1cm-1for DNA as DNA concentration (µg/mL) = (OD260) × (dilution factor) × 
(50 µb DNA/mL)/(1 OD260 unit). The ratio of OD260 and OD280 was calculated for each sample to 
determine the purity. The accepted purity value is between 1.65 and 1.85. DNA plasmids or 
fragments were further verified by agarose gel electrophoresis. Usually intact DNA plasmids or 
fragments should appear as sharp bands without smear.  
 
2.3.4 Agarose Gel Electrophoresis 
Separation of DNA molecules was performed by agarose gel electrophoresis and DNA 
bands were visualized using double stranded DNA binding dyes such as SYBR Safe (Invitrogen, 
Grand Island, NY) or ethidium bromide (Sigma-Aldrich, St. Louis, MO). Low percent gels (0.8 – 
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1% ) usually used for analyses of DNA plasmids or DNA fragments of large MWs, while higher 
percent gels (> 2%) were used for separation of small molecular weight DNA fragments such as 
PCR products. An appropriate amount of electrophoresis grade agarose (EMD Chemicals, 
Gibbstown, NJ) was weighed and mixed with 50 – 100 mL of 1X TAE (Tris-Base, Glacial Acetic 
Acid, EDTA, pH 8.0). The agarose was melted by heating the mixture using an electronic micro-
wave. Then, the mixture was allowed to cool down below 68˚C before adding ethidium bromide 
at a final concentration of 0.5 µg/mL. Then the liquid was poured into a casting apparatus with 
an appropriately sized and numbered comb. The comb was removed after the agarose became 
firmly solidified at room temperature, and then the gel was properly placed into an electropho-
resis device filled with 1 X TAE buffer. Each DNA sample was mixed with an appropriate volume 
of 5 X DNA loading dye (Fermentas, Glen Burnie, Maryland) to make the final loading dye con-
centration to 1 X. A volume of 5 – 20 µL of such sample was loaded to each well. The gel was 
then subjected to electrophoresis for 45 – 90 minutes at 100 – 120 volts at room temperature. 
DNA fragments in the gel were visualized under the UV light with a wavelength of 302 nm using 
a UV transilluminator equipped with a CCD camera.  
 
2.3.5 Agarose Gel Extraction of DNA 
Following gel electrophoresis, the DNA fragment of interest was extracted from the gel 
for applications such as ligation, mutagenesis, and restriction enzyme digest. All gel extractions 
were performed using the QIAquick Gel Extraction Kit (Qiagen, Hamburg, Germany) according 
to the manufacturer’s instruction. The band of interest was excised from the agarose gel with 
UV safety screens and protective eyewear during gel excision. The excised gel piece was 
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weighed in a pre-weighed microcentrifuge tube. Then buffer QG was added to the tube in a 3:1 
ratio (for example, 300 µL buffer QG to 100 mg gel). A 6:1 ratio of QG buffer was added to 
higher percent gels (> 2%). Then, the mixture was incubated at 50˚C for 10 – 15 minutes in or-
der to completely dissolve the gel. The pH of the resultant solution is indicated by a pH indica-
tor contained in buffer QG. The dissolved DNA only efficiently binds QIAquick membrane when 
the color of the mixture shows yellow color, a color similar to buffer QG. Orange of purple color 
after the gel was dissolved indicates a higher pH that has to be returned ≤ 7.5 by adding 10 µL 
of 3 M sodium acetate, pH 5.0 to the tube. After 1 gel volume of 100% isopropanol was added 
to the sample and mixed, the solution was then transferred to a QIAquick column and centri-
fuge at 13,000 rpm for 1 minute. In order to remove any residual agarose, 0.5 mL of Buffer QG 
was added to and the column was centrifuged again at 13,000 rpm for 1 minute. The column 
was then washed with 0.75 mL of buffer PE to remove any excess salt by centrifugation at 
13,000 rpm for 1 minute. The column was dried by centrifugation for an additional 1 minute, 
and then the DNA was eluted with pre-warmed (65˚C) Buffer EB (10 mM Tris-HCl, pH 8.5) or dis-
tilled water. The eluate was stored at -20˚C until use.  
 
2.3.6 Restriction Enzyme Digestion 
All restriction enzymes were purchased from Fermentas, Glen Burnie, MD. Optimal con-
ditions and protocols followed manufacturer’s instructions. A typical restriction reaction system 
usually is composed of 2 µg of plasmid DNA, 1 µL of restriction enzyme, 2 µL of 10X appropriate 
restriction digest buffer, 16 µL of distilled water. Scaled up reactions usually were performed in 
50 µL or 100 µL reactions with 5 µg or 10 µg of plasmid DNA as substrates separately. When 
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PCR products were digested, 0.2 µg of DNA were used in a 20 µL reaction system. If double di-
gest was desired, proper buffer that suitable for both restriction enzymes was used. Sequential 
digest was performed otherwise. A typical double digest with BamHI and EcoRI was composed 
of 2 µg of plasmid DNA, 1 µL of BamHI, 1 µL of EcoRI, 2 µL of 10X Tango™ buffer (Fermenta, 
Glen Burnie, MD), and 14 µL of distilled water. Reaction mixtures usually were incubated for 1-
16 hours at 30-42 ˚C following manufacturer’s recommendations. The digested fragments were 
separated by agarose gel electrophoresis for extraction or analysis of plasmid constructions.  
 
2.3.7 Ligation of CD2 Variants and pGEX-2T Expression Vector 
Desired CD2D1 cDNA or mutants purified from agarose gel were inserted into pGEX-2T 
expression vector (GE Life sciences, Piscataway, NJ). A 3:1 to 5:1 cDNA to pGEX-2T was used for 
the ligation reaction. To a 1.5 mL Eppendorf tube, 50-100 ng of digested and purified pGEX-2T 
vector, proper calculated amount of cDNA fragments, 1 to 2 µL of ligase buffer, 1 µL of T4 DNA 
ligase, and distilled water were mixed together to a total volume of 10 to 20 µL. The reaction 
was placed at room temperature and then at 16 ˚C overnight for maxima ligation. The ligation 
mixture was then transformed to JM109 competent cells. Correct clones were confirmed by 
DNA sequencing or restriction enzyme digestion after mini DNA purification.  
 
2.4 Expression of the Glutathione (GST)-tagged Proteins 
2.4.1 Optimization of Expression for the GST-tagged Proteins  
 Each expression vector construction was test in different cell lines for maxima 
expression level. The BL-21 (DE3), BL-21 (DE3) pLysS and the BL-21(DE3) CodonPlus® competent 
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cell lines were used in this project for protein expression. Usually 5-6 health colonies were cho-
sen from plates with transformed bacterial. Each colony was added to 2 mL LB medium with 
100 µg/mL and incubated 225 rpm for 2 to 3 hours in a shaker. Then isopropyl-β-D-thio-
galactoside (IPTG) was added to a final concentration of 0.2 mM. The cultures were incubated 
for another 3 to 4 hours. An aliquot of 1 mL of each culture was centrifuged in a 1.5 mL Eppen-
dorf tube and pellets were collected. Sample buffer (50 µL, 1X SDS buffer) were added to each 
tube and boiled for 10 minutes. Samples were then analyzed by SDS gel electrophoresis. The 
colony with highest expression level was chosen for further large scale protein expression. If 
desired expression level was not achieved, the chosen colony was subjected to further optimi-
zation on temperature (18˚C to 37˚C), induction time (2 to 16 hours), and IPTG concentration 
(0.1 to 1mM).    
 
2.4.2 Expression of CD2 Variants in Luria Bertani (LB) Medium 
   ProAgio cDNA bearing pGEX-2T expression plasmid was transformed into BL-21(DE3) Codon-
Plus® competent cells. A healthy colony was inoculated into 3 mL LB medium with 100 µg/mL of ampicil-
lin, which was incubated at 37 ˚C until the optical density (O. D.) 600 nm reaches 0.6 - 0.8. 50 µl of cul-
ture were transferred to 50 mL LB medium and incubated at 37 ˚C overnight with agitations. 15mL of 
such culture were added into 1L LB medium and incubated at 250rpm, 37 ˚C. When the reading of O. D. 
600 nm reached 0.8 - 1.0 (roughly 2 to 2.5 hours), a final concentration of 0.2mM IPTG was added to the 
flask. Then temperature was decreased to 30 ˚C and protein expression was induced and incubated for 4 
to 5 hours until the O. D. reach 1.8 - 2.0. Bacteria were collected by centrifugation at 6000 rpm for 
15min. Pellets were transferred to a 50 mL centrifuge tube and temporarily stored at -20 ˚C until usage.   
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2.5 Purification of CD2D1 and ProAgio 
The cell pellet was defrosted and suspended in lysate buffer (30 mL of lysate buffer per 
each liter growth). DTT was added to the pellet mixture to reach a final DTT concentration of 5 
mM.  EDTA was added to the pellet mixture to reach final EDTA concentration of 10 mM.  The 
mixture was blended for 30 seconds. The blended mixture was separated into multiple small 
plastic beakers (< 25 mL per beaker) and each beaker was sonicated 6 times. The duration of 
each sonication cycle is 10 seconds with a 10 minute interval between sonication cycles. For 
lysis of ProAgio pellets, a light sonication was applied. Lysates were further disrupted by passing 
through a French press 40k cell. Once the sonication cycles were complete, the content was 
centrifuged for 30 minutes at 17,000 rpm. The supernatant was filtered using 0.45 m syringe 
filter while the remaining pellet was re-suspended in lysate buffer to repeat above purification 
steps. After cell lysis, the fusion proteins in the supernatant were loaded onto a column of GS4B 
resin (GE lifesciences, Piscataway, NJ). After binding, each column was washed with 50 mL of 1x 
PBS buffer. The fusion proteins were cleaved by thrombin (2.5 mL of 1x PBS buffer with 30 L of 
thrombin (1 unit/L) on the beads following elution of waste materials. The column was first 
kept at 4 C with agitation for 14 hours, and then placed at room temperature for two hours 
before elution. The proteins were eluted using 20 mL of 1x PBS buffer per column. The eluted 
proteins were further purified using a superdex 75 column (GE lifesciences, Piscataway, NJ) in 
the FPLC and 10 mM Tris elution buffer at pH 7.4.  The size exclusion purification was used to 
further purify ProAgio with 1XPBS buffer, while a SP Sepharose column (GE lifesciences, Pisca-
taway, NJ) was applied for the further purification of CD2D1. The protein was bound to the ca-
tionic exchange column using 20 mM acetate buffer at pH 3.5. The protein was eluted with an 
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increasing pH gradient from 3.5 to 8.0 (50 mM Tris buffer). The identities of CD2 variants were 
confirmed by SDS–PAGE. The protein concentration was measured with  ε280 = 11700 M
−1 cm−1 
for CD2D1 and ε280 = 8480 M
−1 cm−1 for ProAgio. Concentrations were further confirmed by a 
Bradford protein assay using bovine serum albumin (BSA) as a standard.  
  
2.6 Purification of ProAgio-PEG   
2.6.1 Site-specific PEGylation of ProAgio 
After cleavage, Y-shaped maleimide PEG (Jenkem Technology, Allen, TX) powders were 
directly added to column at molar ratio of 1:5 to 1:8 (protein to PEG). The molar concentration 
of ProAgio protein was determined by Bradford protein assay using BSA as a standard. Molar 
concentration was calculated same as section 2.5 because each fusion protein molecule only 
contain 1 molecule of ProAgio recombinant protein. Typical binding for each column required 
an average of 100 – 250 mg of PEG. Mixture was incubated at room temperature for 1 hour or 
at 4 ˚C overnight. PEGylated protein was eluted using 1XPBS.  
 
2.6.2 Purification of ProAgio-PEG Using Ion Exchange Chromatography 
 ProAgio-PEG recombinant protein was dialyzed to 5 mM MES sodium Salt pH 6.0 at 4 ˚C.  
Further purify the protein by an AKTA FPLC system (GE Life Sciences, Piscataway, NJ) equipped 
with a SP high performance Sepharose TM Column (GE Life Sciences, Piscataway, NJ). The purifi-
cation program was performed as following program with flow rate at 5 mL/minute. All frac-
tions were collected at 2 mL/tube. First, the instrument was equilibrated with 2 CV (column vo-
lume) of Buffer A (5 mM MES sodium salt, pH 6.0). Samples were injected into a 10 or 50 mL 
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sample loop. Fractions were collected from this point onward. Most free PEG and PEGylated 
GST did not bind to column and form major UV280 absorbance peaks were discarded. Non-
specific bound proteins were washed off with 5 CV of Buffer B gradients (5 mM MES sodium 
salt, 1M NaCl, pH 6.0) from 0% to 10% to remove non-specific bound proteins. Elution of ProA-
gio-PEG started around 50% Buffer B, fraction 35-40.The column was washed with 3 CV of 100% 
of Buffer B and re-equilibrated with 5 CV of 100% of Buffer A. 
A volume of 20 µL of fractions from each UV absorbance peak was loaded into a SDS-
PAGE gel analysis using coomassie blue staining. PEGylation was visualized by iodine staining. 
The 20,000 Y-shape maleimide PEGylated ProAgio migrated between molecular weight (MW) of 
55-kDa to 70-KDa, which was much slower than the calculated MW of 31-kDa. Protein fractions 
with ProAgio-PEG or CD2D1-PEG were pooled together (usually were fractions 36, 37, 38, and 
39), concentrated, and further dialyzed to 1XPBS for further biology functional assays and ani-
mal experiments.  
2.6.3 Protein stability test 
Purified ProAgio was mixed with FBS in a 1:1 ration. The mixture was incubated at 37˚C 
for desired time. Sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel electrophoresis was 
performed to determine the degradation of ProAgio. The disappearance of ProAgio protein 
band was attributed completely to degradation.  
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2.7 Determination of Protein Concentration 
 The concentration of ProAgio and ProAgio-PEG was determined using UV absorbance at 
280 nm and calculated using an estimated extinction coefficient of 8480 M-1 cm-1. For example, 
an UV absorbance 280 nm of 0.848 was equal to 100 µM (11.28 mg/L) of ProAgio or (31.28 
mg/L) of ProAgio-PEG, because that the PEG chain increased the molecular weight of ProAgio 
but did not affect the protein composition. Protein concentrations were further confirmed us-
ing Bradford protein assay using bovine serum albumin as a standard.  
 
2.8 Conformational Analyses by 1D 1H NMR 
For 1D 1H NMR studies on ProAgio and CD2D1, NMR samples were prepared by diluting 
proteins in 10 mM Tris-HCl with 10% D2O at pH 7.4.  Protein concentrations were varied from 
150 to 300 M.  Dioxane was used as an internal reference for the NMR spectra (3.743 ppm).  
All NMR spectra were recorded using Varian Inova 500 MHz and 600 MHz NMR spectrometers.  
Spectra widths of 6600 Hz and 8000 Hz were used at 500 MHz and 600 MHz, respectively.  A 
water suppression pulse sequence from Varian Biopack was used with 8 K complex data points 
at 25 ºC.  All the 1D NMR experiments were collected with 1024 scans. 
The data were processed with the program FELIX98 (MSI).  After Fourier transformation, 
typically a squared sinebell window function shifted over 75º was used.  Post acquisition sup-
pression of the water signal was achieved by deconvolution of a Gaussian function with a func-
tion width of 20. 
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2.9 Assays to determine the in vitro effects of ProAgio 
2.9.1 Determination of Cell Growth 
HUVEC cells were typsinized and seeded into a 96-well plate at 4x104 cells /mL.  After 16 
– 18 hours of attachment, cells were treated 0 – 40 μM of ProAgio-6D31 or CD2D1 for 48 hours. 
Cell proliferation rates were measured by Thiazolyl blue tetrazolium bromide (MTT) (Sigma-
Aldrich, St. Louis, MO) assay. MTT power was diluted in Hank’s balanced salt solution at 
5mg/mL. 1/Tenth of the total culture volume of MTT solution of added to each well and incuba-
tor for additional 4 hours. Then the supernatant was carefully removed and DMSO was added 
to dissolve the formed crystal. Photometry at 490nm was performed using a PerkinElmer Victor 
3 microplate reader (PerkinElmer, Waltham, MA). The absorbance of cell control was designat-
ed as 100%. The proliferation rates were calculated using the equation: proliferation rate of 
treated cells = absorbance of treated cells/absorbance of cell control. The values were plotted 
using Microsoft Excel. 
 
2.9.2 Cell proliferation Assay (BrdU) 
Cell proliferation rates were determined using BrdU cell proliferation kit (Calbiochem, La 
Jolla, CA). All procedures followed the manufacturer’s instruction. Briefly, HUVECs or M4A4 
cells were trypsinized and seeded into 96 well plates at 4x104 cells/mL. Cells were allowed to 
attach for overnight, and then treated with protein and peptide reagents at desired concentra-
tions for 48 hours. Each concentration was tested in triplet wells. BrdU label was 1:2000 diluted 
into fresh tissue culture media, and 20 µL of this working solution were added to each well to 
be labeled. After incubation for an additional 12 hours, cells were fixed, and then incubated 
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with 100 μL of 1:100 diluted anti-BrdU antibodies at room temperature for 1 hour. After wash-
ing 3 times with wash buffer, a peroxidase goat anti-mouse IgG HRP conjugated antibody was 
added to each well for 30 minutes followed by 3 times washes. Tetra-methylbenzidine sub-
strate solution was incubated with each well for 15 minutes and the reaction was stopped by 
2.5N sulfuric acid. The absorbance in each well was measured a PerkinElmer Victor 3 microplate 
reader (PerkinElmer, Waltham, MA) at dual wavelengths of 450 – 540 nm. The proliferation 
rates of different treatment were compared as folds change of control. Each treatment was re-
peated in triplicate, and experiments were repeated 3 times.  
 
2.9.3 Tube Formation Assay 
The in vitro angiogenesis studies were performed using tube formation assay. HUVCs 
were seeded into a 96 well plate coated with 50 µl of martigel (BD Biosciences, San Jose, CA) for 
each well. Before usage, the coated plates were incubated for 30 minutes at 37°C and 5% CO2 
environment to allow matrix to polymerize. A volume of 50 µL of HUVEC cell suspension (2x104 
cells) was added to each well. For examine HUVECs and PC3 cells co-culture (1:1 mixture) 
formed tubules, a volume of 50 µL of HUVEC suspension containing 1x104 cells was added to 
each well. Stimulators, such as 10% FBS or 1x104 cells PC3 cells were supplied with the culture 
media to promote the formation of endothelial tubules. At the same time, protein and peptide 
reagents were added at desired concentrations in duplicate wells for each concentration. Then 
the angiogenesis assay plate was incubated for 6 – 8 hours at 37°C, 5% CO2 atmosphere. Tube 
formations were observed under a light microscope at 50 X magnification (10 X Ocular lens and 
5 X Obj. Lens). Three digital pictures were taken from each well. Experiments were repeated for 
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three times. The total tubule length per 5X Obj. field for each picture was measured using the 
ImageJ software (National Health Institution, Bethesda, Maryland). Branch points were counted 
manually. 
 
2.9.4 GST Pull-down Assay 
 GST pull-down assays were performed according to protocols described by Kaelin and 
colleagues [312]. GST fusion proteins (GST, GST-CD2D1, and GST-ProAgio) were expressed and 
conjugated to GS4B beads as described in section 2.5. Freshly thawed and routinely maintained 
HUVECs at 80% confluence were rinsed with 1 x Hanks Balanced Salt Solution (HBSS), and incu-
bated with 25 ng/mL human recombinant VEGF (Invitrogen, Grand Island, NY) supplied in full-
culture medium without bFGF described in section 2.1 for additional 16 hours at 37 ˚C, 5% CO2. 
Then cells were washed three times with cold 1 X PBS, pH 7.4. All following procedures were 
performed on ice or under 4 ˚C. Cell pellets were collected by centrifugation at 8,000 rpm for 5 
minutes after cells were physically detached from culture flasks by scraping. Cell pellets were 
resuspended and incubated for 2 hours in NETN lysis buffer supplied with 1 X protease inhibitor 
cocktail (20 mM Tris, pH 8.0; 100 mM NaCl; 1 mM EDTA; 10 µg/nl phenylmethylsulfonyl fluo-
ride; 0.1% Nonident P-40; 500 µM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride; 
150 nM aprotinin; 1 µM E-64; and 1 µM leupeptin hemisulfate). EDTA-free protease inhibitor 
cocktail set V was purchased from Calbiochem, La Jolla, CA. Chemical reagents were purchased 
from Sigmal-Aldrich, St. Louis, MO. The lysates were centrifuged at maximum speed for 2 mi-
nutes in a microcentrifuge. Clear supernatant was transferred to a clean microcentrifuge tube. 
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Total proteins in supernatant were diluted to 1 µg/µL, pre-cleared by GS4B beads for 2 hours, 
and then used for pull-down assay. 
 GS4B beads conjugated with 500 µg of GST, GST-CD2D1, or GST-ProAgio was incubated 
with a total of 500 µg of above HUVEC lysate in a volume of 500 µL for overnight by end-over-
end mixing. Beads were washed three times in lysate buffer. Proteins were eluted by boiling at 
95 ˚C for 8 minutes in 1 X SDS sample buffer (50 mM Tris-HCl, pH 6.8; 2% SDS; 10% glycerol; 1% 
βmercaptoethanol; 12.5 mM EDTA; and 0.02% bromophenol blue). For each sample, 20 µL of 
eluates were loaded to SDS-PAGE gel electrophoresis analysis.  
 
2.9.5  Western Blot  
 Proteins in SDS-PAGE gel were transferred to a PVDF membrane by an electronic trans-
fer device (Bio-Rad, Hercules, CA) for 2 hours at 100 Volts at room temperature in transfer buf-
fer.  Protein bands in PVDF membrane were visualized by staining in 2% Ponceau Solution (Sig-
ma-Aldrich, St. Louis, MO) for 1 minute, and then destained by repeated washing in water. 
Membranes were incubated at room temperature for 30 minutes in 1 X TBST blocking buffer 
(50 mM Tris-HCl, pH 7.6; 150 mM NaCl; 0.1% Tween 20; and 5% bovine serum albumin). A pri-
mary mouse anti-human Galectin-1 (anti-Gal-1) monoclonal antibody (Abcam, Cambridge, MA) 
was incubated with the membrane at 1:500 dilutions for overnight at 4 ˚C. Membrane was 
washed three times for 5 minutes each in 1 X TBST washing buffer (50 mM Tris-HCl, pH 7.6; 150 
mM NaCl; and 0.1% Tween 20). A radish peroxidase (HRP)-conjugated goat anti-mouse IgG sec-
ondary antibody (Thermo Fisher Scientific, Waltham, MA) was incubated with the membranes 
at 1:2000 dilutions for 1 hour at room temperature. Membranes were then washed again for 
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three times in washing buffer and briefly dried. Luminata Western HRP substrates were added 
to each membrane (Millipore, Billerica, MA) and developed for 5 minutes. Membranes were 
then examined using a UV transilluminator with an attached CCD camera. 
 
2.10 In Vivo Effects of ProAgio and ProAgio-PEG Using Xenograft Nude Mice Model 
2.10.1 Animal Care 
 Athymic Nude-Foxn1nu mice (Nude mice) at age of 3-4 weeks were purchased from Har-
lan Laboratories, Indianapolis; IN. Animals were housed in animal facilities located at GSU ani-
mal research center. Experimental procedures for all animal studies were reviewed and ap-
proved by Institutional Animal Care and Use Committee (IACUC) at GSU according to the Public 
Health Service (PHS) guide for care and use of laboratory animals (Protocol approval # 2007-
0126). A standard operating procedure (SOP) for working with laboratory animals were fol-
lowed for routine animal handling, intraperitoneal (i.p.) injection, tumor inoculation, tumor 
measurement, and endpoint euthanasia.  
 Animals were routinely monitored every day for any potential abnormality including 
movement, food intake, body weight, alertness, and skin color. For tumor-bearing mouse, all 
tumors must be measured at least twice a day. Any animal with a tumor size exceeding in any 
direction than 1.5 cm, as stated in the IACUC protocol, should be euthanized. Pain levels from 
all procedures were recorded and reported to staff members at the Department of Animal Re-
search (DAR) at GSU. Pain levels were categorized following the U.S. Department of Agriculture 
(USDA) classifications for pain as follows: B represents that animal are being bred, conditioned, 
or held for teaching, testing, experiments, and research; C means that tests will be conducted 
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involving no pain; and D indicates that procedures will be conducted involving accompanying 
pain or distress that will be relieved by treatment with anesthetic, analgesic, or tranquilizing 
drugs.   
 
2.10.2 In Vivo Xenograft Model 
PC-3M-luc-C6 cells were cultured in MEM medium with 8% FBS. Cells were trypsinized 
and suspended in 1 X HBSS mixed with 50% volume of matrix gel. The mixture was kept on ice 
until injection. Animals were placed in an anesthesia induction chamber in a bio-safety II cabi-
net located in a standard operating room in DAR facilities. Animals were anesthetized using 
isoflurane administrated by a vaporizer. Anesthetized animals were kept in a warm re-
circulating water heating pad during anesthesia. The injection area was sanitized with ethanol 
pads. A volume of 100 µL this suspension containing 5X106 cells was subcutaneously injected 
into one flank of each nude mouse. Five to seven days after tumor cell inoculation, treatments 
were initiated when the xenografts were clearly established and had reached a volume of 50–
100 mm3. All reagents were administered by i.p. injection at desired doses (buffer: 1 X PBS; 
ProAgio: 5 mg/kg/day; ProAgio-PEG: 2.5 – 20 mg/kg/day; CD2D1-PEG: 20 mg.kg/day; Avastin: 
20 mg/kg/twice weekly). Tumor sizes and mice weights were measured and recorded every 
other day with a digital caliper and a digital balance. Tumor volumes were measured using for-
mula: Tumor volume (mm3) = π/6 x (length x width x width).  
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2.10.3 Determination of Tumor Weights 
At the end of treatment, animals were euthanized according to the established SOP ap-
proved by DAR. Briefly, animals were placed in a plastic CO2 gas chamber in the DAR facility 
procedure room. CO2 gas valve was slowly turned on, and gas flow will be maintained for at 
least 1 minute after apparent clinical death. Then, the gas valve was turned off. After animals 
were removed from the gas chamber, unintended recoveries were voided by physical euthana-
sia. Then, tumors were carefully dissected from the tumor-bearing mice without adjacent tis-
sues or skins. Tumors ware weighed using a digital balance individually.  
 
2.10.4 CD31 Immunofluorescence (IF) Staining of Frozen Slides 
Fresh dissected normal mouse organs and tumor tissues were placed into cryo-molds, 
covered with OCT compound, and then snap-frozen in liquid nitrogen. Tissue blocks were sliced 
into 10 or 20 µM thick sections using a cryostat. For staining of the endothelial marker, CD31, 
10 – 20 µM thick sections were used. Sections were dried on Superfrost Plus slides (VWR Inter-
national, Radnor, PA) for I hours. Specimens were permeabilized with TBST buffer (0.1 % Triton 
X-100 (Sigma-Aldrich, St. Louis, MO), 50mM Tris-HCl, 150 mM NaCl, pH 7.5) and incubated in 
blocking buffer (5% bovine serum albumin in TBST buffer) for 1 hour at room temperature to 
block nonspecific antibody binding. Then ECs were stained using a rat anti-mouse CD31 (BD 
Pharmingen, San Diego, CA) and a green fluorescence conjugated anti-rat IgG second antibody. 
Briefly, sections were washed three times with TBST buffer for 5 minutes each time with gentle 
agitation. Then, 100 - 200 µl of rat anti-mouse CD31 (1:1000 diluted in TBST buffer) antibodies 
were added to each section and incubated at room temperature for 1 hour or 4 ˚C overnight. 
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Specimens were rinsed again with TBST buffer and mounted in ProLong® Gold Antifade Reagent 
with DAPI (Invitrogen, Grand Island, NY) after briefly drying in air.  
 
2.10.5 Mean Vessel Density (MVD) Determination of in Xenograft Tumors 
Specimens were examined with a Zeiss 700 Axiophot fluorescence microscope (Carl 
Zeiss Optical, Thornwood, NY). In each mouse, three sections were chosen from top and middle 
points of each xenograft. CD31 stained slides were scanned under low magnification (5X objec-
tive and 10X ocular lens). After the highest vessel density was determined in the slides, an area 
of 319.8 X 319.8 µM with the highest amount of vessels was scanned under a 20X objective lens 
and 10X ocular lens. For comparison, all slides were stained under same conditions, and all im-
ages were taken under the same device setting.  Images of from each section were analyzed for 
MVD, vessel count, and branching points. The total number of vessel length within each of the 
image was measured using a Zeiss LSM image browser (Carl Zeiss Optical, Thornwood, NY). 
MVD were determined using methods described by Weidner and coworkers [313]. Briefly, any 
clear pattern of green fluorescent stained EC or EC cluster within the tumor tissue that sepa-
rated from connective-tissues was counted as one vessel. Microvessels in sclerotic areas or ad-
jacent to connective tissues were not considered. At least three MVD from different sections 
within a tumor were examined and counted for statistic analysis. A vessel branching point was 
defined as any green fluorescent staining with a pattern of 3 branches connected into one dot.  
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2.10.6 Determination of Organ Toxicity  
General toxicity was evaluated by measuring body weight changes and observing daily 
behavior and food intakes. In order to determine organ toxicity, major organs including heart, 
kidney, liver, and spleen were dissected out. One set of organs from each mouse were fixed in 
4% paraformaldehyde/PBS solution. Hematoxylin and eosin (H&E) staining of these fixed organs 
were processed in the laboratory of Dr. Hans Grossniklaus at the department of Ophthalmology 
and Pathology at Emory University. Pathological examinations were performed by Dr. H. Gross-
niklaus. In order to determine the vessel toxicity, one set of major organs from each mouse 
were snap frozen into liquid nitrogen with O.C.T imbedding. Organs were then sliced and 
processed for CD31 IF staining using methods described above. At least three different sections 
from each organ were examined for H&E and CD31 IF staining respectively.  
 
2.11  Statistics Analysis 
Quantitative data from cell proliferation and MTT cell viability assays were described in 
mean ± S.D. (standard deviation). In animal experiments, quantitative data were described in 
mean ± S.E.M. (standard error of mean). Statistic evaluations of data from cell proliferation, 
tube formation, and CD31 IF-staining were performed with unpaired student’s t tests (two-
tailed). For evaluation of in vivo data with normal distributions, ANOVA one way tests were per-
formed using SPSS (IBM, Armonk, NY), a statistic software. Otherwise, Welch’s t tests were used 
in order to compare the tumor growth curves of two different treatment groups.  In any case, a 
calculated possibility value less than 0.05 (P < 0.05) was considered statistically significant.  
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Inhibition of angiogenesis is a promising avenue for cancer treatment. Substantial ef-
forts have been made to develop agents that target vascular endothelial growth factor (VEGF) 
and other growth factor pathways. We have developed a new class of anti-angiogenesis pro-
teins by integrating the short anti-parallel β-sheet forming sequences of the endogenous anti-
angiogenesis proteins into a stable host protein, the domain 1 of rat CD2 (CD2D1). The designed 
protein exhibits strong in vitro activity in inhibition of human umbilical vein endothelial cell 
(HUVEC) proliferation with no effects on epithelial cells. Tests with PC-3 xenografts showed that 
the designed protein strongly inhibits tumor growth. Histological analyses indicated that tumor 
mean vascular count is dramatically reduced, while the vessels in other organs are not affected, 
upon the treatments with the developed agents.   
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Solid tumors will not grow beyond 3 – 4 mm in diameter without building up their own 
blood supply. The establishment of tumor blood vessels is also essential for cancer metastasis 
[7, 16, 30]. Anti-angiogenesis, mono-therapy or in-combination with other therapeutic agents, 
represents a very promising approach for cancer treatment (reviewed in [314, 315]). Successes 
have been achieved, such as bevacizumab (avastin, Roche), a FDA approved anti-angiogenesis 
drug [28, 137]. However, clinical studies have revealed that the cancer patient survival benefits 
of anti-angiogenic drugs have thus far been insignificant (reviewed in [316]). In addition, most 
studies in development of anti-angiogenesis agents have been mainly focused on strategies of 
blocking vascular endothelial cell growth factor and its receptor (VEGF/VEGFR) signaling or oth-
er receptor tyrosine kinase (RTK) pathways that play a role in promoting endothelial cell prolife-
ration and migration (reviewed and investigated in [317-322]).   
Studies have revealed a fine balance between endogenous pro-angiogenic factors, such 
as VEGF, FGF, PDGF, and endogenous angiogenesis inhibitors, such as many anti-angiogenic 
peptides generated from ECM (reviewed in [215, 323, 324]). Tipping the balance of pro-
angiogenic and anti-angiogenic will have profound effects on tumor growth. Substantial efforts 
were made in attempting to harness the natural anti-angiogenesis activity to starve cancers. 
Many endogenous polypeptides, such as endostatin, angiostatin, platelet factor 4 (PF4), and 
thrombospondin, in blood circulation have been isolated and identified. Studies indicate that 
these endogenous anti-angiogenesis polypeptides play a critical role in controlling tumor angi-
ogenesis that are vital for growth of primary tumors and metastases [223, 323, 325-327]. The 
detailed molecular mechanism by which these endogenous anti-angiogenic polypeptides exert 
their anti-angiogenesis activity is not well understood. It was noted that a common structure 
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moiety, a short anti-parallel β-sheet with certain amino acid sequence consensus, exists in most 
of these anti-angiogenesis polypeptides. It was revealed that anti-parallel β-sheet is critical for 
the anti-angiogenesis activity [281, 282]. Thus, efforts were made to use short peptides that 
would mimic the structure of the short anti-parallel β-sheet. Experiments demonstrate that the 
peptide mimics indeed has good anti-angiogenesis activity [281]. However, due to in vivo insta-
bility and pharmacological disadvantage, the peptide is not dose effective in the in vivo applica-
tions.   
 
We employed an approach of rational protein design by integrating the short anti-
parallel β-sheet forming amino acid sequences into a β-sheet region of a stable host protein, 
domain one of rat CD2 (CD2D1) (Figure 3.1). The engineered protein (named as ProAgio the-
reafter) was expressed in bacterial E. coli. , and subsequently purified (Figure 3.S1A). The result-
ing protein exhibited structural properties very similar to that of the host protein CD2D1 as 
demonstrated by the 1D 1H-NMR analyses (Figure 3.S1B). To increase protein solubility and 
blood circulation time, the designed ant-angiogenesis protein agent was site-specifically PEGy-
lated using 20-kDa maleimide polyethylene glycol (PEG), a molecule with Y-shaped PEG chain 
(denoted as ProAgio-PEG), at an introduced cysteine residue (Figure 3.S1C). 
 
To determine the effects of our developed protein agent on the endothelial cells, we 
carried out cell proliferation assays using the HUVEC cells. The cells were treated by various 
concentrations of developed protein, ProAgio, buffer, and the host protein, CD2D1. Bevacizu-
mab, a FDA approved anti-angiogenesis drug, was also used in our test as a comparison. It was 
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clear that the ProAgio inhibits endothelial growth media (containing 3 µg/mL of bFGF and 10 of 
µg/mL EGF) induced HUVEC cell proliferation, whereas bevacizumab does not (Figure 3.1B). We 
further tested whether the effects were specific to endothelial cells. To this end, the same cell 
proliferation assays were carried out with HUVECs, endothelial cells and M4A1, an epithelial cell 
type the presence of 5 and 10 µM of ProAgio.  It was clear that strong anti-proliferation effect 
was induced by the agent with HUVEC cells, while no effects were observed with M4A1 cells 
(Figure 3.1C). The observations indicated that the effects of ProAgio were endothelial cell spe-
cific. To further verify the in vitro anti-angiogenesis activity, we carried out the in vitro endo-
thelial cell tube formation assay using HUVEC cells. It was evident that the ProAgio almost com-
pletely disrupted the endothelial tube formed by the PC3 and HUVEC co-culture formed tu-
bubles at concentration of 20 µM (Figure 3.1D).  
 
We next asked whether the developed protein would have activity in inhibition of tumor 
growth in animal models of human cancer cells. To this end, we created a xenograft model of 
PC3 cells using immunodeficient mice. Tumor bearing mice were treated with various concen-
trations of ProAgio-PEG and PEGylated CD2D1 (CD2D1-PEG) (20 mg/kg), and buffer saline for 20 
days via one dose per day (i.p. injection). The treatments were started when the tumor volumes 
reach 50 mm3 (at the seventh day post tumor inoculation). It was clear that ProAgio-PEG inhi-
bited the tumor growth almost completely at the dose of 20 mg/kg, while as controls did, the 
tumors grew at the normal rate in the mice treated with buffer saline and the PEGylated host 
proteins, CD2D1-PEG, at 20 mg/kg (Figure 3.2A). There was a clear dose dependent increase in 
tumor growth inhibition. However, the dose dependence became less dramatic after the dose 
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of 10 mg/kg. To further test the effectiveness of our developed protein agent, we carried out 
treatment experiments with the PC-3 xenograft using ProAgio-PEG and avastin bevacizumab 
side-by-side. We used 20 mg/kg i.p. (twice/weekly) for avastin and 10 mg/kg i.p. daily dose for 
the protein ProAgio-PEG with the same treatment scheme as above. The results demonstrated 
that the ProAgio-PEG was significantly more effective in inhibition of tumor growth than the 
avastin bevacizumab treatment course at the designed doses (Figure 3.2C). By the end of the 
treatment course, tumors in each treatment group were excised and weighed. There were sub-
stantial differences in the tumor weights of the ProAgio-PEG and PEGylated host protein treat-
ment groups. There were also significant differences in tumor sizes between the ProAgio-PEG 
and avastin bevacizumab treatment groups (Figure 3.2B and D). To analyze the anti-
angiogenesis effects of the treatment of the designed agent, we carried out Immunofluores-
cence (IF) staining of CD31, an endothelial marker, with the frozen tissue sections prepared 
from tumors that were collected at the end of each treatment course. IF staining (Table 3.1A) 
showing examples of staining slides demonstrated that the blood vessels were dramatically re-
duced (both in density and length). Statistical analyses of CD31 stains indicated that upon the 
treatment by ProAgio-PEG there were dramatic reductions in micro-vessel density (MVD), in-
cluding branch points, and vessel lengths (Table 3.1). The ProAgio-PEG treatment led to a much 
large MVD reduction compared to that of avastin treatment group (Table 3.1B). 
 
In principle, a good anti-angiogenesis agent should be less toxic to existing blood vessels 
in normal tissue/organs. To assess whether the designed protein disrupted the non-tumor 
blood vessels, we prepared tissue sections from liver, kidney, and spleen that were collected 
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from the mice that were treated by the different agents. The tissue sections were analyzed by 
hematoxylin and eosin (H&E) staining and immunostaining. HE staining revealed that there was 
no obvious abnormality in tissue anatomy structure, and no damage lesion/necrosis was ob-
served (Figure 3.3A). IF staining using the anti-CD31 antibody suggested that there was no sig-
nificant disruption and reduction of blood vessels in the liver, kidney, and spleen upon the 
treatments with ProAgio-PEG and avastin compared to those in the groups that were treated 
with the and PBS buffer saline. We further analyzed any possible cardiovascular damages upon 
the treatment with the designed agents. Hearts were excised at the end of the treatment 
course. The cardiac tissues were sectioned. The tissue sections were analyzed by either H&E 
staining or by IF staining using anti-CD31 antibody. The histology analyses indicated that there 
was no cardiovascular damage upon the treatment with the ProAgio-PEG as compared to those 
in the treatment groups with PEGylated CD2D1 and buffer saline (Figure 3.3B). 
 
We have successfully developed an anti-angiogenesis agent by rational protein design. 
The in vitro and in vivo experiments demonstrate the effectiveness of our designed protein. The 
developed agent is not toxic to normal blood vessels and other tissue/organs, providing a prom-
ising potential for future clinical applications. Most current available anti-angiogenesis agents 
target VEGF/VEGFR or other RTK pathways. Such agents often cause unwanted biological side 
effects [328, 329]. In addition, many cancers are resistant to the inhibition of VEGF/VEGFR 
[330]. Our developed protein is one of a very few examples that do not act through targeting 
VEGF/VEGFR or any other RTK pathways. Importantly, our study provides an example of proof-
of-concept to harness the natural anti-angiogenesis activity to starve cancers. In addition, our 
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study introduced a new strategy to integrate a small bio-active structural motif or an unstable 
short circulating peptide into a stable host protein. The resultant protein overcomes the major 
disadvantage of therapeutically peptides e.g. in vivo instability and unfavorable pharmacologi-
cal properties. This concept can be extended to the design and development of other protein 
drugs. Our system certainly will create a new platform for design of therapeutic agents by de 
novo protein design. 
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Figure 3.1 ProAgio is a De Novo Designed Anti-angiogenic Agent. 
 (A) Anti-angiogenic peptide sequences (TVQMKL and NLKVII) were de novo designed into the N- and C-
terminal β-strands of CD2D1 separately. The homology model of ProAgio was built by a computer pro-
gram, Modeller, using the X-ray crystal structure of CD2D1 (PDB accession ID, 1hng) as a template. Ami-
no acids involved in anti-angiogenic function are color coded. Orange represents polar residues, magen-
ta represents hydrophobic residues, and blue indicates positively-charged residues. (B and C) Different 
views of the ProAgio model structure.   
 
 
 
 
 
 
A B
C
91 
 
 
 
Figure 3.S1 Molecular Cloning and Protein Generation  
The anti-angiogenic peptides sequence (TVQMKL and NLKVII) were designed into the N- 
and C-terminal of CD2D1 separately. Mutations of W7Q, G8M, A9K, D94N, R96K, I97V, L98I, and 
E99I were created by replacing correspondent deoxyribonucleic acids in the cDNA sequence of 
D1-CD2 using a Site-directed® mutagenesis kit (Stratagene, Santa Clara, CA). The ProAgio cNDA 
was inserted into a pGEX-2T vector (GE lifesciences, Piscataway, NJ). The ProAgio protein was 
expressed with a glutathione (GST) tag fused into the N-terminal and purified by GS-4B column. 
Then the GST tag was removed from ProAgio via thrombin cleavage, and the protein was further 
purified by size-exclusion column (Fig. S1A). 1H-NMR analysis showed that ProAgio has an anti-
parallel β-sheet structure that is similar to that of CD2D1 (Fig. S1B). A cysteine mutation (M23C) 
was introduced into CD2D1 and ProAgio in order to site specifically PEGylate both proteins by 
conjugate a 20-kDa maleimide polyethylene glycol (PEG) to the cysteine site. The ProAgio-PEG 
and CD2D1-PEG were purified by cation exchange column (Fig. S1C). 
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Figure 3.S1A Purification of ProAgio by Gel filtration chromatography. Gel filtration chromatography 
was performed using PBS buffer, pH 7.4 with a flow rate of 1 mL/min. ProAgio was eluted in the major 
peak composed of fraction 9 – 15. Insert figure: SDS gel electrophoresis of fraction 6 – 19.     
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Figure 3.S1B Comparison between the 1D H1-NMR Spectra of ProAgio and CD2D1.  NMR samples 
were prepared by diluting proteins in 10 mM Tris-HCl with 10% D2O at pH 7.4. Dioxane was used as an 
internal reference for the NMR spectra (3.743 ppm).  All NMR spectra were recorded using Varian Inova 
500 MHz and 600 MHz NMR spectrometers.   
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Figure 3.S1C  Purification of ProAgio-PEG by Cation-exchange Chromatography. 
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Figure 3.S1C  Purification of ProAgio-PEG by Cation-exchange Chromatography. PEGylated ProAgio 
(ProAgio-PEG) was purified using binding buffer (5 mM MES, pH 6.0) and elution buffer (5 mM MES, 1 M 
NaCl, pH 6.0). Two major UV-280 absorbance peaks (1 and 2) were observed in cation-exchange chro-
matography. Fractions from each peak were collected and analyzed by SDS electrophoresis and coomas-
sie blue staining (insert picture). In the insert picture, Lane 1: pre-stained protein marker (Fermentas, 
Glen Burnie, MD), Lane 2 – 5: elution fraction 3 – 7 from peak 1, and Lane 7 – 10: elution fraction 25 – 28 
from peak 2 containing ProAgio-PEG. In SDS gel, ProAgio-PEG migrated between 55- and 79-KDa molecu-
lar markers, which was slower than actual its actual molecular weight (31-kDa).   
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Figure 3.1B  ProAgio Inhibits EC Proliferation. 4x104 cells/mL of HUVECs were seeded into a 96 well 
plates.  Cells were allowed to attach for overnight, then treated with proteins at 5 or 10 µM for 48 
hours. BrdU label was added to each well for 12 additional hours. Proliferation rates were measured 
under dual wavelengths of 450 – 540 nm. The experiment was repeated 3 times.  
  *: ProAgio (5 µM) versus CD2D1 (5 µM), and ProAgio (10 µM) versus CD2D1 (10 µM) showed statistical-
ly significant differences (P < 0.001, unpaired student’s t test, two-tailed).  
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Figure 3.1C ProAgio has no Anti-proliferation Effects on M4A1 Cells. Cells were seeded into a 96 
well plates at 4 – 1 X 105/ mL overnight in order to gain same confluence as HUVECs (Invitrogen, Grand 
Island, NY).  Then cells were treated with proteins at 5 or 10 µM for 48 hours. BrdU label was added to 
each well for 12 additional hours. Proliferation rates were measured under dual wavelengths of 450 – 
540 nm. The experiment was repeated 3 times. 
  
0
10
20
30
40
50
60
70
80
90
100
CD2D1 ProAgio
C
e
ll 
P
ro
lif
e
ra
ti
o
n
 R
a
te
 (
%
C
o
n
tr
o
l)
Treatment of M4A1
5μM
10μM
98 
 
 
a 
 
b                                                                      c 
  
 
Figure 3.1D ProAgio Inhibits In Vitro HUVEC-PC3 Tube Formation.  
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Figure 3.1D ProAgio Inhibits In Vitro HUVEC-PC3 Tube Formation. (a):  A total number of 1x104 
HUVEC cells and 1x104 PC3 cells were seeded into a 96-well plate coated with 50 µl of matrigel (BD Bios-
ciences, San Jose, CA) each well. Endothelial tubules were allowed to form at 37°C, 5% CO2 atmosphere. 
Formation of endothelial tubules was observed from 6-8 hours. Pictures were taken using 10 x ocular 
and 5 x objective (Obj.) lenses. A typical picture from each treatment group was shown in upper figures. 
(b): Tubule lengths (mm/5 x Obj. field) were measured using ImageJ (NIH, Bethesda, MD) (the lower left 
panel). (c): Numbers of branch point/5 x Obj. field were manually counted (the lower right panel). The 
experiment was repeated 3 times. Data was shown as mean ± S.D..  
***: P < 0.001, unpaired student’s t test, two-tailed (experimental group versus PBS buffer control 
group).  
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Figure 3.2A ProAgio Blocks Growth of PC3 Xenografts in a Dose-dependent Manner.  
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Figure 3.2A ProAgio Blocks Growth of PC3 Xenografts in a Dose-dependent Manner. A vo-
lume of 100 µl (5X106) PC3 cells were subcutaneously injected into nude mice. Treatments were in-
itiated when the xenografts were clearly established and had reached a volume of 50 – 100 mm3. All 
reagents were administered by intraperitoneal injection (i.p.) at desired doses (buffer: 1 X PBS; ProAgio: 
5 mg/kg/day; ProAgio-PEG: 2.5 – 20 mg/kg/day). Tumor dimensions were measured every other day. 
Tumor volume were calculated using formula: Tumor volume (mm3) = π/6 x (length x width x width). 
Statistic significances were evaluated using Welch’s t tests. P < 0.05 was considered significant (n = 6 for 
each group). 
*: ProAgio-PEG (2.5 mg/kg/day) versus Buffer treated group was not significantly different, P > 0.05. 
**: ProAgio (5 mg/kg/day) versus buffer treated, ProAgio-PEG (5 mg/kg/day), and ProAgio-PEG 
(10mg/kg/day) versus buffer treated group were significantly different, P < 0.05. 
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Figure 3.2B ProAgio-PEG Reduces End-point Tumor Weights. 
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Figure 3.2B ProAgio-PEG Reduces End-point Tumor Weights.  A volume of 100 µL (5X106) PC3 
cells were subcutaneously injected into nude mice. Treatments were initiated when the xenografts were 
clearly established and had reached a volume of 50–100 mm3. All reagents were administered by intra-
peritoneal injection (i.p.) at desired doses (buffer: 1 X PBS; ProAgio: 5mg/kg/day; ProAgio-PEG: 2.5 – 20 
mg/kg/day). Tumor from each mouse was dissected in the last day of treatment and weighed by a digital 
balance. Tumor dimensions were measured every other day. Tumor volume were calculated using for-
mula: Tumor volume (mm3) = π/6 x (length x width x width). Statistic significances between groups were 
evaluated using ANOVA one way test (n = 6). P < 0.05 was considered significant. 
*: ProAgio-PEG (2.5 mg/kg/day) versus Buffer- treated group was not significantly different, P > 0.05. 
**: ProAgio (5 mg/kg/day) versus buffer treated, ProAgio-PEG (5 mg/kg/day), and ProAgio-PEG 
(10mg/kg/day) versus buffer-treated group were significantly different, P < 0.05. 
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Figure 3.2C Comparison between ProAgio-PEG and Avastin Treated PC3 Xenografts. 
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Figure 3.2C Comparison between ProAgio-PEG and Avastin Treated PC3 Xenografts. Human 
PC3 cells were subcutaneously injected into nude mice. Treatments were initiated when the xenografts 
were clearly established and had reached a volume of 50–100 mm3. All reagents were administered by 
intraperitoneal injection (i.p.) at desired doses (buffer: 1 X PBS, pH 7.4, 200 µL/day; ProAgio-PEG 20 
mg/kg/day, CD2D1-PEG: 20 mg.kg/day; Avastin: 20 mg/kg/ twice weekly). Tumor from each mouse was 
dissected in the 20th day of treatment and weighed by a digital balance. Tumor dimensions were meas-
ured every other day. Tumor volume were calculated using formula: Tumor volume (mm3) = π/6 x 
(length x width x width). Statistic significances between groups were evaluated using Welch’s t test 
(n=6). P < 0.05 was considered significant. *: P > 0.05 for CD2D1-PEG (20 mg/kg/day) versus Buffer-
treated group; **: P < 0.05 for avastin (20 mg/kg, twice weekly) versus buffer treated group; ***: P < 
0.001 for ProAgio-PEG (20 mg/kg/day) versus buffer-treated group; and P > 0.05 for Avastin (20 mg/kg/ 
twice weekly) versus ProAgio-PEG (20mg/kg/day). 
  
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2D ProAgio-PEG and Avastin Reduces End-point Tumor Weights. 
  
PBS
CD2D1-PEG (20 mg/kg)
Avastin (20 mg/kg)
ProAgio –PEG (20 mg/kg)
0
50
100
150
200
250
300
350
400
450
500
PBS CD2D1-PEG 
(20mg/kg)
Avastin (20 mg/kg) ProAgio-PEG (20 
mg/kg)
Tu
m
o
r 
W
e
ig
h
t 
(m
g)
Treatment
**
***
*
107 
 
 
 
 
Figure 3.2D ProAgio-PEG and Avastin Reduces End-point Tumor Weights. A volume of 100 µL 
(5X106) PC3 cells were subcutaneously injected into Nude mice. Treatments were initiated when the 
xenografts were clearly established and had reached a volume of 50–100 mm3. All reagents were admi-
nistered for 20 days by intraperitoneal (i.p.) injection at desired doses (buffer: 1 X PBS; ProAgio-PEG 20 
mg/kg/day, CD2D1-PEG: 20 mg.kg/day; Avastin: 20 mg/kg/twice weekly). Tumor from each mouse was 
dissected in 20th day of treatment and weighed by a digital balance. Statistic significances between 
groups were evaluated using ANOVA one way test. P < 0.05 was considered significant (n = 6 for each 
group). 
*: P > 0.05 for CD2D1-PEG (20 mg/kg/day) versus Buffer treated group; **: P < 0.05 for Avastin (20 
mg/kg/ twice weekly) versus buffer treated group; ***: P < 0.01 for ProAgio-PEG (20 mg/kg/day) versus 
the buffer treated group; and P > 0.05 for Avastin (20 mg/kg/twice weekly) versus ProAgio-PEG 
(20mg/kg/day). 
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Table 3.1A. MVD Comparison between ProAgio and ProAgio-PEG treated PC3 Xenografts.   
 
 
 
 
  
 
 
PBS 
ProAgio 
(5mg/kg) 
ProAgio-PEG 
(2.5 mg/kg) 
ProAgio-PEG 
(5 mg/kg) 
ProAgio-PEG 
(10 m/kg) 
*Vessel Length 
(µM) 
1326.59 ± 157.53 
b
569.86 ± 64.67 
a
1044.63 ±105.94 
a
 548.57 ± 69.0 
b
 441.29 ± 80.8 
**MVD 15.83 ± 1.78 
a
12.17 ± 1.75 
a
 16.93 ± 1.48 
C
 10.11 ± 1.06 
C
 8.5 ± 1.41 
Branching Point 8.28 ± 1.98 
c
1.39 ± 0.16 
a
 5.8 ± 1.28 
b
 2.78 ± 0.51 
C
 1.56 ± 0.44 
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Table 3.1A. MVD Comparison between ProAgio and and ProAgio-PEG Treated PC3 Xenografts. 
Human PC3 xenograft-bearing nude mouse were treated for 20 days by intraperitoneal (i.p.) injection at 
desired doses (buffer: 1 X PBS; ProAgio-PEG 20 mg/kg/day, CD2D1-PEG: 20 mg.kg/day; Avastin: 20 
mg/kg twice weekly). Snap frozen tumor tissue blocks were sliced into 10 µM thick sections using a 
cryostat. ECs were stained using a rat anti-mouse CD31 (BD Pharmingen, San Diego, CA) and a green flu-
orescence conjugated anti-rat IgG second antibody. After the highest vessel density within a section was 
determined under lower objective lens (5X), an area of 319.8 X 319.8 µM with the highest amount of 
vessels was scanned under a 20X objective lens and 10X ocular lens.    
*Vessel Length: the total number of vessels length within each of the image was measured using a Zeiss 
LSM image browser. Data were shown in µm/319.8 X 319.8 µm area. 
** Mean Vessel Density (MVD):  MVD were determined using methods described by Weidner and co-
workers [330]. Briefly, any clear pattern of green fluorescent stained EC or EC cluster within the tumor 
tissue that separated from connective-tissues was counted as one vessel. Microvessels in sclerotic areas 
or adjacent to connective tissues were not considered. 
a, b, c
 :Statistic significances were evaluated using unpaired Student’s t test (two-tailed). ). All values 
represented as mean ± S.E. (n=6 for each group). P < 0.05 was considered significant. a: P > 0.05, b: P < 
0.05, and c: P < 0.01. All P values were compared between each treatment group versus buffer treated 
group.  
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Table 3.1B MVD Comparison between ProAgio and Avastin Treated PC3 Xenografts. 
  
PBS                     CD2D1-PEG              Avastin ProAgio-PEG
 
 
PBS 
CD2D1-PEG 
(20 mg/kg) 
Avastin 
(20 mg/kg) 
ProAgio-PEG 
(20 mg/kg) 
*Vessel Length 
(µM) 
1326.59 ± 157.53 
a
 1119.02 ± 
169.84 
C
 545.61 ± 147.8 
C
 269 ±79.32 
**MVD 15.83 ± 1.78 
a
 14.33 ± 1.22 
a
 8.44 ±2.10 
C
 5.50 ± 1.27 
Branching Point 8.28 ± 1.98 
a
 8.05 ± 1.72 
b
 2.2 ± 0.91 
C
 0.44 ± 0.16 
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Table 3.1B MVD Comparison between ProAgio and Avastin Treated PC3 Xenografts. Human PC-3 
xenograft-bearing nude mouse were treated for 20 days by intraperitoneal (i.p.) injection at desired 
doses (buffer: 1 X PBS; ProAgio-PEG 20 mg/kg/day, CD2D1-PEG: 20 mg/kg/day; Avastin: 20 mg/kg /twice 
weekly). Snap frozen tumor tissue blocks were sliced into 10 µM thick sections using a cryostat. ECs 
were stained using a rat anti-mouse CD31 (BD Pharmingen, San Diego, CA) and a green fluorescence 
conjugated anti-rat IgG second antibody. After the highest vessel density within a section was deter-
mined under lower objective lens (5X), an area of 319.8 X 319.8 µm with the highest amount of vessels 
was scanned under a 20X objective lens and 10X ocular lens.  The upper panel showed CD31 IF staining 
images of PBS, CD2D1-PEG, ProAgio-PEG and avastin treated tumor tissue. Each picture represented 
mean vessel count (MCV) for each treated group. CD31 was labeled with green fluorescence. Nucleus 
was labeled with DAPI and showed in blue color). 
*Vessel Length: the total number of vessels length within each of the image was measured using a Zeiss 
LSM image browser. Data were shown in µm/319.8 X 319.8 µm area.  
** Mean Vessel Density (MVD):  MVD were determined using methods described by Weidner and co-
workers [313]. Briefly, any clear pattern of green fluorescent stained EC or EC cluster within the tumor 
tissue that separated from connective-tissues was counted as one vessel. Microvessels in sclerotic areas 
or adjacent to connective tissues were not considered.  
a, b, c
 :Statistic significances were evaluated using unpaired Student’s t test (two-tailed). All values 
represented as mean ± S.E. (n=6 for each group). P < 0.05 was considered significant. a: P > 0.05, b: P < 
0.05, and c: P < 0.01. 
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Figure 3.3A ProAgio-PEG has No Organ Toxicities. One set of organs from each mouse were fixed in 
4% paraformaldehyde/PBS solution. Hematoxylin and eosin (H&E) staining of these fixed organs was 
processed in a pathology laboratory at the department of Ophthalmology and Pathology at Emory Uni-
versity. Pathological examinations were performed by Dr. Hans Grossniklaus. Vessel staining was per-
formed using CD31 IF staining (CD31 labeled with green fluorescence, nucleus labeled with DAPI and 
showed in blue color).  
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Figure 3.3B ProAgio-PEG does not Disrupt Normal Organ Blood Vessels. Snap frozen tissue 
blocks were sliced into 10 µM thick sections using a cryostat. ECs were stained using a rat anti-mouse 
CD31 (BD Pharmingen) and a green fluorescence conjugated anti-rat IgG second antibody. This picture 
showed the EC pattern (labeled in green fluorescence) of microvessels in PBS and ProAgio-PEG 
(20mg/kg) treated heart tissues. Nucleus were labeled with DAPI and showed in blue color. 
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CHAPTER 4 
HUMANIZATION OF ProAgio 
4.1 Introduction 
4.1.1 Humanization of ProAgio 
Humanization of ProAgio is aiming to aid potential clinical applications of the designed 
protein agent. As introduced in chapter 1, the initial design of ProAgio is based on the 99-
amino-acid CD2D1 from rat. The advantage of using the rat protein instead of the human CD2 is 
largely due to concerns on protein stability. Decades of structure studies have been done using 
the CD2D1 from rat as discussed in chapter 1. The typical two-layered anti-parallel β-sheet 
sandwich folding conveys incredible structure stability, allowing the protein to withhold a wide 
of range of pH variation and sequence mutations [291]. In addition, rat CD2D1 is able to be ex-
pressed in bacterial E. coli systems with a high protein yield with well-folded 3D structure. In 
contrast, the human CD2 (denoted as huCD2 in this chapter) requires an N-linked glycosylation 
in its domain 1 region to stabilize its folding, so that the protein expression of huCD2 in a labor-
atory level has been problematic. Similar strategies have been widely adopted in producing an-
tibody drugs, for example in the case of bevacizumab. Humanization, however, is necessary for 
our designed ProAgio to be applied to clinical therapies with minimal immunological responses.  
In this chapter, the similarity between the domain 1 of rat CD2 and huCD2, applied 
strategies for re-design of rat ProAgio into the human host protein, preliminary data using in 
vitro and in vivo models will be discussed. The designed ProAgio using the human host protein 
is named as huProAgio. 
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4.1.2 Biological Functions of huCD2  
The human homologue of rat CD2, huCD2, is a 50 – 55-kDa transmembrane glycoprotein 
receptor mainly expressed in T lymphocytes and NK cells [331]. In 1980s, the cell adhesion func-
tion of huCD2 was first identified when anti-CD2 antibody disrupted the T lymphocyte aggrega-
tion with sheep red blood cells (SRBC), a phenomenon is known as “rosette” [291]. Rosetting 
with SRBC had been widely accepted as a marker to identify T lymphocytes in 1970s. Later on 
studies have shown that huCD2 specifically recognizes CD58 expressed on the surface of anti-
gen-presenting cells (APC) and functions as a co-receptor to TCR during the major histocompa-
tibility complex (MHC)-mediated antigen recognition process [332].  Therefore, huCD2 plays a 
role in initiating cellular immune responses. Except for its adhesion function, huCD2 has also 
been indicated in signaling transduction. Hünig and colleagues have demonstrated that huCD2 
serves as an alternative activation signaling molecule to T lymphocytes [333]. This activation is 
usually accompanied with the subsequent release of IL-12 by T lymphocytes, and it is suggested 
that cytoplasmic tail part of huCD2 is required for transduction of the stimuli [334].  
 
4.1.3 Comparison of the Domain 1 of huCD2 and Rat CD2 
The cell adhesion function of huCD2 is located in the domain 1 of its extracellular region 
[335]. Withka and coworkers reported the 3D structure of the 105-amino-acid adhesion domain 
of huCD2D1 (huCD21 – 105) calculated from 2D homonuclear NMR data in 1993 [302]. The 
huCD21 – 105 protein folds into a typical Ig-folding that is very similar to its rat homologue [302]. 
Basically, there are total 9 anti-parallel β-sheet strands (named as A, B, C, C’, C’’, D, E, F, and G 
separately) connected by flexible loop regions. Anti-parallel strands (G, F, C’’, C’, C, and E) are 
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leveled in one layer, whereas the other three strands (B, D, and E) compose a second layer of β-
sheet on the opposite side [302]. The A β-strand is next to strand G, and they are parallel to 
each other. In the middle of these two layers, a hydrophobic core is constituted by a serial of 
conserved hydrophobic residues from both layers. The ligand binding region is involved in 
strands G, F, C and C’’, while a glycosylation at Asn65 on the opposite layer of β-sheets is re-
quired for its folding and structural stability [336].   
Detailed protein sequence alignments between human and rat CD2 are shown in Table 
4.1. The amino acid similarity between these two proteins is relatively low.  A total number of 
42 out 105 amino acids in huCD21-105 are same as those of rat CD21-99, which gives them a ~40% 
identity. Within these 42 identical amino acids, 22 of them are hydrophobic residues, especially 
those amino acids contributed to the hydrophobic core region. For example, amino acids Leu19, 
Tyr60, Leu68, and ILE70 located on the D, E, and B strands, and residues Trp35, Ala45, Phe47, 
and Tyr81 on the C, C’ F, and G strands are identical to the correspondent amino acids in rat 
CD21-99.  
Although their sequence identity is low, the 3D structure alignment between these two 
proteins is surprisingly high [300, 301]. Alignment of the crystal structures of rat CD21-99 (PDB 
accession ID, 1hng) and huCD21-105 (PDB accession ID, 1hnf) carried out using software program, 
Pymol, are shown as Figure 4.1A – C. It is notable that not only the backbone but also the side 
chain directions of each aligned amino acid are highly agreeable. The overlay 3D structure indi-
cates that the N and C-terminal regions correspondent to the rat ProAgio anti-angiogenic region 
have similar side chain distribution. Side chains of Glu8, Trp10, and Ala12 on β-strand A, and 
those of Asp99, Lys101, and Gln 103 shown as red in Figure 4.1C are all facing toward the sur-
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face of the protein. This feature is critical for humanization of rat ProAgio using the huCD21-105 
as a host protein, especially when maintain the certain side chain direction is desired for the 
design of anti-angiogenic peptides. 
 
4.2 Design of the huProAgio 
4.2.1 Rational for Design of the huProAgio  
Rational for design of huProAgio is based on our knowledge and experiences obtained 
from the successful design of rat ProAgio. The key of our rat ProAgio design greatly depends on 
the structural similarity between the domain 1 of rat CD2 and other endogenous anti-
angiogenic proteins, such as PF4, TSP-1, and endostatin et al. As discussed above, the 3D struc-
tures of the domain 1 of rat and human CD2 are highly identical, so that changes in the same 
region of huCD2 are much likely to convey the same structural and biological effects.  
Several facts have to be taken into consideration when design huProAgio using rat 
ProAgio as a reference. First, whether or not the chosen region for anti-angiogenic function will 
maintain the same side chain directions as rat ProAgio did. Second, factors that affect the pro-
tein stability such as the glycosylation and PEGylation should also be paid close attention to, so 
that protein production will be feasible. At last, since CD2 is an adhesion molecule, its ligand 
interaction should be abolished in order to avoid undesired side effects. Design strategies aim-
ing to solve each of those concerns will be address one by one as follows.  
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4.2.2 Design of the Anti-angiogenic Regions in huProAgio 
The host protein is the first 1 – 104 amino acids in of the human CD2 molecule (se-
quence is shown in Table 4.1). In order to differentiate this host protein from the tradition 1 – 
105 amino acids domain 1 of human CD2, the host protein huCD21-104 will be denoted as 
huCD2D1 here after. This one amino acid change is less likely to bring out any structural altera-
tions since Arg105 is located in the end of the C-terminal region of the protein, and has few 
NOE constrains.  
The anti-angiogenic function of ProAgio relies on amino acids positioned from 5 – 10 in 
β-strand A and 94 – 99 in β-strand G as listed in Table 1.1. Those residues are aligned to amino 
acids 8 – 13 and 99 – 104 individually. There are total 12 amino acids in these two regions. 
Among them, only 4 are different residues. By calculation, it is 67% identical to the same region 
of rat CD2, a much higher rate compared with the overall 40% identity between the whole do-
main 1 regions of these two proteins. These comparison comparisons further supported the 
hypothesis to design the anti-angiogenic short sequences by mutating those particular amino 
acids. The anti-angiogenic sequences used to design huProAgio are similar as those of ProAgio, 
and they are SVQMKL and NLKVII. The N- and C-terminal sequences of original huCD2D1 and 
the designed huProAgio are listed as Table 4.2. As shown in the same table, mutations of 
Glu8Ser, Thr9Val, Trp10Gln, Gly11Met, Ala12Lys, Ile102Val, Gln103Ile, and Glu104Ile have to be 
made in order to create the desired anti-angiogenic sequences.  
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4.2.3 Glycosylation and PEGylation of huProAgio 
Unlike rat CD2D1, the domain 1 of huCD2 is glycosylated at Asn65, and it is critical for 
the protein folding and stability [302, 336]. Due to this reason, purification of the domain 1 of 
huCD2 relies on two different expression systems, either using mammalian system such Chi-
nese hamster ovary (CHO) cells or bacterial E. coli. cells. CHO cells will allow huCD2 to be ex-
pressed with a single N-linked high mannose glycosylation chain attached to Asn65 [302, 337]. 
Another widely adopted method is to express the domain 1 of huCD2 in E. coli systems without 
the N-linked glycan. Although enzymes required to make this post-translational modification 
are absent in E. coli cells, mutations are necessary to be made in order to obtain a stable ex-
pression and folded protein. In this study, three mutations (Lys61Glu, Phe63Leu, and Thr67Ala) 
are introduced to facilitate expression and purification using E. coli cells [338].   
As discussed in Chapter 3 and 5, a site-specific PEGylation of ProAgio is via a mutation, 
Met23Cys. Residue Met23 in rat CD2 is aligned to Met26 in human CD2, so that mutation of 
Met26Cys is also introduced into the huProAgio protein sequence for the same purpose. Same 
as Met23 in rat CD2, Met26 in human CD2 is also located in the flexible loop region and ex-
posed to the solvent as referred to the PDB file, 1hnf [300]. Since ProAgio can be successfully 
PEGylated, it is presumed to be able to be modified by maleimide PEG in the same manner.  
 
4.2.4 Abolish the Ligand Recognition between CD2-CD58 
The nature ligand of huCD2 has been proven to be the CD58 molecule (also known as 
LFA-3, lymphocyte function-associated antigen 3) [332, 339]. The CD2-CD58 interaction has 
been well studied [338, 340]. The affinity between these two cell surface adhesion molecules 
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was reported at 1 – 10 µM range with fast Kon (association) and Koff (dissociation) rates, which 
suggest that huCD2 binds to CD58 at a relatively low affinity, but the binding is very dynamic 
manner [341]. The human CD2 also reported to binds to other ligands, such as CD48 and CD59, 
in a very low affinity with a Kd value ranged around 0.5 mM [341, 342].  To this end, only the 
CD2-CD58 interaction is consider in this project to abolish the biological functions of CD2.  
Our strategy to abolish the biological functions of huCD2 is set by introducing muta-
tion(s) in the ligand binding surface that will disrupt the CD2-CD58 interaction. The binding sur-
face between CD2 and CD58 was investigated by Wang et al [338].  Several pairs of amino acids 
on the interface are critical for CD2-CD58 interaction by forming hydrogen bonds and charge-
charged interactions.  A detailed summary of each amino acids involved in the counter interac-
tion is listed in their paper. Briefly, Lys43, Tyr86, Asp32, Arg48, Lys51, and Lys34 of huCD2 are 
among the most essential residues that contribute to the binding. Generally, the least amount 
of mutations helps to avoid structural mis-foldings, so that we intended to choose a single mu-
tation that effectively abolishes the CD2-CD58 interaction while brings minimal affects to struc-
tural integrity. First of all, Kim et al produced a serial of huCD2 mutants with each of them har-
boring one alanine substitution to each interface residues [340]. Secondly, as demonstrated by 
their studies, a single Tyr86Ala mutation totally disabled the CD2-CD58 interaction indicated by 
rosetting and binding assays [340]. Thirdly, 1H NMR spectra of this Tyr86Ala mutant indicates a 
similar 2D folding to that of the wild type protein. These facts determined that Tyr86Ala muta-
tion is a suitable candidate in order to evade the biological consequences of the host protein, 
huCD2D1.  
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4.3 Protein Sequence of the Designed huProAgio  
The complete protein sequence of the designed huProAgio is shown as Figure 4.2. This 
protein is intended to be expressed and purified from E. coli expression systems without the N-
linked glycan chain. Several mutations for individual purposes discussed through this chapter 
4.1 are summarized as follows. First, As listed in Table 4.1, mutations of Glu8Ser, Thr9Val, 
Trp10Gln, Gly11Met, Ala12Lys, Ile102Val, Gln103Ile, and Glu104Ile are introduced in order to 
create the desired anti-angiogenic sequences (SVQMKL and NLKVII) at positions 5 – 10 in β-
strand A, and 94 – 99 in β-strand G in the host protein. Second, three amino acids mutations 
(Lys61Glu, Phe63Leu, and Thr67Ala) will be made so that the designed huProAgio could be ex-
pressed in E. coli cells the in non-glycosylated form. Third, an amino acid mutation (Tyr86Ala) 
will abolish the interaction between huCD2D1 and CD258 [340]. At last, an amino acid mutation 
(Met26Cys) will allow huProAgio to be site-specifically PEGylated in Cys26 for elongation of 
blood circulation retention time, increase in protein solubility, and possible improvement of 
protein stability.  
The high mannose N-glycan linked to the domain 1 of huCD2 has been demonstrated to 
not only facilitate its folding but also stabilize the 3D structure [336]. Although the glycosylated 
huCD21-105 has been produced in mammalian CHO cells, the cost of this method is high com-
pared to alternative expression systems such as yeast. An additional model was designed for 
expression huProAgio in the pichia pastoris, and it complete amino-acid sequence was shown in 
Figure 4.3. In this model, except for Lys61, Phe63, and Thr67 were kept so that Asn65 can be 
modified with N-glycan, all other mutations are same as that of the designed model for the bac-
terial system shown as Figure 4.2.  Yeast pichia pastoris system, if properly optimized, is a su-
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preme choice for expression of human recombinant proteins. With an additional secretion sig-
nals, proteins are secreted, which greatly accelerates purification processes [343]. In addition, 
protein yield is much higher compared to using E. coli and mammalian expressions.  For exam-
ple, protein yield of human serum albumin using pichia pastoris expression could reach as high 
as 3.6g/L, while the yield of non-glycosylated huCD21-105 in E. coli cells was reported at 15 mg/L 
[338, 343].  
 
4.4 3D Structure of the designed huProAgio  
Figure 4.1 illustrated the designed model structure of huProAgio built by a computer 
program (Modeller) using the X-ray crystal structure of huCD2 (PDB accession ID, 1hng). Anti-
angiogenic sequences (SVQMKL and NLKVII) are introduced at amino acid positions 5 – 10 in β-
strand A, and 94 – 99 in β-strand G in the host protein. The predicted structure is highly agree-
able with the crystal structure of human CD21-105 [300]. The β-strand A and G parallel pairs next 
to each other. Since strand G also has side chain interactions with strand F and G, the designed 
anti-angiogenic short peptides will be restrained as a β-sheet structure. The simulated 3D struc-
ture also predicts that side chains of Ser8 pairs with Asn99, Glu10 pairs with Lys101, and their 
side chains are facing toward the protein surface. Lys12 in the end of β-strand A and Ile104 
forms interactions, and their side chains are expected to be at the same level of that of Ser-
Asn99 and Glu-Lys101.  
The designed mutation site (Met26Cys) for site-specific PEGylation is designed at the 
long BC loop region. It side chain is expected to be well solvent-exposed, which will increase the 
PEGylation rate. In addition, the BC loop are on the at opposite direction to where the anti-
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angiogenic short peptides are located, so that PEG chain linked to Cys28 is less likely to affect 
the designed anti-angiogenic function. Other mutations, such as Lys61Glu, Phe63Leu, and 
Thr67Ala for abolishing N-glycosylation, Tyr86A for evading CD2-CD58 interaction are mutation 
sites that are well studied, and their correspondent mutants were expressed as folded proteins 
[338, 340]. For those reasons, these additional mutations are expected to bring minimal affects 
to the structure stability of ProAgio.  
 
4.5 Preliminary Data for HuProAgio 
4.5.1 Optimization of cDAN Sequences for Expression 
The cDNAs coding for huProAgio designed for E. coli and yeast pichia pastoris were syn-
thesized by Epoch Life Science, INC at Missouri City, TX. Codons were optimized for expression 
in E. coli and yeast expression systems by Epoch Life Science using their proprietary software. 
Several strategies were used to create optimized codons for each species. As shown in Figure 
4.5, when aligned by online program, LALIGN, the optimized cDNA sequences of huCD2D1 and 
that of huProAgio aiming for E. coli expression have 78.5% identity and 85.9% similarity. Figure 
4.6 showed that the cDNA sequences of human versus that of the yeast expression optimized 
huProAgio have slightly less identity, 79.1%. These two different cDNAs are expected to im-
prove the huProAgio expressions in E. coli or yeast cells.  The synthesized huProAgio cDNA were 
further cloned to a bacteria expression vector, pET30a (Novagen, Madison, WI) and expressed 
in bacterial BL-21(DE3) cells (unpublished data by R. Chakram). Figure 4.7 indicated that both 
huCD2D1 and huProAgio had high level of protein expression.  
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4.5.2 Refolding and Buffer Selection   
The bacterial expressed huProAgio (named as his-huProAgio) tagged with an N-terminal 
histidine hexamer designed for purification using Ni-NTA columns. Urea refolding of the ex-
pressed huProAgio from inclusion bodies produced proteins with limited stability. According to 
different buffer recipes tested by Ravi Turaga in our lab, under neutral pH condition (pH 7.4), 
the refolded protein precipitated in the presences of a variety compounds, such as 10 – 20 % 
glycerol, 0.5 – 1 M arginine, 1% N-laurycyl sarcosine. The same set of experiments also indi-
cated that his-tag huProAgio was soluble under pH higher than 10. These results prompted us 
to examine the possibility of refolding huProAgio by gradually decreasing pH instead of urea 
concentrations. In addition, our previous experience with rat ProAgio showed that a buffer con-
taining a combination of glycine and arginine might increase protein solubility (Table 5.2). Tak-
en these two concerns together, a buffer recipe consisted of 5 mM Tris, 50 mM arginine, 50 
mM glycine, 150 mM NaCl and 2 mM DTT was designed as a basal buffer for pH refolding of hu-
ProAgio.  A low concentration of Tris (5 mM) with 150 mM NaCl was used with expections to 
bring minimal side effects when the protein is injected into nude mice.    
A batch of huProAgio protein resuspended in 0.5 M arginine, pH 10.8 was gradually di-
alyzed into buffers at pH 9.5, pH 8.5, and then to pH 7.5. All buffers are composed of the same 
basal recipe indicated as above with adjusted pH levels. The huProAgio protein was soluble un-
der each step till pH 7.5. As shown in Figure 4.8, the protein concentration was around 40 µM. 
There was no difference in protein concentration between pH 8.5 and pH 7.5. A fraction of pro-
tein sample at pH 8.5 was tested for thrombin cleavage. Protein was incubated with 20 units of 
thrombins (GE lifesciences, Piscataway, NJ) for 2 hours at room temperature. The mixture was 
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then passed through a benzamidine Sepharose 6B (GE lifesciences, Piscataway, NJ) packed col-
umn 10 times to remove thrombin. Upon removal of his- tag, huProAgio did not show obvious 
precipitation but the final concentration was less than his-tagged form (28 µM compared to 44 
µM).  
This method was repeated with the same batch of protein. Results indicated as Figure 
4.9 showed that his-huProAgio reached a maximum concentration of 100 µM. The protein 
showed obvious precipitation when concentrated beyond 100 µM. In this second experiment, 
the concentration after refolding was consistent with the previous one, 38 µM versus 44 µM. A 
similar recipe composed of 50 mM arginine, 50 mM glycine, and 2 mM DTT in PBS buffer (pH 
8.0) was selected for purification of his-tagged huProAgio proteins that were applied for drug 
efficacy testing using PC3-Luc xenograft model.  
 
4.5.3 Evaluation of the In Vitro Effect of His-huProAgio 
Above refolded his-huProAgio was subjected to in vitro testing using HUVECs.  Prolifera-
tion rates were shown in Figure 4.10. At 10 µM concentration, his-huProAgio exhibited higher 
anti-proliferation rate compared to ProAgio. A 96% reduction in proliferation rate was observed 
compared to buffer treated controls. At higher concentration, however, proliferation rate was 
inhibited by 32% compared to 73% of ProAgio treated group. This result not only suggested that 
the bacterial expressed huProAgio has comparable in vitro anti-angiogenesis effect as ProAgio 
but also demonstrated that our humanization strategy was successful. The reason why his-
huProAgio dropped inhibitive effects at lower concentration is worth investigating. It might 
suggest that his-tag interferes with the secondary structure of his-ProAgio.   
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4.5.4 Evaluation of the In Vivo Effect of huProAgio 
The in vivo effect of huProAgio was evaluated using the same PC3 xenograft model as 
did with ProAgio. Purified huProAgio was soluble up to 100 µM in buffer conditions indicated as 
above: 50 mM arginine, 50 mM glycine, and 2 mM DTT in PBS buffer (pH 8.0). The experiment 
was initiated when volumes of tumor implants reached 50 – 100 mm3, the 5th day in this case. A 
total of 16 doses of buffer control, 10 mg/kg/day of endostar and huProAgio were admini-
strated via i.p. injection.  
As shown in Figure 4.11, huProAgio demonstrated significant anti-tumor effect over the 
treatment course. The average tumor volume of huProAgio treated group was significantly re-
duced during the first week of treatment. HuProAgio slowed down tumor growth by 6 days. At 
the end of treatment, the average end tumor volume was 263.74 and 109.92 mm3 for buffer 
and huProAgio group separately, which indicated a 59.3% reduction rate (t = 3.53, P = 0.0054, 
unpaired student’s t test, two-tailed) in tumor volume comparing the huProAgio treated group 
to the buffer control. Since the starting tumor volumes were 80 mm3 for both groups, buffer 
control group gained 2.2 times in tumor volume while there was 0.5 times increase in huProA-
gio treated group. Those measurements were further demonstrated by the end point tumor 
weights indicated in Figure 4.12. There was up to a 40% reduction rate (t = 2.78, p = 0.02, un-
paired student’s t test, two-tailed) in the end-point tumor mass when compared with huProA-
gio treated and buffer control groups.  
The toxicities of his-huProAgio were monitored by observation of physical, behavior, 
and weight changes of each experimental mouse. No mice behaved abnormally. No sign of ill-
ness for each mouse until the end point treatment. Figure 4.13 indicated that there were no 
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body abnormal body weight changes during the whole course of treatment. These observations 
suggested that our designed huProAgio is not toxic, but the actual toxicities have to be demon-
strated in further pre-clinical animal models.  
 
4.6  Conclusion 
In this chapter, a detailed design strategy of using human CD21-104 as a host protein was 
discussed. Although there is only 40% amino acid similarity between rat CD21-99 and human 
CD21-104, these two proteins are aligned well in 3D structures. Two anti-angiogenic sequences 
(SVQMKL and NLKVII) were introduced at amino acid positions 5 – 10 in β-strand A, and 94 – 99 
in β-strand G in human CD21-104. The predicted model structure was highly agreeable with the 
crystal structure of human CD21-105. The designed his-huProAgio was expressed in bacteria and 
purified. Using in vitro and in vivo xenograft models, it was demonstrated that his-huProAgio 
inhibited HUVECs proliferation and tumor growth. These results not only shed light on further 
clinical application of ProAgio, but also highlighted the significance of de novo protein design 
strategy as a novel approach for drug discovery and development.  
Future challenges of huProAgio will include optimization of protein expression, solubili-
ty, formulation, and in vivo evaluation of pharmacological and pharmacokinetic properties of 
huProAgio.  
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Table 4.1 Comparison of Rat CD21-99 and huCD21-105  
 
Rat CD21-99 hCD21-105 Side Chain Direction 
D2 N5 N-Terminal 
S3 A6 N-Terminal 
G4 L7 Inside 
*T5 *E8 Outside 
*V6 *T9 Inside 
*W7 *W10 Outside 
*G8 *G11 Inside 
*A9 *A12 Loop 
*L10 *L13 Loop 
G11 G14 Loop 
H12 Q15 Loop 
G13 D16 Outside 
I14 I17 Inside 
N15 N18 Outside 
L16 L19 Inside 
N17 D20 Outside 
I18 I21 Inside 
P19 P22 Inside 
N20 S23 Loop 
F21 F24 Inside 
Q22 Q25 Loop 
M23 M26 Loop 
T24 S27 Loop 
D25 D28 Loop 
D26 D29 Loop 
I27 I30 Inside 
D28 D31 Outside 
E29 D32 Outside 
V30 I33 Inside 
R31 K34 Outside 
W32 W35 Inside 
E33 E36 Outside 
 R34 K37 Loop 
G35 T38 Loop 
  S39 Loop 
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D40 Loop 
S36 K41 Loop 
T37 K42 Sideway 
L38 K43 Outside 
V39 I44 Inside 
A40 A45 Inside 
E41 Q46 Outside 
F42 F47 Inside 
K43 R48 Outside 
R44 K49 Loop 
K45 E50 Loop 
M46 K51 Loop 
K47 E52 Sideway 
P48 T53 Inside 
F49 F54 Outside 
L50 K55 Inside 
K51 E56 Loop 
S52 K57 Loop 
G53 D58 Loop 
A54 T59 Loop 
F55 Y60 Inside 
E56 K61 Outside 
I57 L62 Inside 
L58 F63 Outside 
A59 K64 Loop 
N60 N65 Loop 
G61 G66 Loop 
D62 T67 Outside 
L63 L68 Inside 
K64 K69 Outside 
I65 I70 Inside 
K66 K71 Outside 
N67 H72 Loop 
L68 L73 Inside 
T69 K74 Loop 
R70 T75 Outside 
D71 D76 Outside 
D72 D77 Inside 
S73 Q78 Outside 
G74 D79 Inside 
T75 I80 Outside 
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Y76 Y81 Inside 
N77 K82 Outside 
V78 V83 Inside 
T79 S84 Outside 
V80 I85 Inside 
Y81 Y86 Outside 
S82 D87 Loop 
T83 T88 Loop 
N84 K89 Loop 
G85 G90 Loop 
T86 K91 Loop 
R87 N92 Loop 
I88 V93 Loop 
L89 L94 Inside 
N90 E95 Outside 
K91 K96 Sideway 
A92 I97 Outside 
L93 F98 Inside 
*D94 *D99 Outside 
*L95 *L100 Inside 
*R96 *K101 Outside 
*I97 *I102 Inside 
*L98 *Q103 Outside 
*E99 *E104 C-terminal 
 
R105 C-terminal 
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Table 4.1 Protein Sequence Comparison between Rat CD21-99 and huCD21-105. The 1-99 amino 
acids of rat CD2 are listed in the first column. The 1-105 amino acids are listed in the second column. The 
directions of both sequences are indicated in the last column. Amino acids that are same in rat CD21-99 
and huCD21-105 are shown in bold. Amino acids located in the loop regions are labeled as loop. All other 
amino acids are located within different β-sheet strands. Side chain directions of amino acids located 
within β-sheet strands are indicated as following. Outside: amino acid side-chain is facing toward the 
protein surface; Inside:  amino acid side-chain is facing opposite of the protein surface; Sideway: amino 
acid side chain is parallel with the β-sheet strand at which it is located.   
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Figure 4.1 Structural Comparisons of Rat CD21-99 and huCD21-105. (A and B) The overall ribbon dia-
grams of rat CD21-99 (PDB accession ID, 1hng) and huCD21-105 (PDB accession ID, 1hnf) are shown in gray 
and yellow colors separately. (C) 3D Structural alignment of rat CD21-99 and huCD21-105. Side chains of 
amino acids involved in design of the anti-angiogenic sites are shown in red color (only side-chains facing 
toward the protein surface are shown here). Sequences are aligned by Dr. Hsiau-Wei Lee using a com-
puter program, Pymol.  
 
 
 
Rat CD21-99 HuCD21-105
A B
C
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Table 4.2 N- and C- Terminal Amino Acids of huCD2D1 and huProAgio 
 
 
 
 
 
 
 
 
 
*: Mutated amino acids in huProAgio are shown in bold. 
 
 
 
 
 
 
 
        10         20      *  30         40         50         60  
KEITNALSVQ MKLGQDINLD IPSFQCSDDI DDIKWEKTSD KKKIAQFRKE KETFKEKDTY  
 
        70         80      ** 90        100  
ELLKNGALKI KHLKTDDQDI YKVSIADTKG KNVLEKIFNL KVII  
 
 
 
Figure 4.2  Protein Sequence of huProAgio for E. coli Expression Systems. Amino acids in-
volved in anti-angiogenic sites are underlined. The three amino acids mutations (Lys61Glu, Phe63Leu, 
and Thr67Ala) that stabilize the non-glycosylated protein in E. coli expression systems are shown in bold 
[338]. An amino acid mutation (Tyr86Ala) that abolishes the interaction between huCD2D1 and CD58 are 
labeled with double stars [340]. An amino acid mutation (Met26Cys) that allows huProAgio to be site-
specifically PEGylated in Cys26 is labeled with single star. 
  
Amino Acid  8 9 10 11 12 13 99 100 101 102 103 104 
huCD2D1 Glu Thr Trp Gly Ala Leu Asp Leu Lys Ile Gln Glu 
*huProAgio Ser Val Gln Met Lys Leu Asn Leu Lys Val Ile Ile 
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        10         20      *  30         40         50         60  
KEITNALSVQ MKLGQDINLD IPSFQCSDDI DDIKWEKTSD KKKIAQFRKE KETFKEKDTY  
 
        70         80     **  90        100  
KLFKNGTLKI KHLKTDDQDI YKVSIADTKG KNVLEKIFNL KVII 
 
 
 
Figure 4.3  Protein Sequence of huProAgio for Yeast Expression Systems. Amino acids in-
volved in anti-angiogenic sites are underlined. An amino acid mutation (Tyr86Ala) that abolishes the in-
teraction between huCD2D1 and CD258 are labeled with double stars [340]. An amino acid mutation 
(Met26Cys) that allows huProAgio to be site-specifically PEGylated in Cys26 is labeled with single star. 
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Figure 4.4 Overall Ribbon Structure of the Designed huProAgio. The homology model of huProA-
gio is built by a computer program, Modeller, using the X-ray crystal structure of huCD2 (PDB accession 
ID, 1hnf) as a template. Amino acids involved in huProAgio design are color coded as following. Red: side 
chains of amino acids involved in anti-angiogenic sites (only side chains facing toward the protein sur-
face are shown here); Cyan: three amino acids mutations (Lys61Glu, Phe63Leu, and Thr67Ala) that sta-
bilize the non-glycosylated protein in E. Coli expression systems[338]; Blue: an amino acid mutation 
(Tyr86Ala) that abolishes the interaction between huCD2D1 and CD258 [340]; Magenta:  an amino acid 
mutation (Met26Cys) that allows huProAgio to be site-specifically PEGylated in Cys26. This computer 
model is simulated by Dr. Hsiau-Wei Lee.  
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Orig   AAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGACATCAACTTGGAC 
       :::::::: :: :: ::  ::::::::::::: ::  :::::::::: :::::  ::::: 
Opti   AAAGAGATCACTAACGCACTGGAAACCTGGGGCGCGCTGGGTCAGGATATCAATCTGGAC 
 
 
Orig   ATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAAACTTCAGAC 
       ::::: :: :::::..  .  :: :: :: :::::::: ::::::::.::::::::.::  
Opti   ATTCCGAGCTTTCAGTGCTCCGACGACATCGACGATATCAAATGGGAGAAAACTTCTGAT 
 
 
Orig   AAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAGATACATAT 
       :::::.:::::::: ::.::: :.:::::::::::.:: :::::.:::::.:: :: ::  
Opti   AAGAAGAAGATTGCCCAGTTCCGTAAAGAGAAAGAAACCTTCAAAGAAAAGGACACCTAC 
 
 
Orig   GAGCTACTGAAAAATGGAGCGCTGAAAATTAAGCATCTGAAGACCGATGATCAGGATATC 
       :::::.:::::.:: ::.::::::::::: ::.::::::::.:::::::::::.:: ::: 
Opti   GAGCTGCTGAAGAACGGTGCGCTGAAAATCAAACATCTGAAAACCGATGATCAAGACATC 
 
               
Orig   TACAAGGTATCAATATATGATACAAAAGGAAAAAATGTGTTGGAAAAAATATTTGATTTG 
       :::::.::.:: ::    :::::.::::: ::.:: ::  :::::::.:: :::::  :: 
Opti   TACAAAGTGTCCATCGCGGATACTAAAGGCAAGAACGTTCTGGAAAAGATCTTTGACCTG 
 
 
Orig   AAGATTCAAGAG 
       ::.:: :::::: 
Opti   AAAATCCAAGAG 
               
 
Figure 4.5 Comparison of Optimized cDNA Codons of huProAgio for E. coli Expression.   Sequence 
alignment of the original (upper panel) and codon-optimized (lower panel) cDNA sequences was done 
using an online software, LALIGN. An estimated 78.5% identity (85.9% similarity) in 312 base pairs (bps) 
was shown between the original and optimized sequences. The codon optimization for expression in E. 
coli systems were perforeed by Epoch Life Science, INC located at Missouri City, TX using their pro-
prietary software.  
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E.     AAAGAGATCACTAACGCACTGTCCGTGCAAATGAAACTGGGTCAGGATATCAATCTGGAC 
       :::::.:: ::::::::.:::.  :::::::::::::::::.::.:: :::::  :.::: 
Yeast  AAAGAAATTACTAACGCTCTGAGTGTGCAAATGAAACTGGGACAAGACATCAACTTAGAC 
 
 
E.     ATTCCGAGCTTTCAGTGCTCCGACGACATCGACGATATCAAATGGGAGAAAACTTCTGAT 
       :: ::.:: :::::::: :: :: :: :: :: :: :::::::::::.::.::::::::  
Yeast  ATCCCAAGTTTTCAGTGTTCTGATGATATTGATGACATCAAATGGGAAAAGACTTCTGAC 
 
 
E.     AAGAAGAAGATTGCCCAGTTCCGTAAAGAGAAAGAAACCTTCAAAGAAAAGGACACCTAC 
       ::::::::.::::: ::.::: :.::.:::::.::::: :::::.:::::::: :::::: 
Yeast  AAGAAGAAAATTGCTCAATTCAGAAAGGAGAAGGAAACTTTCAAGGAAAAGGATACCTAC 
 
 
E.     GAGCTGCTGAAGAACGGTGCGCTGAAAATCAAACATCTGAAAACCGATGATCAAGACATC 
       .:. :: : ::::: :::.:. ::::::: ::.:: :: ::.:: ::::::::::::::: 
Yeast  AAATTGTTTAAGAATGGTACATTGAAAATTAAGCACCTTAAGACAGATGATCAAGACATC 
 
 
E.     TACAAAGTGTCCATCGCGGATACTAAAGGCAAGAACGTTCTGGAAAAGATCTTTAACCTG 
       :::::::: :: :: :: :::::.::.:: ::::::::  ::::.:::::::: :: ::  
Yeast  TACAAAGTCTCAATTGCCGATACAAAGGGTAAGAACGTGTTGGAGAAGATCTTCAATCTT 
 
 
E.     AAAGTGATCAT 
       ::.:: ::::: 
Yeast  AAGGTTATCAT 
 
 
 
Figure 4.6 Comparison of Optimized cDNA Codons of huProAgio for Yeast Expression.   Sequence 
alignment of the cDNA codon sequences optimized for E. coli (upper panel) and yeast (lower panel) ex-
pression systems using the online software, LALIGN. An estimated 79.1% identity (87.1% similar) in 312 
bps was shown between the original and optimized sequences. The cNDA codons were optimized for 
expression in yeast expression systems by Epoch Life Science, INC. using their proprietary software. 
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Figure 4.7 Bacterial Expression of HuCD2D1 and HuProAgio. Expression levels of different 
bacterial clones were analyzed by SDS-PAGE gel electrophoresis of bacteria lysates. Lane 1 – 4 (from left) 
BL-21(DE3) clones before and after (BI, AI) IPTG induction. Lane 5 – 8) BL-21(DE3) clones before and af-
ter (BI, AI) IPTG induction. Courtesy of R. Chakram.  
  
HuCD2D1                                 HuProAgio
15 kDa
35 kDa
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Figure 4.8 Concentration of HuProAgio after pH Refolding. His-tagged huProAgio were refolded in 
50 mM arginine, 50 mM glycine, and 2 mM DTT in PBS buffer at indicated pH values. Protein concentra-
tions were measured by Bradford protein assay using BSA as a standard. Concentrations were indicated 
in micromoles.  
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Figure 4.9 Maximum Concentration of HuProAgio after pH Refolding.  His-tagged huProAgio 
were refolded in 50 mM arginine, 50 mM glycine, and 2 mM DTT in PBS buffer (pH 8.0) at indicated pH 
values. At the end of refolding process, protein was concentrated by centrifugation at 8,000 rpm in a 
centrifugal filter unit (Millipore, Billerica, MA).  Protein concentrations were measured by Bradford pro-
tein assay using BSA as a standard. Concentrations were indicated in micromoles.  
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Figure 4.10 His-huProAgio Inhibits Proliferation of HUVECs.  HUVEC cells were treated with 
CD2D1, ProAgio, and his-huProAgio for 48 hours at 5 and 10 µM separately. 20 µL of 1:2000 diluted 
BrdU were added to each well for additional 12 hours. Proliferation rates were measured by under ab-
sorbance 450 – 540 nm and shown as percentage of buffer control.  Data were shown as mean ± S.D.. 
The experiments were repeated 3 times. 
**:  ProAgio (5 µM) versus CD2D1 (5 µM), ProAgio (10 µM) versus CD2D1 (10 µM), and his-HuProAgio 
(10 µM) versus CD2D1 (10 µM) showed statistically significant differences (P < 0.001, unpaired student’s 
t test, two-tailed).  
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Figure 4.11 Tumor Growth Curve of ProAgio Treated PC3 Xenografts. 5x106 of PC3 cells were im-
planted subcutaneously into nude mice (n = 6 for each group). All agents were administered for 16 days 
by intraperitoneal injection (i.p.) at desired doses (buffer: 1 X PBS, pH 7.4, 200 µL/mouse/day; Endostar: 
10 mg/kg/day; and huProAgio: 10 mg/kg/day). Treatments were started until tumor volume reached 50 
– 100 mm3. Tumor dimensions (length and width) were measured using a caliper every other day. Tumor 
volume were calculated as π/6 x (length x width x width). Data were shown as mean ± S.E.. Statistic sig-
nificances were evaluated using Welch’s t test. P < 0.05 was considered significant. 
*: Endostar (10 mg/kg/day) versus Buffer treated group was not significantly different, P > 0.05. 
**: HuProAgio-PEG (10 mg/kg/day) versus buffer treated group was significantly different, P < 0.05. 
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Figure 4.12 Tumor Weights of HuProAgio Treated Xenografts. 5x106 of PC3 cells were implanted 
subcutaneously into nude mice (n = 6 for each group). All agents were administered for 16 days by 
intraperitoneal injection (i.p.) at desired doses (buffer: 1 X PBS, pH 7.4, 200 µL/mouse/day; Endostar: 10 
mg/kg/day; and huProAgio: 10 mg/kg/day).  On the last day of treatment, xenografts were dissected and 
measured individually. Data were shown as mean ± S.E..  
*:  huProAgio (10 mg/kg/day) versus buffer treated group showed statistically significant differences (P < 
0.05, unpaired student’s t test, two-tailed).  
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Figure 4.13 Body Weights of Treated Nude Mouse. 5x106 of PC3 cells were implanted subcuta-
neously into nude mice (n = 6 for each group). All agents were administered for 16 days by intraperito-
neal injection (i.p.) at desired doses (buffer: 1 X PBS, pH 7.4, 200 µL/mouse/day; Endostar: 10 
mg/kg/day; and huProAgio: 10 mg/kg/day). The body weight of each mouse was monitored every other 
day. Weight were shown as mean ± S.E. .  
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CHAPTER 5 
CLONING, PROTEIN PURIFICATION, AND PEGYLATION  
 
5.1 Introduction of 6D31-ProAgio 
In our initial design, the anti-angiogenic peptides (TVAQMKL and NLKVII) were framed 
separately into the N- and C- termini of a CD2D1 variant protein, 6D31 instead of the wild type 
CD2D1. 6D31 (also named as CD2.trigger) was designed and constructed as a Ca2+- binding pro-
tein by the research group led by Dr. Jenny J. Yang from GSU [311]. Li and colleagues reported 
that two reverse electronic charge mutations (Arg31Asp and Lys43Asp) together with Glu29 
and Glu41 coordinately formed a Ca2+- binding pocket on the surface of GFCC’C’’ β-sheet 
strands of CD2D1 [311]. This designed metal binding pocket allowed 6D31 to adopt reversible 
conformational changes induced by positively charged metal ions. Li and coworkers suggested 
that 6D31 was structurally unfolded in the absence of positively-charged metal ions [311]. Upon 
binding to Ca2+, La3+, or Tb3+, charge-charge interactions between metal irons and the nega-
tively-charged metal binding pocket triggered refolding of 6D31 into a β-sandwich structure 
same as that of wild type CD2D1.  
The difference between using 6D31 versus wild type CD2D1 as a host protein mainly fo-
cused on metal binding capability. Our initial hypothesis was to design a dual function protein 
with anti-angiogenic function and radio-toxicity. In the 6D31-ProAgio model, anti-angiogenic 
peptides were framed into the same position as we did later on with the wild type CD2D1. Since 
the metal binding pocket of 6D31 is far from the N- and C- terminal strands, it should still func-
tion if the overall 3D protein structure remains the same. The metal binding feature will provide 
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a possibility to load the designed 6D31-ProAgio with radioactive metal ions that are toxic to the 
local tumor tissues. Preliminary studies in this chapter suggested that wild type CD2D1 sur-
passes 6D31 in structural stability, so that the final version of ProAgio discussed throughout this 
dissertation was designed using wild type CD2D1 as a host protein. Since early experiences of 
expression and purification of 6D31-ProAgio helped to pave the way for ProAgio studies, in this 
chapter, molecular cloning, protein purification, and PEGylation of 6D31-ProAgio and ProAgio 
were both summarized.  
 
5.2 Molecular Cloning of 6D31-ProAgio 
The 6D31 cDNA was a gift from Dr. Jenny J. Yang from GSU.  It was cloned into a pGEX-
2T bacterial expression vector (GE lifesciences, Piscataway, NJ) between restriction enzyme 
recognition sites, BamH I and EcoR I, indicated in Figure 5.1. A thrombin cleavage site is located 
right before BamH I restriction recognition site. A 26-kDa glutathione S-transferase (GST) gene 
is located in the 5’-end of the cleavage site as a fusion tag.  In order to create 6D31-ProAgio 
cDNA, a series of mutations was introduced into the parental cDNA using primers listed as Table 
5.1. Total 18 base pairs were substituted, which resulted in 8 amino acids mutations (Trp7Gln, 
Gly8Met, Ala9Lys, Asp94Asn, Arg96Lys, Ile97Val, Leu98Ile, and Glu99Ile) in the N- and C-
terminal β-strands of 6D31 separately.   
 
5.3 Expression and Purification of 6D31-ProAgio  
6D31-ProAgio was expressed as a GST-fusion protein in a BL-21 (DE3) bacteria strain, BL-
21(DE3) CodonPlus® competent cell line (stratagene, Santa Clara, CA). Purification procedures 
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were adapted from protocols developed for CD2D1 and 6D31 by members of Dr. Jenny J. Yang’s 
research group from GSU [291, 311]. IPTG concentrations were optimized using 2 mL-scale cul-
tures. In Figure 5.2, it showed that 0.1 - 0.3 mM of IPTG was sufficient to induce protein expres-
sion. Larger scale protein expressions were done using 1 L culture induced under a relative low 
IPTG concentration (0.2 mM) at temperature (30˚C) for 4 hours. These precautions were in-
tended to increase the soluble forms of 6D31-ProAgio to be expressed. The GST tag was utilized 
to purify the fusion protein from cellular extracts using a Glutathione 4B affinity (GS4B) column 
(GE lifesciences, Piscataway, NJ), and then removed by on beads thrombin cleavage. Further 
purification using different methods including ion or cation exchange, gel filtration and other 
chromatographies would by applied if separation of thrombin was desired. Normally, after 
thrombin cleavage, GST tags remained bound to the affinity column while CD2D1 or 6D31 were 
able to be eluted using buffered saline at neutral pH. In this case, however, after thrombin clea-
vage 6D31-ProAgio was not eluted from the GS4B column as expected using phosphor buffered 
saline (PBS) at pH 7.4. Major efforts were drawn to overcome this challenge using a variety of 
elution conditions, such as gradually increasing salt concentration up to 1 M, or higher pH to 
10.0, but none of them yielded satisfying results. Finally, a combination of reducing condition 
and higher pH (50 mM Tris buffer, 10 mM reduced glutathione, 150 mM NaCl, and pH 10.0) 
successfully eluted all proteins including the cleavage GST tags and 6D31-ProAgio as shown in 
Figure 5.2. Clearly, the 6D31-ProAgio was separated by thrombin cleavage, but it still attached 
to the GST affinity column together with GST. This phenomenon resulted in two major sepa-
rated bands at 11-kDa (represented 6D31-ProAgio) and 26-kDa (represented GST) exhibited by 
SDS-PAGE gel stained with coomassie blue.  
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The eluted mixture was further separated by Gel filtration Chromatography (GFC) (Fig-
ure 5.3 A and B). Two major elution peaks were observed: fractions 6 – 7 and 12 – 13. SDS-
PAGE gel electrophoresis analysis showed that the first peak (fraction 6 – 7) consisted of GST 
while the second peak (fraction 12 – 13) contained majority of 6D31-ProAgio. It was possible 
that GST had conformational changes that provoked the protein to be continuously eluted out 
until fraction 11 – 12. Although fractions 12 – 14 were mixed with trace amount of GST, those 
fractions were collected and further used for in vitro testing of biological function.   
 
5.4 Evaluation of the In Vitro Effect of 6D31-ProAgio 
 The in vitro biological effect of 6D31-ProAgio was evaluated by MTT cell viability assay 
using HUVECs and an epithelial colon cancer cell line, HCT116 (Figure 5.4 and 5.5).  A final con-
centration of 4 µM 6D31-ProAgio and control proteins including GST, CD2D1, and 6D31 were 
incubated with the cells seeded into 96-well plates for 48 hours. Cell viabilities were deter-
mined by MTT assays. Figure 5.5 suggested that compared to control proteins (GST and CD2D1), 
6D31-ProAgio showed significant inhibitive effect on HUVECs but not HCT116 cells. Because 
6D31-ProAgio showed obvious precipitation, half of the protein sample was filtered through a 
0.2 µM syringe filter. The filtered 6D31-ProAgio sample still significantly reduced viability of 
HUVECs except for being less effective, which is expected because the filtered sample con-
tained lower concentration of protein compared to the non-filtered one. The host protein, 
6D31, also showed inhibitive effect. It was not clear whether 6D31 truly affected growth of HU-
VECs because this experiment was not repeated due to difficulties in low protein yield and 
quick precipitation. 
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5.5  Molecular Cloning of ProAgio 
As discussed above, 6D31-ProAgio showed significant precipitation when its concentra-
tion exceeded 50 μM. This low concentration brought challenges to determine its structure and 
biological functions. It was highly possible that this precipitation was due to poor structural sta-
bility after extensive mutation. In order to solve this problem, the wild type CD2D1 was chosen 
to be the host protein instead of 6D31, which was discussed in chapter 1 and following ses-
sions. Compared to 6D31, the wild type CD2D1 is stable in a wide range of pH, temperatures, 
and salt concentrations. In addition, purification of CD2D1 has produced high yield of proteins 
with well established protocols explored by Dr. Jenny J. Yang’s research group. Those advantag-
es were expected to improve the protein stability and increase solubility. This protein was des-
ignated as ProAgio in all chapters of this dissertation.  
Molecular cloning of ProAgio was based on 6D31-ProAgio cDNA. Since the anti-
angiogenic region contained 8 amino acids mutations already being produced in 6D31 cDNA, 
mutations were made in the metal binding site in order to mutate the 6D31 host into wild type 
CD2D1. Site-directed mutagenesis reactions were carried out using primers indicated as Table 
5.2. Two back mutations Asp31Arg and Asp43Lys were made, which abolished the metal bind-
ing property. Another deletion was made to remove a restriction enzyme recognition site that 
was designed for insertion of other peptide sequences.  
 
5.6 Expression and Purification of ProAgio  
ProAgio was expressed as a GST-fusion protein same as 6D31-ProAgio did. ProAgio was 
expressed in high level and purified using GS4B columns. Expression and purification were 
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shown as Figure 5.6. Analysis by SDS-PAGE gel electrophoresis indicated that the GST-ProAgio 
had high affinity for GS4B columns. After on column cleavage by thrombin, proteins were 
eluted with 10 mM reduced glutathione in 50 mM Tris buffer (pH 8.0) and further purified using 
gel filtration chromatography. Figure 5.7 showed the UV 260 nm absorbance of each fraction. 
Similar to 6D31-ProAgio, two major peaks containing GST and ProAgio separately were eluted. 
Analyses of gel filtration fractions (Figure 5.8) suggested that majority of GST was separated 
from ProAgio. The separation was much more improved compared to that of 6D31-ProAgio but 
the resolution of gel filtration chromatography was still not able to completely remove GST 
from ProAgio. Although the amount of GST was much less than separation of 6D31-ProAgio, it 
interrupted with further structural studies of ProAgio (data not shown). In order to solve this 
problem, this method was further improved by elution of ProAgio using PBS instead of reduced 
glutathione.  Without competition from reduced glutathione, GST remained bound to GS4B so 
that only ProAgio was eluted. One technical challenge for PBS elution was the local ProAgio 
concentration.  Up to 10 mg of GST fusion protein could bind to 1 mL of GS4B beads. Frequent-
ly, precipitation of ProAgio was observed after thrombin cleavage. This aggregation could be 
significantly improved by increasing the NaCl concentration up to 500 mM. The high salt was 
able to successfully elute ProAgio without GST, which resulted in high protein purity upon gel 
filtration chromatography separation as shown in Figure 3.1SA. This phenomenon suggested 
that ProAgio might have a preference to aggregate, and high salt concentration facilitated the 
disassociate process.  
As the expected, the purified ProAgio shows higher stability than 6D31-ProAgio but less 
than CD2D1. Without freezing, the concentration of 6D31-ProAgio reached 100 – 120 μM, but 
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storage of this protein in -20˚C resulted in protein precipitation, which posed a challenge to 
functional studies that require high concentration of protein stock.  
 
5.7 Evaluation of the In Vitro Effect of ProAgio 
The purified ProAgio was used for in vitro evaluation of the anti-angiogenic function of 
ProAgio. Figure 5.9 clearly demonstrates that ProAgio inhibits HUVEC cell growth by 80% com-
pared with CD2D1 at the concentration of 5 – 10 μM. HUVECs treated with CD2D1 shows 
slightly decrease of viability at higher concentration. The possible reason is probably the fact 
that most endogenous anti-angiogenic proteins have β-sheet structure and CD2D1 is a well 
formed β-sheet protein. This experiment illustrates that CD2D1 as a host protein is able to sup-
port the anti-angiogenic peptides and enhance their effect in inhibition of endothelial cell 
growth but not cancerous epithelial cells.  
 
5.8 Solubility and Stability of ProAgio 
In order to increase the solubility of ProAgio, individual or a combination of sucrose, 
trehalose, lactose, mannitol, arginine, glutamatic acid, trehalose dehydrate, Tween 20, 
PEG8000 and NaCl were added to the HEPES and PBS buffer solutions indicated as Table 5.3. All 
those recipes were studied by Dr. J. H. Yang from Dr. Jenny J. Yang’s laboratory from GSU. Pro-
tein was diluted in low concentration and concentrated by vacuum-frozen drying. After thawing 
at room temperature, the soluble protein in all recipes were around 10 – 20 μM, which was 
consistent with previous observations. To this end, all these ingredients failed to significantly 
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increase protein solubility. In later studies, ProAgio proteins were either fresh purified or di-
luted to concentration < 10 µM, and then stored at -20˚C and re-concentrated after thawing.  
Protein stability of ProAgio was tested by incubation with fetal bovine serum (FBS).  
When mixed with serum at 1:1 ratio (volume), most ProAgio proteins were degraded by four 
hours (Figure 5.10).  
 
5.9 PEGylation of ProAgio 
As discussed in section 5.6, ProAgio showed limited protein solubility and stability, 
which prompted us to PEGylate ProAgio. PEGylation has been widely adopted as an effective 
method to prolong half lives of proteins and peptides, improve their solubility, and decrease 
immunogenicity [344]. Different amino acid residues such lysine, arginine, cysteine residue, N- 
and C-termini were mostly used PEGylation site. In the case of ProAgio, PEGylation on lysine, 
arginine and terminal residues risked losing anti-angiogenic function because our designed mu-
tation sites were located in the N- and C- terminal β-strands with lysine and arginine mutations. 
After a comparison of different PEGylation methods, we chose to site-specifically PEGylate 
ProAgio with maleimide-PEG maleimide reagents with different molecular weight. Maleimide-
PEG chains of 20-kDa were used to PEGylate ProAgio and the PEGylated protein, ProAgio-PEG 
was used for animal studies. Since original ProAgio did not include any cysteine residue, a 
Met23Cys mutation was made in order to facilitate the site-specific PEGylation and its simu-
lated model structure was shown as Figure 5.11. Met23 was chosen as the PEGylation site is 
because several reasons. First, it was located in the flexible loop region that was less likely to 
affect overall protein structure compared to residues involved in the hydrophobic core region. 
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Secondly, Met23 was laid in opposite to the framing region, which reduced the possibility of 
blocking biological functions of ProAgio. In addition, methionine and cysteine have the most 
structural similarity. All these criteria made Met23 the best choice as a site-specific PEGylation 
site.  The PEGylated ProAgio was designated as ProAgio-PEG in this dissertation.  
Met23Cys mutated ProAgio showed less stability compared to ProAgio. After thrombin 
cleavage, proteins were precipitated on GS4B columns. High concentration of L-arginine (500 
mM) in PBS was used to solubilize ProAgio. As shown in the first left lane in Figure 5.13, not on-
ly ProAgio mutant but also GST was eluted from GS4B. PEGylation was successful as showed by 
other lanes in Figure 5.12. There are 4 cysteine residues on GST protein, so it was also PEGy-
lated during the procedure. In later experiment, it showed that high concentration of arginine 
eluted a large amount of GST, which posed difficulties to separate GST-PEG from ProAgio-PEG 
by cation-exchange chromatography. An on column PEGylation was developed to efficiently 
PEGylate ProAgio as described in Chapter 2. This method sufficiently solubilized ProAgio. Fur-
thermore, GST-PEG was also eluted in a smaller amount compared to L-Arginine elution. The 
mixture was subjected to further purification using cation exchange chromatography. As shown 
in Figure 3.1SC, at pH 6.0, PEG and GST-PEG did not bind to cation exchange column, which led 
to sufficient separation. The purified ProAgio-PEG showed extensive solubility with concentra-
tion that reached up to 1 mM. It was used for later animal studies to investigate its anti-
angiogenesis functions during tumorigenesis.   
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5.10 GST Pull-down Assay 
 Galectin-1(Gal-1) has been shown as an important target for synthetic anti-angiogenic 
peptide, Anginex [345].  In order to determine if Gal-1 is the possible target for ProAgio, a GST 
pull-down assay was performed As shown in Figure 5.13, Cell lysates from VEGF-activated HU-
VECs were mixed with GST, GST-CD2D1, GST-ProAgio conjugated GS4B beads. Pull-down of Gal-
1 was tested by a mouse monocolonal antibody against human Gal-1. Panel C showed that a 
equal amount of GST, GST-CD2D1, and GST-ProAgio were added to HUVEC-lysate. A minor pro-
tein degradation was observed in GST-ProAgio. Panel B indicated that Gal-1 was constitutively 
expressed in VEGF-activated HUVECs. Panel A showed that Gal-1 was associated with ProAgio. 
GST or CD2D1 did not precipitate with Gal-1. This result suggested that Gal-1, an important pro-
angiogenesis protein was a possible target for ProAgio. Further experiments are needed in or-
der to confirm this targeting in huProAgio. 
 
5.11 Evaluation of In Vivo Effects of ProAgio-PEG 
 The Cys23 PEGylated ProAgio was used for in vivo evaluation using PC3 xenograft model 
(Figure 5.14A-C). As shown in Figure 5.14, when treated at 10 mg/kg/day, it was clear that 
ProAgio-PEG effectively slowed down the growth of xenograft tumors, while the control protein 
CD2D1-PEG did not. ProAgio-PEG reduced the end point tumor mass by 35% (P < 0.05, unpaired 
student’s t test, two tailed). Compared to buffer control group, it significantly reduced tumor 
angiogenesis as indicated by CD31 IF staining shown in Figure 5.14C.  
 In this set of animal experiment, the starting point was 4 weeks post inoculation com-
pared to 7 and 5 days post inoculation in the same models discussed in Chapter 3 and 4 respec-
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tively. Together with these findings with early treatment with ProAgio and humanized ProAgio, 
it was convincing that ProAgio sufficiently inhibited tumor angiogenesis at early and late stage 
of tumor growth.  
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Figure 5.1 Expression Vector pGEX-2T With Thrombin Cleavage and Cloning Sites.   The 
6D31 or CD2 cDNAs were inserted between the two indicated cloning sites with a stop codon (TAG) be-
fore EcoR I. The pGEX-2T image was adapted from www.gelifesciences.com/pGEX. 
  
Cloning Site
Leu Val Pro Arg Gly Ser Pro Glu Phe Ile
CTG GTT CCG CGT GGA TCC CCG GAA TTC ATC
Thrombin Cleavage Site
BamH I EcoR I
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Table 5.1  Synthetic Primers for Generating 6D31-ProAgio cDNA 
 
 
 
 
 
 
 
 
 
 
Table 5.1  Synthetic Primers for Generating 6D31-ProAgio cDNA.   Total 18 base pairs were substi-
tuted, which produced 8 amino acid mutations at the N- and C- terminal strands of the parental 6D31. 
  
Mutations  Primer 
W7Q 5’-GAGACAGTGGGACCGTCCAGATGAAACTGGGTCATG 
G8M, A9K 5’-CCAGAGACAGTGGGACCGTCTGGATGAAACTGGGTCATGGCATCAACCTGAA 
D94N, 
R96K, I97V 
5’-GACACGTATCCTGAACAAGGCACTGAATTTGAAAGTTCTAGAGTAGAATTCCCGGGTCGA 
L98I, E99I 5’-ACGTATCCTGAACAAGGCACTGAATTTGAAAGTTATTATCTAGAATTCCCGGGTCGAC 
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Figure  5.2  Optimization of IPTG Concentration for 6D31-ProAgio Expression.  Different con-
centrations of IPTG (0 – 1 mM) were incubated with BL-21(DE3) bacteria for 4 hours at 30˚C.  20 µl of 
sample from 1 mL lysate were loaded to each lane. The molecular weight of GST-ProAgio was shown at 
35-kDa. 
  
35 kDa
IPTG               0        0.1     0.2      0.3      0.4     0.5      0.6      0.8      1.0mM 
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Figure 5.3A Glutathione Elution of 6D31-ProAgio. Elution fractions were examined by SDS-PAGE 
gel electrophoresis and coomassie blue staining. The first two lanes from left indicated the PBS elution. 
Other lane showed proteins (cleavage GST and 6D31-ProAgio) that were eluted from glutathione 4B af-
finity column (GE lifesciences, Piscataway, NJ) using 10 mM reduced glutathione. The upper bands at 
26-kDa were GST cleaved from GST-ProAgio fusion protein. The lower bands at 11-kDa were ProAgio 
after cleaved from GST-6D31-ProAgio fusion protein.  
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Figure 5.3B Elution fractions of 6D31-ProAgio Using Gel Filtration Chromatography. Fractions (1 to 
14) were examined by SDS-PAGE gel electrophoresis and coomassie blue staining. Upper bands (26-kDa) 
represented GST. Lower bands (11-kDa) were 6D31-ProAgio.  
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Figure 5.4 6D31-ProAgio Inhibited HUVEC Growth. HUVECs and HCT116 cells were seeded 
into a 96-well plate. Cells were treated with 6D31-ProAgio for 48 hours. Pictures were taken under 400X 
magnification.  
  
HCT116
HUVEC
PBS                                 6D31-ProAgio (4 µM)
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Figure 5.5 6D31-ProAgio Reduced HUVEC Viability.  HUVEC were seeded into 96-well plates 
and treated with GST, CD2D1, 6D31, filtered 6D31-ProAgio (6D31-ProAgio (F)), and 6D31-ProAgio. All 
proteins were added to cells at a final concentration of 4 µM except for the filtered 6D31-ProAgio.    
**: 6D31-ProAgio (4 µM) versus CD2D1 (4 µM) and the filtered sample of 6D31-ProAgio (10 µM) versus 
CD2D1 (10 µM) showed statistically significant differences (P < 0.05, unpaired student’s t test, two-
tailed). P values were based on three triplicate wells. The experiment was performed only once because 
of limited protein solubility.  
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Table 5.2 Synthetic Primers for Generating ProAgio cDNA. 
 
 
 
 
 
 
 
 
Table 5.2 Synthetic Primers for Generating ProAgio cDNA. Reactions of site-directed mu-
tagenesis were carried out using 6D31-ProAgio cDNA as a template using indicated primers.  
  
Mutations  Primer 
D31R 5’- GATGATATTGATGAGGTGCGATGGGAGAGGGGGCACC 
D43K 5’- CACCCTGGTTGCCGAGTTTAAAAGGAAGATGAAG  
DelCCAAGGCCT 5’- GAAGATGAAGCCTTTTTTGAAATCGGGAGCATTTGAGATCTTAGCAAATG 
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Figure 5.6 Expression and Purification of ProAgio.  ProAgio was expressed as a GST fusion 
protein (37-kDa) in BL-21(DE3) bacteria and purified by GST 4B affinity columns. The GST tag was re-
moved by thrombin cleavage. From left to right, each lane represented: before induction (BI), after in-
duction (AI), supernatant of cell lysates (S), pellet of cell lysate (P), unbound waste (W), GS4B beads 
bound to cell lysate (BAB), GS4B beads after washed with PBS, and GS4B beads after thrombin cleavage 
(BAC). The 26-kDa bands shown in lane BAC represented cleaved GST, and the 10-kDa band indicated 
ProAgio. 
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Figure 5. 7  Purification of ProAgio Using Gel Filtration Chromatography.  ProAgio was eluted 
from GS4B column using elution buffer 10mM reduced glutathione, 50 mM Tris buffer, pH 8.0 and then 
subjected to gel filtration chromatography. Absorbances of eluted fractions were monitored using a UV 
detector at a wavelength of 280 nm. Peak 1 indicated GST eluates, and Peak 2 represents ProAgio 
eluates.  
  
Peak 1
Peak 2
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Figure 5.8 Elution fractions of ProAgio Using Gel Filtration Chromatography. Fractions (1 to 14) 
were examined by SDS-PAGE gel electrophoresis and coomassie blue staining. Upper bands (26-kDa) 
represented GST (Peak 1 in Figure 5.7). Lower bands (11-kDa) in fraction 10 – 14 were ProAgio (Peak 2 in 
Figure 5.7).  
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Figure 5.9 ProAgio Reduced Viability of HUVECs.  HUVECs were seeded into 96-well plates and 
treated with CD2D1 and ProAgio at different concentration for 48 hours. A total 100 µL of ProAgio was 
added to each well and incubated for additional 4 hours. Viability was evaluated by the absorbance of 
MTT at wavelength of 490nm. The experiment was repeated three times. 
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Table 5.3  *Solubility Test for ProAgio. 
 
 
  
Sample Chemicals 
Start 
Concentration 
End  
Concentration 
Soluble 
ProAgio 
in HEPS (µM) 
Soluble 
ProAgio 
in PBS (µM) 
1 NaCl 45 mM 450 mM 11.37 11.51 
2 Glycerol 0.5% 5% 8.65 8.88 
3 Glycerol 1% 10% 8.99 9.36 
4 Sucrose 1.5% 15% 9.13 11.37 
5 Lactose 0.8% 8% 7.43 11.17 
6 Mannitol 0.8% 8% 8.3 8.33 
7 Trehalose 1.5% 15% 10.04 10.55 
8 
Trehalose 0.6% 6% 
16.0 16.68 Tween 20 0.001% 0.01% 
PEG 800 0.1% 1% 
9 
Arginine 5 mM 50 mM 
22.02 19.66 
Glycine 5 mM 50 mM 
Tween 20 0.001% 0.01% 
PEG800 0.1% 1% 
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 Table 5.3  *Solubility Test for ProAgio. 
 *Individual or a combination of sucrose, trehalose, lactose, mannitol, arginine, glutamatic acid, 
trehalose dehydrate, Tween 20, PEG8000 and NaCl were added to the diluted HEPES and PBS 
buffer solutions in a start concentrations indicated as column 3. After concentration, the end 
concentration of each solvent was indicated as column 4. The starting and end protein concen-
tration using each buffer recipe were listed as column 5 and 6.  
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Figure 5.10 Protein Stability of ProAgio in FBS. Purified ProAgio was incubated with FBS at a 
1:1 ratio (volume) at 37 ˚C for 0.5, 1, 2, 4, 16 and 22 hours. The second left lane represents the purified 
ProAgio without FBS, and the third lane is FBS alone. Degradation of ProAgio was started after 2 hours of 
incubation with FBS.  
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Figure 5.11 Simulated ProAgio Model for Site-specific PEGylation. The overall ribbon diagrams of 
ProAgio Met23Cys were built on the crystal structure of CD2D1 (PDB accession ID, 1hng). Side chains of 
amino acids (yellow color) involved in design of the anti-angiogenic sites are shown in green color. Trp32 
and its only side chains are shown in red. Met23Cys is shown in blue. Sequences are aligned by Dr. 
Hsiau-Wei Lee using a computer program, Pymol.  
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Figure 5.12  PEGylation of ProAgio. 
  
M       BP          2h 4h           O/N             M      BP       2h 4h        O/N
70 -
55 -
27 -
15 -
10 -
35 -
55 -
70 -
35 -
27 -
15 -
Coomassie Staining Iodine Staining
Lane: 1       2             3                4               5                 1       2         3               4           5
10 -
173 
 
 
 
Figure 5.12  PEGylation of ProAgio.  ProAgio bearing a Met23Cys mutation were purified by GS4B 
affinity columns and eluted using PBS containing 500 mM L-arginine as shown in lane 2. Protein and a 
20-kDa Y-shaped maleimide-PEG (one 10-kDa PEG chain in each arm) were mixed at 1:5 molar ratios. 
Different incubation conditions including 2 hours, 4 hours at room temperature, and overnight at 4˚C 
were shown in lane 3 to 5. SDS-PAGE gel was first stained with iodine isoproponol (right panel). Then it 
was destained by repeated wash with water, and re-stained with Coomassie staining (left panel). Iodine 
isoproponol stains the PEG chain, so that the right panel indicated that 2 hours at room temperature 
was sufficient to PEGylated ProAgio. The branched maleimide-PEG slowed down protein migration rates 
in SDS-PAGE gel. ProAgio-PEG bands were located between molecular markers of 55-KDa and 70-kDa 
(overlapped with excess maleimide-PEG in the right panel). GST has four cysteine residues, and it mi-
grated slower than 250-kDa molecular marker. ProAgio-PEG was confirmed by Coomassie staining (left 
panel). Pure ProAgio-PEG protein was purified by cation-exchange chromatography as shown in Figure 
3.1.SC.  
  
174 
 
Figure 5.13 ProAgio Interacts with Galectin-1. Cell lysates from HUVECs were mixed with GST-
ProAgio conjugated GS4B beads. Mixtures were incubated overnight at 4 ˚C.  Panel A: Gal-1 pulled down 
by GST, GST-CD2D1, or GST-ProAgio conjugated GS4B beads and then  detected by a monoclonal anti-
Gal-1 antibody; Panel B: 5% input for Gal-1 expressed in whole cell lysate for each sample (detected by 
anti-Gal-1 antibody); and Panel C: 5% input for GST, GST-CD2D1, or GST-ProAgio added to each sample 
(detected by Ponceau staining). Lane 1: pull-down by GST conjugated GS4B beads; Lane 2: pull-down by 
CD2D1 conjugated GST-GS4B beads; and Lane 3: pull-down by ProAgio-GST conjugated GS4B beads.   
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Figure 5.14A ProAgio-PEG Inhibits PC3 Xenograft Model. 
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Figure 5.14A ProAgio-PEG Inhibits PC3 Xenograft Model.  A volume of 100 µL (5X106) PC3 cells 
were subcutaneously injected into nude mice. Treatments were initiated at the 4th week after tumor 
inoculation. All agents were administered for 14 days by intraperitoneal injection (i.p.) at desired doses 
(buffer: 1 X PBS, pH 7.4, 200 µL/mouse/day; CD2D1-PEG: 10 mg/kg/day; and ProAgio-PEG 10 
mg/kg/day). Tumor dimensions were measured using a digital caliper every other day. Tumor volume 
were calculated using formula: Tumor volume (mm3) = π/6 x (length x width x height). Data were shown 
as mean ± S.E.. Statistic significances were evaluated using Welch’s t test. P < 0.05 was considered signif-
icant. 
*: CD2D1-PEG (n = 5, 10 mg/kg/day) versus Buffer treated group (n = 4) was not significantly different, P 
> 0.05. 
**: ProAgio-PEG (n =5, 10 mg/kg/day) versus buffer treated group was significantly different, P < 0.05. 
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Figure 5.14B Tumor Weights of HuProAgio Treated Xenografts.  A volume of 100 µL (5X106) PC3 
cells were subcutaneously injected into nude mice. Treatments were initiated at the 4th week after tu-
mor inoculation. All agents were administered for 14 days by intraperitoneal injection (i.p.) at desired 
doses (buffer: 1 X PBS, pH 7.4, 200 µL/mouse/day; CD2D1-PEG: 10 mg/kg/day; and ProAgio-PEG 10 
mg/kg/day). Tumor dimensions were measured using a digital caliper every other day. Tumor volume 
were calculated using formula: Tumor volume (mm3) = π/6 x (length x width x height). Data were shown 
as mean ± S.E.. Statistic significances were evaluated using Student’s t test (unpaired, two tailed). P < 
0.05 was considered significant. 
**: ProAgio-PEG (n =5, 10 mg/kg/day) versus buffer treated group (n = 4) was significantly different, P < 
0.05. 
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Figure 5.14C ProAgio-PEG Inhibits Xenograft Tumor Angiogenesis. Snap frozen tissue blocks were 
sliced into 20 µM thick sections using a cryostat. ECs were stained using a rat anti-mouse CD31 (BD 
Pharmingen, San Diego, CA) and a green fluorescence conjugated anti-rat IgG second antibody. This pic-
ture showed the ECpattern (labeled in green fluorescence) of microvessels in 1 X PBS buffer (pH 7.4, 
200 µl/mice/day), CD2D1-PEG (10mg/kg/day), and ProAgio-PEG (10mg/kg/day) treated tumor tissues.  
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CHAPTER 6 
CONCLUSION AND SIGNIFICANCE 
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 Based on important structural features of endogenous anti-angiogenic proteins and 
peptides, we developed a de novo designed protein agent that inhibits tumor angiogenesis.  
 As reviewed in section 1.9.5, many endogenous anti-angiogenic proteins and peptides 
such as PF4, endostatin, and TSP-1 peptides share several characterized structures within areas 
of β-sheets. First, these β-sheet regions are composed of anti-parallel β-strands consisted with 
amino acids arranged by alterations between charge/polar and hydrophobic residues. Second, 
side chains of charge/polar amino acids are located on the opposite surface to that of hydro-
phobic residues. Last, most charged residues are lysines and arginines forming a positive-
charged and solvent-exposed surface on the β-sheet region or on the whole protein surface. 
Furthermore, investigations performed with PF4, endostatin, TSP-1, and other extracellular ma-
trix proteins have demonstrated that anti-angiogenic effects of these proteins depend on only 
small fragments of these proteins. These evidences led us to the hypothesis of designing and 
developing novel protein agent by crafting small anti-angiogenic peptides into a stable parental 
β-sheet protein domain. 
 Our designed protein models were described extensively in sections 1.10 and 4.2, sepa-
rately. Both Figure 1.4 and 3.1 illustrated the computational simulated structure of our de-
signed protein agent, ProAgio. Two peptides (TVQMKL and NLKVII) derived from endogenous 
anti-angiogenic proteins can mimic all three important structural features summarized as above 
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if they pair with each other to form a β-sheet structure. It was a challenge to choose a suitable 
protein to host these two peptides in order to maintain the specific β-sheet characters. The 
extracellular domain 1 of rat CD2 molecule, CD2D1 was chosen as the parental protein. This 99-
amino-acid protein domain has been well studied and expressed using bacterial expressing sys-
tems. A total of 9 strands composed of this stable β-sheet protein with a solved 3D structure as 
introduced in Chapter 1. Within the 9 β-strands, the two anti-angiogenic peptides (TVQMKL and 
NLKVII) that mimic the β-sheet regions of endogenous anti-angiogenic proteins were crafted 
into N- and C- terminal β-strands of CD2D1, separately. Mutagenesis studies were performed 
using a cDNA of CD2D1 to achieve mutations listed in Table 1.1. The simulated 3D structure 
showed in Figure 3.1 clearly predicted that amino acids of TVQMKL in the N-terminus will pair 
with those of NLKVII in the C-terminus to produce a β-strand pair that stabilized these two short 
sequences.  
 Since β-sheet features are critical for the crafted peptides to inhibit angiogenesis, it is 
important to examine whether or not our designed protein, ProAgio forms a stable structure as 
predicted. Solving the unknown 3D structure of a protein requires complicated techniques such 
as NMR spectroscopy or X-ray crystallography. In our case, since the parental CD2D1 has a 
solved 3D structure, the comparison between 1D 1H-NMR spectra of CD2D1 and ProAgio will be 
sufficient to support the predicted 3D structure. For this purpose, 1D 1H-NMR spectra of bac-
terial expressed ProAgio was examined and compared with that of its parental protein, rat 
CD2D1. As shown in Figure 3.S1B, the aromatic amino Trp32 and another residue Val78 located 
in the hydrophobic core region of ProAgio formed same peaks as those of rat CD2D1, which in-
dicated that the hydrophobic core region of ProAgio was well formed. The overall similarity be-
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tween these two spectra suggested that rat ProAgio retains a similar fold as that of CD2D1. The 
differences between these two spectra in regions of 0.0 – 1.5 ppm showed that there were side 
chain changes, which was expected because there were a total of 8-amino-acid mutations.  
   
6.2 ProAgio inhibits EC Proliferation and Tube Formation  
 In Chapter 3 and 4, evaluations of the drug effects using different in vitro bio-assays and 
a human PC3 tumor xenograft model in nude mice clearly demonstrated that our designed pro-
tein agent, ProAgio is a potential candidate for inhibition of tumor angiogenesis.  
ECs are “building blocks” for the inner layer of blood vessels, so that EC proliferation is a 
prerequisite for the occurrence of angiogenesis. Different bio-assays such as cell counting, MTT, 
[3H]thymidine, and BrdU assays that measure proliferation/viability rates of cultured ECs have 
been applied as major tools to evaluate of in vitro effects of pro- or anti- angiogenic agents (re-
viewed in [346, 347]). Usually a combination of two or more different methods will give more 
reliable conclusions. Two different methods including MTT and BrdU assays were used to eva-
luate the in vitro effect of ProAgio. MTT assays reflect the cell number, while BrdU assays 
measure DNA synthesis during the S-phase of cell cycles.  
More than 19 kinds of primary ECs from different adult tissues are commercially availa-
ble now as reviewed in reference [347]. ECs of different origins tend to behave differently, and 
primary cultured ECs are expensive and difficult to be maintained [348]. To date, HUVECs are 
still widely used ECs in in vitro angiogenesis bio-assays (reviewed in [347, 349]). Commercially 
available primary HUVECs were purchased and maintained in our laboratory as introduced in 
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2.1. Since HUVECs are primary cells that become senescent when cultured in medium, only HU-
VECs within 3 – 9 passages were used for in vitro assays.  
As shown in Figure 3.1B, it was clear that ProAgio significantly reduced proliferation 
rates of HUVECs (72% reduction at concentration of 5 µM compared to cells treated with buffer 
controls). The inhibitory effects were further evaluated using MTT cell viability assays showing 
that IC50 of ProAgio was 2.6 µM. IC50 is an important indicator for drug efficacy, so that values of 
several most characterized anti-angiogenic protein or peptide agents reviewed in Chapter 1 
were discussed in order to compare them to ProAgio. Avastin is a FDA approved monoclonal 
antibody that specifically neutralizes VEGF [138]. Wang and coworkers reported that avastin 
inhibited VEGF induced EC proliferation with an EC50 of 0.36 nM. Endostatin inhibits prolifera-
tion of HUVECs with IC50 values between 4 – 390 nM [208, 350, 351]. Another endogenous anti-
angiogenic protein, angiostatin inhibits bovine capillary endothelial cells with an IC50 of 135 nM 
[222]. A 33-amino-acid β-sheet peptide inhibits proliferation of HUVECs with an IC50 of 2.5 µM, 
while its 11-amino-adic peptide derivative, 6DBF7 has an IC50 of 15 µM [281, 286]. Compared to 
these listed values, the inhibitory efficacy of ProAgio was comparable to peptides but less than 
these of avastin and endogenous proteins.   
The IC50/EC50 values drew from in vitro bio-assays for proteins or peptides are difficult to 
predict actual in vivo effects because each protein has unique molecular weight, 3D structure, 
resistance to protease degradation, and tissue penetration. Although ProAgio has weaker in 
vitro effects than other endogenous proteins and avastin in inhibition of EC proliferation, it is 
not necessary that the in vivo effects of ProAgio would not be comparable to these of avastin or 
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endogenous proteins. The in vivo effects of ProAgio were tested and compared to that of avas-
tin, which will be discussed in this Chapter. 
In addition to inhibition of EC-proliferation, ProAgio also reduced the ability of HUVECs 
to form endothelial tubes in vitro. In 1989, Lawley and Kubota found that HUVECs and human 
dermal microvascular ECs seeded onto the surfaces of matrigel coated cell-culture plates un-
derwent morphologic change and differentiated into capillary-like tubes [352].  Unlike EC-
proliferation and migration assays that focus on only one aspect of ECs, endothelial tube forma-
tion assay has become a popular in vitro angiogenesis assay that partially simulates the process 
of in vivo capillary formation. As reviewed in section 1.2, angiogenesis is a multi-step process 
that involves in a cascade of events such as EC-proliferation, migration toward chemoattrac-
tant, attachment, and formation of tubules. Since capillary structures are usually observed 
within 8 – 12 hours when a tube formation assay is performed, it mainly assesses EC-migration, 
attachment, and formation of tubules [352].  
Besides ECs, the other major components of tube formation assay are matrices, such as 
fibronectins, collagens, and matrigels (reviewed in [347]). Matrigel potently induces ECs to form 
endothelial tube, and is composed of solubilized extracellular and basement membrane pro-
teins extracted from Engelbreth-Holm-Swarm (EHS) sarcoma, a mouse tumor that rich in extra-
cellular matrices [352]. Donovan and coworkers showed that a type of growth factor reduced 
(GFR) matrigel containing lower levels of cytokines and growth factors can avoid over-
stimulation of ECs that associates with standard matrigel [353]. In addition, they demonstrated 
that not only ECs but primary human fibroblasts and several non-EC human tumor cell lines in-
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cluding MDA-MB (metastatic breast carcinoma), U87-MG (glioblastoma), and PC3 (human me-
tastatic prostate carcinoma) also formed endothelial tubes on GFR matrigel [353].  
In our animal studies, a human PC3 cell line was used to generate nude mice xenograft 
models. It has been shown that tumor angiogenesis not only predicts pathologic stage but also 
correlates with tumor metastasis of clinical prostate carcinomas [354, 355]. Ravindranath and 
coworkers found different level of VEGF expression in normal prostate, benign and malignant 
prostatic tumors, and cultured prostatic carcinoma cell lines including PC3 cells [356]. In order 
to simulate angiogenesis in PC3 tumors, we used HUVECs co-cultured with PC3 cells to perform 
tube formation studies. ProAgio dramatically reduced the amount of tubule formed and total 
tubular lengths under 5 X Objective fields in HUVECs and PC3 co-culture (P < 0.001, unpaired 
student’s t test, two-tailed), as shown in Figure 3.1D. It also showed that the control drug, avas-
tin, also inhibited the formation of tubules and tubular counts under the same experimental 
conditions. It has been demonstrated that avastin inhibits VEGF-stimulated formation of endo-
thelial tubules [357]. Since avastin is a humanized anti-VEGF monoclonal antibody, avastin may 
neutralize VEGFs secreted by PC3 cells, therefore, inhibited ECs to form tubules. ProAgio, in the 
other hand, might inhibited tube formation by reducing the ability of ECs to migration or attach 
to each other. These findings indicated that ProAgio has potential to inhibit tumor angiogene-
sis.   
Our preliminary data (not shown) indicated that ECs suspended in growth factor and 
FBS-deprived culture medium can form endothelial tubes after they were seeded on GFR-
matrigel, but these capillary structures were quickly dismissed because by shrinkages of EC-
formed branches. The possible reason might be that growth factor and serum-deprivation pro-
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motes EC-apoptosis or reduced EC-migration. When a low concentration of FBS (2%) was added 
into the culture medium, ECs formed well-structured tubules. This condition was applied to 
tube formation studies used a co-culture of HUVECs and PC3 cells.  
 
6.3  PEGylation of ProAgio 
 PEGylation is a process that covalently conjugates PEG polymeric chains to other mole-
cules (reviewed in [344]). It has been widely adapted in bio-medical field, especially in modifica-
tion of proteins and peptides. The most common PEG chains are ethylene oxide polymers. PEG 
chain casts a “mask” on the surface of the conjugates, and each ethylene oxide unit in PEG 
binds water molecules. Due to these characters, linkage of water soluble PEG chains to proteins 
or peptides not only increases their molecular sizes, but also provides many advantages includ-
ing: i) preventing immunogenicity, ii) reducing renal filtration, iii) resisting protease degrada-
tion, iv) changing bio-distribution, and v) increasing stability and solubility (reviewed in [358]). 
Therefore, PEGylation is an important tool to improve PK/PD parameters of therapeutic protein 
and peptide drugs.   
 A PEG polymer has to be prepared into a derivative with an activate functional group 
that reacts with specific amino acids. Depending on the different types of functional group, PEG 
chains can be coupled to N-terminal amino group, lysine, arginine, aspartic acid, histidine, 
cysteine, C-terminal amino group, and others (reviewed in [344]). Most proteins are abundant 
in lysines, so that conjugating PEGs to –NH2 group of lysine and arginine is a commonly used 
PEGylation method. Bell and colleagues compared the impacts of different PEGylation methods 
on the biological activity of IFN-α2, a 20-kDa cytokine used for treatment of viral infection and 
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inhibition of tumor growth [359]. They concluded that a single 20- or 40-kDa maleimide-PEG 
coupled to a Met111Cys mutant of IFN-α2 is significantly more efficient in increasing protein 
half life and retaining anti-tumor activity than lysine- or histine-PEGylation [359].  
For above reasons, a cysteine PEGylation site was introduced by a Met23Cys mutation in 
ProAgio. Because no native cysteine residues exist in ProAgio, this single mutation allowed site-
specific PEGylation of ProAgio. A simulated model structure of Met23Cys-mutated ProAgio 
without PEG was illustrated in Figure 5.12 and introduced in section 5.8. The cysteine-
PEGylated protein, ProAgio-PEG was highly soluble in PBS, pH 7.4. It was later used for animal 
studies. 
Proteins PEGylated with long PEG chains migrated slower than these without PEGylation 
[359, 360]. The molecular weight (MW) of unmodified ProAgio is 11-kDa. After conjugated to a 
Y-shaped 20-kDa maleimide-PEG, the apparent MW of ProAgio-PEG was indicated between 55 
– 70-kDa as shown in Figure 5.12, which was confirmed by iodine-staining of the PEG chain and 
coomassie protein staining. After it was further purified, the apparent MW remained consis-
tently at the same location as shown in Figure 3.1SC.   
  
6.4 ProAgio Inhibits Growth and Angiogenesis of Xenograft Tumors  
 Since tumor growth is dependent on angiogenesis, xenograft tumors have become a 
type of commonly used method to investigate tumor growth and angiogenesis [16-18]. There 
are several advantages to use xenograft models. First, the growth of subcutaneously-grown 
tumors in immunocompromised mice is easy to be monitored. Second, tumor xenografts can be 
easily dissected and used to evaluate tumor angiogenesis by different EC surface-marker stain-
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ing techniques. Third, it allows studying drug uptakes and distribution. Pre- and clinical data has 
showed that tumor angiogenesis contributes to the pathogenesis of prostatic carcinoma, so 
that in this study the inhibitory effects of ProAgio were examined using a PC3 xenograft nude 
mice model [354-356].  
Our preliminary data indicated that compared to buffer (PBS, pH 7.4) control-treated 
group, treatment with ProAgio-PEG (10 mg/kg/day) significantly inhibited the growth and angi-
ogenesis of PC3 xenografts as shown in Figure 5.14A-C. Next, we examined the anti-tumor effi-
ciency of the non-PEGylated ProAgio and the dose-dependence in ProAgio-PEG-treated groups. 
The mean tumor mass for each treatment group (n = 6) was measured on the 20th day after the 
initial dose, and was statistically analyzed using AVONA (one way) Post Hoc tests. Treatment 
with the non-PEGylated ProAgio (5 mg/kg/day) resulted in a 45.72% (P < 0.05) reduction rate in 
tumor mass, indicating that ProAgio significantly inhibited tumor growth of PC3 xenografts. 
When the PEGylated protein was considered, the end-point mean tumor mass for treatments 
with ProAgio-PEG at a low dose (2.5 mg/kg/day) showed no significant difference (P > 0.05) 
from that of the buffer-treated group as shown in Figure 3.2B. Treatments with ProAgio-PEG at 
5 mg/kg/day and 10 mg/kg/day strongly inhibited tumor growth compared to the buffer-
treated group, resulting in 36% (P < 0.05) and 65% reduction (P < 0.01) in tumor masses, sepa-
rately (shown in Figure 3.2B). Thus, it demonstrated that PC3 xenografts responded to ProAgio-
PEG treatments in a dose-dependent manner. These statistic analyses indicated that the effec-
tive dose for ProAgio and ProAgio treatment is 5 mg/kg/day in nude mice models. 
In this study, treatments with ProAgio and ProAgio-PEG at 5 mg/kg/day for 20 days re-
sulted in a mean end-point tumor mass of 243.33 ± 53.14 mg and 285 ± 59.99 mg, separately, 
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which suggested no significant differences between these two groups. The tumor growth 
curves shown in Figure 3.2A also exhibited no differences. It has been shown that PEGylation 
has a tendency to decrease in vitro protein bio-activities (reviewed in [358]). ProAgio-PEG was 
site-specifically PEGylated in a cysteine residue, a method that has less impact on protein func-
tions than non-specific ones [359]. The overall anti-angiogenic effect of ProAgio-PEG was ex-
pected to be less than that of ProAgio because the coupled PEG chain may mask the protein 
surface. In vivo effects, however, are not solely determined by in vitro bio-activities. One of the 
advantages of PEGylation of ProAgio was to improve PK/PD parameters, thus it may have equal-
to-better in vivo effects compared to these of the non-PEGylated protein. Because ProAgio-PEG 
has longer circulating retention time compared to ProAgio, it is possible that increasing treat-
ment course will demonstrate differences in anti-tumor efficiencies between these two pro-
teins. Even if ProAgio showed better tumor-inhibitory effects, we still expect to use humanized 
ProAgio-PEG as a therapeutic agent in clinical studies due to protein solubility and less immune 
responses.  
It is important to compare our designed protein agents directly to VEGF/VEGFR inhibi-
tors, the most widely used category of anti-angiogenic agents. Therefore, animal studies were 
performed in order to compare treatments with ProAgio-PEG (20 mg/kg/day) to avastin (20 
mg/kg/twice weekly) for 20 days. The reason for using avastin as a positive control was mainly 
because avastin is a protein drug that has been approved by FDA for the treatment of several 
types of solid tumors (reviewed in section 1.7.1.1.1). The circulating half-life for avastin is 23.1 
days, so that avastin is commonly distributed in an interval of twice weekly [138]. Daily adminis-
tration of ProAgio-PEG was determined by referring to circulating half-lives of literature-
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reported PEGylated proteins. Proteins coupled with different length of PEG chains vary in circu-
lating half-lives. Baker and coworkers reported that PEGylation of INFβ1, a 20-kDa cytokine 
coupled with a 20-kDa maleimide-PEG increased the protein circulating half-life from 0.98 mi-
nutes to 13 hours [360]. Rosendahl and colleagues showed that the half-lives of IFN-α2 were 
22, 34, and 32 hours when it was modified with 10, 20, and 40-kDa maleimide-PEGs, separately 
[359]. ProAgio is an 11-kDa protein; therefore, we speculated that when it was coupled with a 
20-kDa maleimide-PEG, its circulating half-life would be 13 – 30 hours. Thus a daily dose was 
necessary to maintain its ED50 in vivo.  
When the end-point tumor masses were compared, both treatments with ProAgio-PEG 
and avastin dramatically reduced tumor masses (P < 0.01), while treatments with the buffer 
control and the parental protein (CD2D1-PEG, 20 mg/kg/day) showed no statistic significances. 
Treatment with ProAgio-PEG (20 mg/kg/day) for 20 days resulted in a 68% reduction rate in 
tumor mass, which was slightly higher than that of avastin (59%). As discussed above, the end-
point tumor mass reduced 65% when mouse were treated with ProAgio-PEG at 10 mg/kg/day. 
In addition, when tumor growth curves for ProAgio-PEG (20 mg/kg/day), ProAgio-PEG (10 
mg/kg/day), and avastin (20 mg/kg/twice weekly) were compared (shown in Figure 3.2A and 
3.2C), it suggested that ProAgio-PEG achieved the same level of anti-tumor effect as avastin did 
at 10 mg/kg/day; however, it is an indirect comparison because of differences in circulating 
half-lives and anti-angiogenic mechanisms. 
Cluster of differentiation 31 (CD31), also known as platelet endothelial cell adhesion 
molecule-1 (PECAM-1) is one of the major components in EC intercellular junctions [361]. Im-
munohistochemical staining of CD31 has been a useful method for identification of vasculatures 
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in different human and mouse tissues including tumors [362-364]. In order to determine the 
anti-angiogenic effects from treatments with our designed protein agents, CD31 IF-staining pat-
terns of above tumor tissues dissected from different treatment groups were analyzed and data 
were listed in Table 3.1A and 3.1B. Three indicators including mean vessel length, mean vascu-
lar density (MVD), and mean branch points were statistically analyzed using unpaired student’s 
t tests (n = 6, two-tailed). The treatment with the non-PEGylated ProAgio (5 mg/kg/day) re-
sulted in a 65% reduction rate (P < 0.05) in mean vascular length and an 83% reduction rate (P < 
0.05) in branch points in PC3 xenografts, which were significantly different from these treated 
with the buffer control. The MVD, however, failed to be effectively reduced by the treatment of 
ProAgio at 5 mg/kg/day (12.16 ± 1.75/counted-field) compared to buffer-treated group (15.83 ± 
1.78/counted-field). The treatment with ProAgio-PEG at 5 and 10 mg/kg/day resulted in 36% (P 
< 0.01) and 46% (P < 0.01) reductions in MVD, separately. In addition, treatments with ProAgio-
PEG not only substantially reduced mean vessel lengths and MVDs, but also dramatically inhi-
bited the formation of new vascular branches. Reduction rates in branch points/counted-field 
for 2.5, 5, and 10 mg/kg/day of ProAgio-PEG treated xenograft groups were 30% (P = 0.23), 72% 
(P < 0.05), and 80% (P < 0.01), suggesting a strong dose-dependent effect. Angiogenesis is the 
process that new blood vessels form from existing ones, so that these statistic analyses demon-
strated that our designed agents significantly inhibited tumor growth by preventing the occur-
rence of angiogenesis.  
The anti-angiogenic effects of avastin (20 mg/kg/twice weekly), CD2D1-PEG (20 
mg/kg/day), and ProAgio-PEG (20 mg/kg/day) were compared by statistic analyses of CD31 IF-
staining patterns of tumor tissues from each treatment groups as indicated in Figure 3.2C and 
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Table 3.1B. Treatment with CD2D1-PEG (20 mg/kg/day) did not affect the mean vessel length, 
MVD, and mean branch points in tumor tissues. The treatment with ProAgio-PEG (20 
mg/kg/day) resulted in a dramatic reduction rate in mean vessel length (80%, P < 0.01), MDV 
(65%, P < 0.0001), and near complete elimination of branch points (95%, P < 0.0001). Same as 
indicated by the mean end-point tumor mass, treatment with avastin (20 mg/kg/twice weekly) 
resulted in reduction rates of 58% (P < 0.01) in mean vessel length, 46% (P < 0.05) in MVD, and 
73% (P < 0.05) in mean branch points, which were at the same levels as these of ProAgio-PEG 
(10 mg/kg/day) treated group (reduction rates of 67%, 46%, and 81% for mean vessel length, 
MVD, and mean branch points, separately).  
In summary, the treatment with ProAgio (5 mg/kg/day) significantly inhibited tumor 
growth and angiogenesis in PC3 tumor xenografts. Treatments with ProAgio-PEG from 2.5 to 10 
mg/kg/day showed dose-dependent anti-tumor and anti-angiogenic effects in vivo. A dose of 10 
mg/kg was expected to be the optimal dose for future studies in nude mice models. Tumor 
growth and angiogenesis were inhibited at the same levels for treatments with 10 mg/kg/day of 
ProAgio-PEG and avastin 20 mg/kg/twice weekly. At 20 mg/kg/day, ProAgio dramatically inhi-
bited tumor growth and near completely reduced tumor angiogenesis. These studies demon-
strated that our design approaches have great potentials to be applied in the development of 
anti-angiogenic protein agents.  
 
 6.5 Targeting Mechanisms of ProAgio  
 As shown in Figure 3.1B, and 3.1C, ELISA assays using anti-BrdU antibody demonstrated 
that ProAgio inhibited proliferation of ECs but not that of a type of epithelium-original cells, 
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M4A1 (breast cancer). Compared to traditional cytotoxic drugs, targeting endothelial cells is 
one of the major advantages for anti-angiogenic agents. It is commonly reported that endogen-
ous anti-angiogenic proteins and peptides specifically inhibit the growth of ECs, but the target-
ing mechanisms remain elusive (reviewed in [21, 196, 240, 365]). Galectin-1(Gal-1) belongs to a 
family of lectins with a conserved carbohydrate recognition domain (CRD)  [366]. Gal-1 regu-
lates a wide range of cellular processes including cell growth, migration, adhesion, invasion, and 
apoptosis (reviewed in [367]). As demonstrated by pull down assays, Gal-1 is a potential anti-
angiogenic target for ProAgio. 
 ProAgio interact with Gal-1 expressed in HUVECs, whereas CD2D1 did not as shown in 
Figure 3.4.  Over-expression of Gal-1 has been observed in a number of different types of tumor 
stroma, such as colon [368], lung [369], pancreas [370, 371], bladder [372], and prostate can-
cers [373]. Studies have suggested two major mechanisms of how Gal-1 contributes to tumor 
progression. First, Gal-1 promotes tumor metastasis by enhancing the cell-cell adhesion be-
tween tumor cells and ECs [374-377]. Second, Gal-1 facilitates tumor cells to escape from im-
mune responses through immuno-suppressive functions [378, 379]. In addition to these two 
mechanisms, Thijssen and co-workers by using a Gal-1-null (Gal-1-/-) mice model demonstrated 
that Gal-1 plays an essential role in promoting tumor angiogenesis, and it is a target for a syn-
thetic anti-angiogenic peptide, anginex [345]. Since ProAgio interacts with Gal-1, it is possible 
that ProAgio exerts anti-angiogenic function via inhibition of Gal-1.  
Gal-1 is a major immune-modulator that maintains T-cell homeostasis and survival by 
inhibiting T-cell activation [380], promoting cell-cycle arrests and apoptosis of activated but not 
quiescent T-cells [381-385], and reducing the secretion of IL-2 and IL-10 [383]. Since blockage of 
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Gal-1 expression inhibited tumor growth, studies suggested that Gal-1 promotes apoptosis of 
tumor-infiltration T-cells, resulting in immune suppressive environments that protect tumor 
cells from immune responses [378, 379]. Moreover, Zhou and coworkers demonstrated that 
cytotoxic T lymphocytes (CTLs) specifically kill proliferating ECs, which strongly inhibits tumor 
angiogenesis [386]. Therefore, inhibiting the immunosuppressive function of Gal-1 may be 
counted as one of the anti-angiogenic mechanisms for ProAgio. This theory can be applied to 
clinical patients or animal models with normal T lymphocytes except for the nude mice models 
that were used to study the in vivo activities of ProAgio in the present work. Because nude mice 
do not have thymus nor do them produce functioning T-cells, enhancing the function of CTLs 
cannot explain the anti-angiogenic function of ProAgio in these animal studies. Several similar 
nude mouse models have been used to prove anti-angiogenic effects of anginex, the synthetic 
peptide targeting Gal-1.   
Based on previous studies, several signal pathways are speculated to explain possible 
anti-angiogenic mechanisms of ProAgio involved in these animal cases. Gal-1 is a typical cytop-
lasmic protein, but it is also exported to ECM [387-390]. Cytoplasmic Gal-1 has different binding 
partners from extracellular Gal-1. Firstly, the extracellular Gal-1 functions as a β-galactoside-
binding protein with different affinities to various glycosylated cell surface receptors and ECM 
proteins (reviewed in [367]). It increases cell adhesion and migration capabilities of different 
types of cells [375-377]. As reviewed in section 1.2, EC migration and adhesion are critical 
processes required for angiogenesis, which can be evaluated by in vitro EC tube formation as-
says. ProAgio inhibited HUVECs to form endothelial tubules as shown in Figure 3.1D and dis-
cussed in section 6.2, so that ProAgio may inhibit angiogenesis by disrupting the interaction be-
194 
tween Gal-1 and integrins. ProAgio may dissociate or prevent Gal-1 from interacting with inte-
grins expressed in ECs, resulting in reduced EC adhesion and migration. Secondly, the cytoplas-
mic Gal-1 binds to H-Ras-GTP in a glycosylation-independent manner [391]. In human tumor 
cells, the cell-membrane-anchored H-RAs-GTP recruits cytoplasmic Gal-1 to form a stable com-
plex that subsequently activates Raf-MEK-ERK pathway [392, 393]. It has been shown that tu-
mor ECs in F9 teratocarcinoma and B16F10 mouse melanoma planted in gal-/- mice uptake Gal-
1 secreted by these tumor cells [394]. ECs cultured in vitro also uptake Gal-1, which subse-
quently promotes EC proliferation and migration through activation of Raf-MEK-ERK pathway 
[394]. We have confirmed that ProAgio inhibited EC-proliferation. The anti-proliferative me-
chanism of ProAgio may lie on inhibition of ECs from uptaking extracellular Gal-1. Alternatively, 
ProAgio may be accompanied Gal-1 to enter ECs, blocking Gal-1 to be recruited by H-Ras-GTP, 
resulting in blockage of the Raf-MEK-ERK pathway.   
 
6.6 Humanized ProAgio for Therapeutic Applications 
The parental protein for ProAgio is the extracellular domain 1 part of rat CD2D1 (refer to 
1.10.4). Table 4.1 compared amino acid sequences and side chain directions in these two pro-
teins. The human counterpart of CD2D1, huCD2D1 forms a same 3D structure as rat CD2D1, but 
it is N-glycosylated. Because N-glycan is critical to the folding and stability of huCD1D1, expres-
sion of huCD2D1 requires either mammalian expression system or mutations that abolish the 
N-glycosylation site (refer to section 4.2.3). Compared to human CD2D1, rat CD2D1 is a non-
glycosylated protein so that expression and purification of rat CD2D1 is more convenient and 
cost efficient in laboratory settings [300, 336, 338]. More importantly, the expressed rat CD2D1 
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is stable with many detailed structural studies on different site-mutations and insertion [298, 
308, 311, 395]. For these reasons, rat CD2D1 was used to demonstrate our design approach and 
protein was expressed in a small scale for in vitro and in vivo studies shown in Chapter 3 and 5. 
As discussed in section 4.1.1, ProAgio was re-designed using the first 104-amino-acid fragment 
of human CD2 (huCD21-104) as the parental host protein. The detailed design strategy was listed 
in section 4.2.2. The re-designed protein was denoted as huProAgio in order to be differen-
tiated from ProAgio. A number of human protein and peptide drugs has been successfully man-
ufactured and applied in patients with different types of disease [396, 397]. With advances in 
protein drug production techniques, huProAgio is expected to be used in future clinical studies 
and treatment of cancer patients.  
Rational for design the anti-angiogenic region of huProAgio and strategies for eliminat-
ing the N-glycosylation, facilitating cysteine-PEGylation, abolishing CD2-CD58 interaction was 
introduced in details in section 4.2 (also refer to section 4.2, Figure 4.2, and Figure 4.3). In order 
to facilitate protein expression in different systems, the N-glycosylation site was maintained for 
yeast expression. In order to express the protein in our laboratory using bacterial systems, 
three mutations (Lys61Glu, Phe63Leu, and Thr67Ala) were introduced. A simulated model 
structure of huProAgio without glycosylation was illustrated in Figure 4.1 and discussed in sec-
tion 4.4. The cDNA for huProAgio were optimized for yeast and bacterial expression, separately 
(cDNA sequences shown in Figure 4.5 and 4.6). A BL-21 (DE3) bacterial stain expressed the non-
glycosylated huProAgio with an N-terminal his-tag (his-huProAgio), and the protein was purified 
and further tested for in vitro and in vivo effects. As discussed in section 4.5.2, the purified his-
huProAgio showed limited solubility. Optimization of buffer conditions showed that 50 mM ar-
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ginine, 50 mM glycine, and 2 mM DTT increased protein solubility. Because the purified his-
huProAgio is not PEGylated, the suspected reason for limited solubility without DTT, arginine, 
and glycine is that Cys28 originally designed for PEGylation was solvent-exposed and facilitated 
dimerization of the expressed protein. It is expected that the solubility issue will be solved by 
cysteine-PEGylation in future.  
The in vitro and in vivo tests were preliminary using non-PEGylated his-huProAgio. As 
shown in Figure 4.10, at concentration of 10 µM, his-huProAgio exhibited stronger anti-
proliferation effect compared to ProAgio. The anti-tumor effect of non-PEGylated his-
huProAgio was examined using PC3 xenograft model described in previous Chapters. His-
huProAgio showed significant tumor inhibitory effect compared to buffer control group (t = 
3.53, P = 0.0054, paired student’s t test) and induction of end-point tumor mass (t = 2.78, p = 
0.02, paired student’s t test). Different purification strategies, structural modification, and drug 
delivery methods are expected to optimize the solubility and structural stability of huProAgio; 
however, these preliminary data suggested that the recombinant huProAgio has potential to be 
developed into an anti-angiogenic protein agent.  
Although the goal of present study was to demonstrate an effective strategy to design 
novel anti-angiogenic agents, it is valuable to discuss future clinical outlooks and pitfalls for hu-
ProAgio. The following discussions were based on results showed in Chapter 3 and 4.   
 
6.7 Human CD2-CD58 and Rat CD2-CD48 Interactions  
 The CD2-CD48 (in rat) and CD2-CD58 (in human) interactions was considered differently 
in the present study.  
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Firstly, the CD2-CD58 interaction was abolished during the design of huProAgio by a sin-
gle Tyr86Ala mutation (refer to section 4.2.4). The intact CD2 molecule is a transmembrane gly-
coprotein expressed on T lymphocytes, NK cells, and thymocytes with cell adhesion and immu-
no-regulatory functions [293]. The first 104-amino-acid fragment used in this study is located in 
the extracellular domain part of CD2, and it has only been indicated in the cell adhesion func-
tion of CD2. In human species, CD58 is the natural ligand to CD2 [398]. Inhibition of CD2-CD58 
interaction impairs the ability of T lymphocytes to recognize cell surface antigens [340] and 
blocks T lymphocytes activation [399], therefore; huProAgio will compromise immune response 
if it affects CD2-CD58 interaction in human. There are several reasons to choose a single muta-
tion to abolish CD2-CD58 interaction. The CD2-CD58 interaction has been well studied using X-
ray crystallography and NMR analysis, suggesting several hot spots involved in ligand recogni-
tion [338, 340]. Among these amino acids in the binding surface, disrupting the interaction be-
tween Tyr86 of CD2 and Lys34 of CD58 most sufficiently abolished the binding of these two mo-
lecules [340]. In addition, Tyr86 is located at the flexible loop region instead of the rigid β-sheet 
of huCD2, so that Tyr86Ala mutation was expected to bring the least effects on protein struc-
tural stability, which is confirmed by the NMR studies carried out by Kim and coworkers [340]. 
These previous studies facilitated us to use Tyr86Ala mutation as a strategy to avoid possible 
clinical side effects caused by change of T lymphocytes function/activation in cancer patients.  
Although Tyr86 was mutated in huProAgio, it still necessary to confirm that huProAgio 
does not affect CD2-CD58 interaction. A classic method, E-Rosetting assay, can be performed to 
determine whether or not huProAgio will affect the cell-cell adhesion function of T lymphocytes 
mediated by CD2 [400]. Exogenously expressed CD58 adhesion domain can be used to deter-
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mine huProAgio-CD58 binding in vitro [340, 401]. Since CD2-CD58 binding surface is disrupted 
by Tyr86Ala mutation, it is suggestive that huProAgio may not bind to CD58 in vitro and in vivo. 
CD2 binds to CD58 with a Kd of 1 – 10 µM, whereas Tyr86Ala mutation decreases the affinity of 
CD2 to CD58 by 100 – 1000 folds [340]. If huProAgio does bind to CD58 with a low affinity, acti-
vation and functions of T lymphocytes has to be examined using animal models. Otherwise the 
binding of huProAgio-CD58 could be further reduced or abolished by additional mutations in 
the binding surface.  
Secondly, CD48 is the natural ligand of rat and mouse CD2 instead of CD58 in human 
[296, 341]. CD2-CD48 interaction of rat ProAgio was not taken into consideration because of 
two reasons. First, rat CD2 bind CD48 with a low affinity (Kd  = 60 – 90 µM) [296, 297]. Theoreti-
cally, the experimental protein concentrations (50 – 100 µM of 200 µL for i.p. injection) used in 
animal model will not produce serum ProAgio concentrations that are sufficient to disrupt CD2-
CD48 interaction. Second, nude mice were used for evaluation of in vivo effects of rat ProAgio, 
so that the anti-angiogenic and anti-tumor functions observed were less likely to be caused by 
suppressing activation or functions of T lymphocytes.   
 
6.8 Advantages Using ProAgio as a Therapeutic Agent 
 After bevacizumab was approved by FDA, anti-angiogenic therapy has become a new 
line of treatment excepted to bring exceptional benefits to cancer patients, such as low toxicity, 
less drug resistance, and flexibility to inhibit a broad spectrum of tumors. In the past several 
decades, although a great body of knowledge regarding mechanisms of angiogenesis has pro-
vided valid targets for anti-angiogenic studies, a majority of current FDA approved anti-
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angiogenic drugs are VEGF/VEGFR inhibitors (reviewed in sections 1.5 and 1.7). VEGF/VEGFR 
inhibitors such as anti-VEGF monoclonal antibody, bevacizumab (Avastin, Genentech/Roche), 
and small molecule VEGGR inhibitor, sunitinib (Sutent®, Pfizer) were ice-breakers for anti-
angiogenic therapy and they have been applied to cancer patients with different types of tu-
mors since 2004. As clinical and research data compiled within past a decade, several draw-
backs of VEGF/VEGFR inhibitors have been suggested (reviewed in section 1.8). Other agents 
including EGFR inhibitor, mTOR inhibitors, and immuno-modulators have anti-angiogenic ef-
fects but do not specifically inhibit tumor angiogenesis (reviewed in section 1.7).  
Compared to the above agents, ProAgio has several advantages. Firstly, these marked 
agents are indirect angiogenesis inhibitors by targeting one or several signaling pathways that 
mediate(s) EC proliferation or apoptosis. It has been shown that tumor cells intrinsically resist 
treatment with VEGF/VEGFR inhibitors by stimulating redundant pro-angiogenic factors such as 
FGF, PIGF or PDGF, resulting in drug resistance (reviewed in [181]). Growth factor triggered EC 
proliferation/migration is the key to this phenomenon. ProAgio directly target ECs to inhibit EC 
proliferation and formation of tubules. Direct angiogenesis inhibitors damages the “building 
block” for new blood vessels regardless of different sources of stimulants (reviewed in [136]), 
so that cancer patients treated with ProAgio will theoretically have less chance to experience 
drug resistance. Secondly, inhibition of multiple signal pathways has been considered as prom-
ising solution to solve above drug resistance; however, combination of anti-VEGF and anti-EGF 
monoclonal antibody drugs have produced controversial results about improving anti-tumor 
efficacy in different clinical trials [402, 403]. The combination of an anti-EGF antibody, panitu-
mumab with bevacizumab increased toxicity and reduced progression-free survival (PFS) rate in 
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metastatic colorectal cancer [403]. Small molecule TKIs usually inhibits several signal pathways 
and more efficient at inhibiting angiogenesis, but they have higher toxicity compared to monoc-
lonal antibodies (reviewed in [179]). The ant-angiogenic mechanisms of ProAgio are indepen-
dent of growth factors, so that adverse effects can be avoided if ProAgio replaces these contro-
versial combinational treatment regimes. Thirdly, our in vitro data showed that ProAgio inhi-
bited EC-proliferation without significant effects on epithelium-original cells. One of the advan-
tages of using ProAgio or other endogenous anti-angiogenesis proteins is low toxicity. Tumor 
vessels are structurally and functionally abnormal with less protected and disconnected ECs 
compared to normal vasculatures as reviewed in section 1. 4. These features allow direct anti-
angiogenic agents specifically target proliferating tumor ECs, resulting in less side effects. Toxic-
ities had not been observed ProAgio treated animals. In contrast, VEGF signaling have been 
shown to regulate normal organ homeostasis, and treatments with VEGF/VEGFR inhibitors as-
sociated with complications involved in multiple organ systems, especially heart and kidney (re-
viewed in [170]). In future studies, long-term toxicity of ProAgio is necessary to be examined in 
pre- and clinical trials.  
All the above reasons led to a wave of discovery and development of endogenous anti-
angiogenic proteins and peptides that directly target ECs with low toxicity and broad anti-tumor 
spectrum. As reviewed in section 1.9, to date, numerous investigations have documented a 
large number of matrix-derived or non-matrix-derived endogenous proteins, protein fragments, 
and peptides that sufficiently inhibit tumor angiogenesis in a variety of tumor models. Unfortu-
nately, except for endostatin none has been successfully applied to treat cancer patients. It is 
not clear why these endogenous proteins or peptides failed clinical trials, however; three as-
201 
pects could affect their activities and applications. Firstly, most of them are fragments or pep-
tides derived from ECM proteins with limited structural stability and protein solubility. For ex-
ample, endostatin is highly positively charged protein fragments that is soluble in low pH and 
forms precipitation in neutral pH [289]. Compared to endogenous anti-angiogenic protein or 
protein fragments derived from ECM proteins, ProAgio is soluble in isotonic buffer at neutral pH 
(PBS, pH7.4). Secondly, the “default” biological functions of endogenous proteins, such as TSP-
1, PF4, ILs, and IFNs have high potential to cause side effects if used as anti-angiogenic agents. 
Although the humanized ProAgio (huProAgio) was derived from the extracellular domain 1 of 
CD2 (CD2D1), the cell adhesion function caused by CD2-CD58 interaction was crippled in order 
to avoid its “default” function in regulating immune responses. Thirdly, although dissecting en-
dogenous proteins will avoid trigger non-angiogenesis related activities and in some cases in-
crease solubility, but lack of pharmacological properties and high production cost usually hinder 
small peptides to be developed into anti-angiogenic drugs. NMR evidences suggested that 
ProAgio is protein with a stable β-sheet sandwich structure that not only conveys importance 
structural features, but also resists to protease degradation, resulting in a longer in vivo half life 
and higher targeting efficiency. With regard to expenses, bacterial or yeast fermentation tech-
niques will facilitate the mass production of ProAgio in a relative lower cost compared to syn-
thetic peptides.    
In summary, ProAgio demonstrated a de novo designed methods to produce protein 
agents that can overcome not only the disadvantages of existing marked anti-angiogenic drugs 
(VEGF/VEGFR and EGFR inhibitors) but also the shortcomings of endogenous proteins and pep-
tides undergoing drug development. Our studies highly suggested that the humanized ProAgio, 
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huProAgio is expected to produce higher anti-angiogenic efficiency, lower toxicity, and lower 
risk of drug resistance than these mentioned above. Backed up by low manufacture cost, sim-
plicity in formulation, and proper modifications favoring in vivo pharmacokinetic parameters, 
huProAgio will have a high potential to become the next generation of anti-angiogenic drug.  
 
6.9  Clinical Outlook of HuProAgio  
To date, a large portion of anti-angiogenic drug research and development has focused 
on antibodies and proteins. Antibodies, proteins, and peptides remain as attractive drug candi-
dates because they have high affinity, specificity, and safety. Like many of the endogenous anti-
angiogenic proteins such as PF4, angiostatin, anastellin, and restin, studies used rat ProAgio 
proved that our designed agent specifically targeted ECs not epithelial cells. Studies with ProA-
gio and huProAgio indicated that both agents strongly inhibit tumor growth and angiogenesis in 
animal models. In addition, the ligand binding capability of CD2D1 (the parental protein of hu-
ProAgio) was crippled to avoid possible immune responses. These profiles will assure the effica-
cy and safety profiles of huProAgio.  
In general, angiogenesis inhibitors are considered as a new category of low toxic and 
well-tolerable anti-cancer therapy. They lack cytotoxic anti-cancer drug related side effects such 
as alopecia, severe myelosuppression, neural, renal, and gastrointestinal toxicities (reviewed in 
[170]). The possible side effects of huProAgio are expected to be confined to complications 
caused by disruption of angiogenesis. Wound healing, bleeding, and gastrointestinal perfora-
tions are the most common complications when angiogenesis is perturbed (reviewed in [170]). 
The occurrences of these complications are expected in huProAgio-treated cancer patients, but 
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the incidences will depend on the serum concentration of huProAgio. As a protein agent that 
directly targets ECs, huProAgio is less likely to cause side effects related to inhibition of the phy-
siological functions of pro-angiogenic signal pathways. For example, as reviewed in section 1.8, 
VEGF not only activates ECs, but also plays an important role in the maintenance of body ho-
meostasis, especially in the cardiovascular system. The most common side effects associated 
VEGF/VEGFR inhibitors are hypertension, MI, and congestive heart failure. VEGF is highly ex-
pressed in renal glomeruli and tubules, and mediates renal functions, which may contribute to 
proteinuria is also commonly occurred in bevacizumab-treated cancer patients [404-406]. 
ProAgio is a de novo designed protein that is not involved in above physiological processes, 
suggesting it will have fewer chances to affect cardiovascular and renal systems compared to 
VEGF/VEGFR inhibitors.  
If safety is demonstrated in pre- and clinical trials, huProAgio can be used to treat many 
types of tumors because angiogenesis is a general mechanism for growth of most solid tumors. 
As reviewed in section 1.7, anti-angiogenic drugs including VEGF/VEGFR and EGFR inhibitors 
have been approved to treat patients with NSCLC, glioblastoma, RCC, breast cancer, hepatocel-
lular carcinoma, and others. Recombinant human endostatin (rh-endostatin, Endostar®) was 
approved to treat NSCLC in China in 2005 [190]. In animal models, human endostatin has been 
used to inhibit more than 15 different types of human tumor xenografts in mice models (re-
viewed in [196]). HuProAgio effectively inhibited the growth of PC3 xenograft models, but it is 
important to test it on animal models with different types of human tumors.  
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6.10 Clinical Challenges for HuProAgio  
To date, hundreds of endogenous proteins and peptides have been discovered and in-
vestigated in pre- and different stages of clinical trials, but only rh-endostatin has succeeded to 
pass clinical approval. It is not clear why these proteins and peptides showed robust anti-cancer 
effects in experimental animal models, but failed to exhibit the same effect in humans. We ex-
pect huProAgio to be a highly efficient anti-angiogenic agent with low toxicity and a broad anti-
cancer spectrum; however, clinical trials may demonstrate that huProAgio shows no significant 
inhibitory effects in inhibition of tumor growth and angiogenesis. Several aspects that might 
contribute to these circumstances are speculated and discussed as follows. 
On one hand, as a protein drug, huProAgio has intrinsic challenges that will hinder the 
therapeutic applications. Torchilin and coworkers summarized major obstacles for protein and 
peptide drugs in a review: i) short circulation time generated by fast renal filtration and enzy-
matic degradation, ii) immune responses, and iii) uptake by non-target tissues [407]. Our design 
approach has taken these obstructive factors into consideration. First, ProAgio adapts a well-
folded β-sheet sandwich structure that more resists to protease degradation than peptide do. 
Second, ProAgio was re-designed into huProAgio to avoid possible cross-species immune res-
ponses. Third, a site-specific PEGylation method was used to elongate circulation time, reduce 
immune responses, and improve pharmacokinetic and pharmacodynamic features of huProAgio 
with PEGylated L-asparaginase (Oncospar®, Enzon), IFN-2a and -2b as successful examples. If 
huProAgio fails to show expected clinical effects despite of these factors, exchanging PEGyla-
tion conjugates, modifying protein structure, or adapting advanced drug delivery methods are 
valuable avenues to further overcome these possible obstacles. For example, encapsulation of 
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huProAgio in tumor-vasculature-targeting liposomes is a promising delivery method. Liposomes 
are spherical vesicles composed of phospholipid bilayers with an inner aqueous space that is 
suitable for encapsulation of anti-cancer drugs, proteins, and peptides (reviewed in [407]). 
Chang and colleagues reported that coupling tumor vasculature homing peptides with a dox-
orubicin (Lipo-Dox; LD)-containing liposome as a methods that significantly promoted accumu-
lation of doxorubicin in tumor endothelium and enhanced its anti-cancer activity [408]. This 
technique can avoid immunogenicity, prolong blood circulation time, increase drug concentra-
tion in tumor ECs, and reduce uptake by non-targeting tissues or organs (reviewed in [409]).  
On the other hand, except for above impediments, lack of efficient targeting may play 
an essential role if our designed protein agents fail to show expected effects. It is important to 
clarify the anti-angiogenic mechanisms of huProAgio. As discussed in section 6.5, Gal-1 was a 
potential anti-angiogenic target for our designed protein agents, but it may not be the only pro-
tein that interacts with ProAgio in vivo. Further studies are necessary in order to portray the 
exact picture of how huProAgio exerts anti-angiogenic functions. These protein-protein interac-
tions profiles will provide solid ground on monitoring and improving drug efficacy. By far our 
design approach has focused on importance β-sheet structural features of endogenous anti-
angiogenic proteins and peptides including alternation of charge/polar and hydrophobic resi-
dues, constitution of amphipathic surfaces with the positive-charged surface exposed to sol-
vent. Within the designed anti-angiogenic portion of huProAgio, it is critical to identify the most 
important residues that determine protein-protein binding between huProAgio and its partner. 
Substitutions of these amino acids will affect the binding affinity of huProAgio. Consequently, 
the anti-angiogenic effects of huProAgio will also be enhanced or reduced by different muta-
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tions. Furthermore, identification of downstream targets will help to establish the anti-cancer 
spectrum of huProAgio.  For example, if Gal-1 is the only target for huProAgio, it has to be ap-
plied to patients with cancers over-expressing Gal-1.  
In addition, efficacies of novel anti-cancer drugs are constantly tested in patients with 
late stage cancers. Within advanced tumors, tumor vasculatures have established usually with 
the existence of necrotic and hypoxic areas. Under these circumstances, any anti-angiogenic 
drug may fail to demonstrate beneficial effects because at this stage angiogenesis contributes 
less to tumor growth. Regimens combining VEGF/VEGFR inhibitors with cytotoxic agents or ra-
diotherapies are commonly used to treat cancer patients (reviewed in [410]). For these reasons, 
it is necessary to use huProAgio in combination with traditional anti-cancer therapies instead of 
being applied as a single agent. Since exponential tumor growth only occurs after new blood 
vessels are established, it is critical to apply anti-angiogenic therapy in early stage of cancer 
growth [5, 18]. Future advances in early cancer diagnosis will greatly expand the therapeutic 
prospective of anti-angiogenic agents.  
Furthermore, tumor angiogenesis is a multi-step process choreographed by a number of 
cellular signal pathways, a large amount of proteins, and different types of cells. Compelling 
pre-clinical investigations have demonstrated that combining agents with different anti-
angiogenic mechanisms can significantly reduce tumor angiogenesis than a single one does 
[411-413]. As discussed in section 6.8, current available VEGF/VEGFR and EGFR inhibitors exhi-
bit limited anti-cancer effects as a single agent, and combination of these two have not pro-
duced consistent clinical outcomes. ProAgio is a direct anti-angiogenic agent targeting ECs. 
Combination of ProAgio with VEGF/VEGFR or EGFR inhibitors will curb tumor angiogenesis from 
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two independent angles, which will enhance treatment efficacy. Besides, it is possible that 
combination of ProAgio with other direct anti-angiogenic agents will also be more effective. For 
example, studies have shown that endostatin and anastellin have addictive in vitro effects 
[414].  
 
6.11 Conclusions and Future Directions 
We have successfully developed an anti-angiogenesis agent by rational protein design. 
Most current available anti-angiogenesis agents target VEGF/VEGFR or other RTK pathways. 
Such agents often cause unwanted biological side effects. In addition, many cancers are resis-
tant to the inhibition of VEGF/VEGFR. Our developed protein is one of a very few examples that 
do not act through targeting VEGF/VEGFR or any other RTK pathways. Importantly, our study 
provides an example of proof-of-concept to harness the natural anti-angiogenesis activity to 
starve cancers. In addition, our study introduced a new strategy to integrate a small bio-active 
structural motif or an unstable short circulating peptide into a stable host protein. The resultant 
protein overcomes the major disadvantage of therapeutically peptides, e.g. in vivo instability 
and unfavorable pharmacological properties.  
In vitro models showed that ProAgio effectively inhibit HUVEC cell growth and formation 
of endothelial tubes. The drug efficacy of ProAgio was further examined in a xenograft model. It 
was demonstrated that ProAgio inhibits tumor growth in a dose dependent manner. ProAgio 
also surpassed avastin in inhibition of tumor growth using the same model. These effects were 
further confirmed by MVD count in tumor tissues from different treated group. These in vitro 
and in vivo experiments demonstrate the effectiveness of our designed protein. The developed 
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agent is not toxic to non-cancerous blood vessels and other tissue/organs, providing for future 
potential clinical applications. 
In addition, humanization of ProAgio was also carried out in this study utilizing the same 
strategy as with rat CD2D1. The designed huProAgio protein was expressed and purified in bac-
terial with an N-terminal his-tag. Anti-angiogenic effect of designed huProAgio is also examined 
in in vitro and in vivo models same as ProAgio. The refolded protein showed proliferation-
inhibitory effect toward HUVECs. Further treatment of PC3 xenograft tumor model using hu-
ProAgio demonstrated its strong anti-angiogenic activity.  Since human and rat CD2D1 share 
40% amino acid similarity, it was evident that host protein did not significantly affect the de-
signed anti-angiogenic effects of designed agents. In addition, these findings in huProAgio fur-
ther demonstrated the efficacy of our design strategies.  
The concept of this study can be extended to the design and development of other pro-
tein drugs. Our system certainly will create a new platform for design of therapeutic agents by 
de novo protein design. 
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APPENDIX  
LIST OF COMMON BUFFERS 
Lysate buffer, Preparation for 250 mL: 
1% sarcosyl (N-lauroyl sarcosine) 2.5 g 
 10 mM DTT    0.385 g 
 1 mM EDTA    0.10 g 
 5 M inhibitor (AEBSF)  2.5 mL 
 Fill to 250 mL with 1x PBS pH 7.3 
 
10x PBS, Preparation for 1 L:  
 NaCl      81.750 g  
KCl       2.009 g  
 Na2HPO4*7H2O    27.075 g  
 KH2PO4     2.448 g  
 Add 1 L ddH2O. Verify pH at or near 7.3 
 
Luria-Bertani (LB) broth medium (1L) 
 Bacto-tryptone    10 g 
 Bactone-yeast extract   5 g 
 NaCl      10 g 
 Add distilled water to 1 L 
 Adjust pH to 7.0 with NaOH and autoclave 
